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‘A main cause of philosophical disease – a one‐sided diet: one nourishes one's 
thinking with only one kind of example.’  
Ludwig Wittgenstein 
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SUMMARY  
Introduction 
Coronary heart disease (CHD) is one of the leading global causes of morbidity and mortality. The 
underlying biological mechanisms are well understood, and a host of causal risk factors for the 
disease have been identified, mainly related to diet, smoking and physical activity.  Evidence-based 
treatments for the disease are also available, reducing mortality and improving quality of life.  
The decline in CHD mortality rates observed in most developed countries since the 1960s represents 
a most remarkable epidemiological phenomenon. However, this decline is not universal, and may 
now be in jeopardy. Thus, the mortality decline has recently plateaued in young adults in the United 
States. Furthermore, the absolute burden of disease is set to increase mainly because of an 
increasingly ageing population, and will represent a heavy burden to high, middle and low income 
countries alike. Furthermore, CHD incidence may rise in future because of recent adverse trends in 
major CHD risk factors, namely the worldwide increases in obesity and diabetes prevalence observed 
since the 1980s. Moreover, new technology and improved treatments are decreasing case fatality in 
CHD patients, increasing life expectancy and thus expanding the pool of patients surviving with 
clinically apparent disease. Finally, and crucially, important socioeconomic inequalities persist, 
perhaps reflecting disease determinants. The complex interplay of these factors and potential 
changes over time together suggest that the CHD epidemic may still be evolving. Further attention is 
therefore essential. 
The analysis of time trends in disease specific mortality can thus potentially help us to understand 
the population dynamic of diseases such as CHD, warn about key changes and perhaps offer some 
novel insights for better prevention and control. However, most previous analyses have been 
focused on age-adjusted rates that might conceal important differences by age or by socioeconomic 
status, which might provide further understanding of trend drivers.  
 
Aims and objectives: 
 
My aim is to study recent coronary heart disease mortality time trends in different countries, in 
order to better understand the current state of the CHD epidemic. Furthermore, I will analyze the 
relative importance of CHD treatments and risk factors as drivers of the mortality trends. Finally, I 
will consider the Public Health implications of my findings. 
 
My objectives therefore are:  
1. To summarize our current understanding of Coronary Heart Disease (CHD) causation 
2. To describe recent CHD mortality time trends focusing on age and gender specific trends by 
identifying periods with similar rate of change in diverse populations (England & Wales, the 
Netherlands, Poland and Australia). 
3. To describe recent CHD mortality time trends by Socio-Economic Status in England and 
Scotland. 
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4. To quantify the role of risk factors and evidence-based treatments as drivers of the CHD 
mortality trends, first using a modelling approach in Poland, and then in England while also 
considering socioeconomic factors. 
5. To consider the public health policy implications of dynamic trends in coronary heart 
disease mortality. 
 
 
Methods 
CHD mortality trends were analysed using the joinpoint regression approach.  Widely used in cancer 
epidemiology, but rarely in CHD, this method explores trend data to find points in time (“joinpoints”) 
that define segments where the trend has a constant pace of change. The key strength of this 
technique is objectivity- (it avoids the detection of potentially biased patterns when trends are 
described using time intervals defined subjectively by the researcher). Joinpoint avoids this potential 
bias by essentially removing the observer from the selection process, instead using a formal and 
objective exploration of the time-series data.  My analysis therefore focused on age-adjusted rates, 
then age and gender specific rates. The analysis for Scotland and England also considered socio-
economic status (using area-based measures of material deprivation).  
The contributions of risk factors and treatments to the observed CHJD mortality trends in Poland 
were studied using the IMPACT model, a comprehensive, population-based model of CHD 
epidemiology. The model goal is to quantify the decline in coronary heart disease deaths in the 
Polish population between 1991 and 2005 which might be explained by risk factor changes and by 
treatments. The model is comprehensive, incorporating all usual treatments for coronary heart 
disease and heart failure plus all major cardiovascular risk factors, including smoking, blood 
pressure, cholesterol, diabetes, obesity and physical activity.  
Similar analyses but also exploring the socio-economic differences were conducted in England, using 
a modified IMPACT model (IMPACTsec). That was used to estimate the contribution of risk factors 
and evidence based treatments to the observed decline in mortality in England between 2000 and 
2007, for each quintile of the index of multiple deprivation.  
 
Results 
Age-adjusted trends in England and Wales, Scotland, Australia and the Netherlands conceal 
important recent age specific patterns. In these countries, the age-adjusted rates show continuing 
declines; however, among young adults a recent period of slowing down of the rate of decline in 
CHD mortality has been observed.  Furthermore, trends are very dynamic, and the patterns can 
change surprisingly quickly. In the Netherlands, the sustained period of minimal change in young 
adults was followed by a period of further decline. Poland offers a strikingly different example of 
trend dynamism. After a period of constant increase, Poland showed a sudden, sharp decline in CHD 
mortality rates within a period of a very few years. This decline occurred in all age and gender 
groups, and still continues.  
The recent mortality trends are probably attributable more to changes in risk factors rather than 
medical treatments. For example, using the IMPACT model to study the decline phase of the Polish 
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CHD epidemic, approximately 55% of the observed fall in mortality might be attributed to changes in 
risk factors, and only about a third to evidence based therapies.  
Because of the social patterning of risk factors levels, further insights on the role of risk factors as 
major contributors to trend changes can be obtained by studying trends in levels stratified by 
socioeconomic circumstances. Scotland and England offer particular opportunities for detailed 
studies of trends in CHD mortality using high quality data including socioeconomic status. The 
resulting picture is complex. The recent flattening in CHD mortality trends observed in young adults 
was confined to the most deprived groups in Scotland, but was more uniform in England.  A marked 
deterioration of medical care is implausible, meaning that the most likely explanation for this recent 
flattening of CHD mortality must be adverse trends in major cardiovascular risk factors.  
The CHD mortality modelling in England produced intriguing results. As expected, socio-economic 
patterning of risk factor changes were observed. For example, decline in smoking levels contributed 
more to the observed decline amongst the more deprived groups.  Social patterning was less clear 
among young adults in England. Moreover, the IMPACT SEC model analysis suggested that 
approximately half the CHD mortality fall was attributable to improved treatment uptake, with 
benefits occurring surprisingly equitably across all social groups. A similar analysis of the Scottish 
trends is therefore urgently needed to gain better insights on the drivers of the socioeconomic 
patterning underlying the observed trends.  
 
Conclusions 
The recent flattening in CHD mortality in young adults seen in many countries experiencing an 
overall decline in deaths strongly suggests that favourable trends can reverse. Furthermore, the 
rapid reversal observed in some age groups in the Netherlands and in the entire population in 
Poland suggests that recovery can occur very quickly.  
These rapid mortality changes have been observed in many countries and cannot easily be dismissed 
as artefact.  There is a strong case to mainly attribute these trends to changes in cardiovascular risk 
factors, since marked deterioration of medical care in these affluent countries appears implausible.  
This interpretation is also consistent with evidence from the rapid risk reductions observed in 
randomised drug and diet trials. Furthermore, several populations experienced “natural 
experiments” when socio-economic events producing beneficial effects on cardiovascular risk factors 
were rapidly followed by dramatic changes in CHD mortality.  
These rapid mortality changes challenge some aspects of our current understanding of CHD 
causation. Specifically that the temporal relationship between changes in risk factors and changes in 
fatal outcomes are probably operating over much shorter timescales than previously assumed, 
within a few years rather than decades. 
The public health implications of these findings are thus clear: large changes in CHD burden can be 
achieved quickly, probably reflecting trends in dietary and other cardiovascular risk factors. 
Population level prevention interventions might therefore be both powerful and rapid.  
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1 INTRODUCTION 
 
 
 
Cardiovascular disease (CVD) and particularly coronary heart disease (CHD), is one of the leading 
global causes of morbidity and mortality. The underlying biological mechanisms  are well understood, and 
a host of risk factors for the disease has been identified, mainly during the 20th century. Effective 
treatments for the disease are also available, reducing mortality and the substantial impairments 
imposed by these diseases  on quality of life and wellbeing.  
  
 Our substantial knowledge on causes and treatment suggest that the disease can fall to a point far 
below its current mass occurrence, if not reach an ideal minimal endemic level. 
 
The decline in CVD mortality rates since the 1960s has been one of the most remarkable 
phenomena in epidemiology. However, this decline may now be in jeopardy. The absolute burden of 
disease is set to increase mainly because of an increasingly ageing population. Furthermore, CVD 
incidence may rise because of adverse trends observed in major risk factors for the disease, namely the 
worldwide increase in obesity and diabetes prevalence observed since the 1980s.  Furthermore, new 
technology and improved delivery of existing treatments are decreasing case fatality, increasing life 
expectancy and thus, increasing the pool of people remaining alive but with clinically apparent disease. 
 
The complex interplay of these factors is conceivably the main driver of CVD disease burden in a 
population. If so, this interplay then has direct implications for the potential preventative and therapeutic 
options available to tackle the heavy burden of CVD in so many populations.  
 
The analysis of time trends in disease specific mortality can thus potentially help us to understand 
the population dynamic of these diseases, warn about key changes and perhaps offer some novel insights 
for better control.  
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1.1 AIMS  
 
My aim is to study recent coronary heart disease mortality time trends in different countries, in 
order to better understand the current state of the CHD epidemic. Furthermore, I will analyze the relative 
importance of CHD treatments and risk factors as drivers of the mortality trends. Finally, I will explore the 
Public Health implications of my findings.  
 
 
 
1.2 OBJECTIVES OF THIS THESIS 
 
1. To summarize our current understanding of Coronary Heart Disease (CHD) causation 
2. To describe recent CHD mortality time trends focusing on age and gender specific 
trends by identifying periods with similar rate of change In England & Wales, the 
Netherlands, Poland and Australia. 
3. To describe recent CHD mortality time trends by Socio-Economic Status in England and 
Scotland. 
4. To quantify the role of risk factors and evidence-based treatments as drivers of the CHD 
mortality trends, first using a modelling approach in Poland, and then also considering 
socioeconomic factors in England. 
5. To explore the public health policy implications of dynamic trends in coronary heart 
disease mortality.    
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2 CORONARY HEART DISEASE 
 
 
2.1 INTRODUCTION 
Coronary heart disease encompasses a range of clinical syndromes that have as underlying 
aetiology progressive atherosclerosis of the coronary arteries supplying the myocardium. This 
phenomenon consists of the development of “plaques” in the wall of arteries. These plaques 
undergo extensive inflammatory, thrombotic and metabolic changes that result in the impairment of 
myocardial blood flow over a range of timescales, from chronic progressive restriction of the blood 
flow to sudden occlusion.  
2.2 BIOLOGY, NATURAL HISTORY AND CLINICAL ISSUES  
2.2.1 Atheromatosis 
Atheroma is one of the lipid storage disorders. Over the last century, evidence has emerged 
suggesting cholesterol as a crucial factor in its formation.1 Low density Lipoproteins (LDL) transports 
blood cholesterol, which then enters the arterial intima. There the LDL molecules become oxidized 
and can act as potent promoters of the atherogenesis process. This process includes the induction of 
endothelial and smooth cell activation, secretion of inflammatory mediators and expression of 
adhesion molecules, leading to leukocyte accumulation in the subendothelium. This inflammatory 
response in turn can promote further oxidation of the LDL particles and resulting in the activation of 
macrophages that engulf the LDL particles to become “foam cells” (cells loaded with lipids). These 
activated macrophages can then further contribute to damage by various secreted mediators or by 
adding thrombogenic and antigenic debris to the lesion, fostering the progress of the resulting 
atherosclerotic plaque.2 
Additionally, macrophages can present fragments derived from oxidized LDL particles as 
antigens to recruited T cells, an activity that supports the crucial role of lipids both in innate and 
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adaptive immune responses in atherosclerosis.2 This is a crucial feature of atheromatous disease, as 
lipid metabolism and thrombotic and inflammatory mechanisms are closely linked.  
2.2.2 Clinical Syndromes 
The obstruction of blood flow in the coronary arteries might result in diverse clinical 
syndromes. The atherosclerotic build up in the coronary arteries may start very early in life3,4 and the 
disease can manifest itself with symptoms of chronic obstruction of the blood flow to the 
myocardium, resulting in anginal chest pain (Chronic Stable Angina). However, thrombotic and 
inflammatory phenomena shorten dramatically the timescales for the evolution of the disease by 
making the atheroma plaque unstable. This in turn could result in thrombosis and the development 
of acute obstructions to the blood flow, known as the acute coronary syndromes. Depending on the 
amount of myocardium muscle compromised, these syndromes are further subdivided in myocardial 
infarction (with and without ST elevation) and unstable angina. But perhaps the most dramatic 
consequence of sudden occlusion of the coronary arteries is the occurrence of ischemia induced 
malignant cardiac rhythm disturbances resulting in Sudden Cardiac Death. This is often the first 
clinically evident manifestation of the disease. Here, few therapeutic options other than prevention 
are available.  
The life expectancy of people developing any form of CHD is substantially reduced, and their 
quality of life is also significantly decreased5, suggesting that preventing CHD events from happening 
in the first place is potentially associated with a significant reduction in disease burden. 
Furthermore, because one of the main consequences of atherosclerotic obstruction is the loss of 
myocardial muscle, a common occurrence in many of these patients is the subsequent development 
of heart failure, a condition with particularly high mortality, poor quality of life and with high 
consumption of healthcare resources.  
2.3 PUBLIC HEALTH IMPORTANCE 
CHD and CVD both exert a heavy burden on society. They consistently feature among the 
leading causes of morbidity and mortality in both developed and developing countries. CHD has a 
profound impact on resource use, is associated with profound health inequalities and causes an 
inordinate amount of impaired quality of life.  
Interestingly, our knowledge about CHD causation, prevention and therapeutic strategies is 
extensive, indeed it epitomises evidence-based medicine.  
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2.3.1 The UK Burden 
In 2007, there were approximately 193,000 deaths attributable to cardiovascular disease, 
representing some 34% of the total deaths in the UK. Of these, almost 90,000 were attributed to 
CHD, meaning that one in five deaths in men and 1 in six deaths in women could be attributed to 
CHD. 6  
Crucially, CHD is the main cause of premature mortality (under 75 years). In the UK, 19% of 
and 10% of premature deaths in men and women are due to CHD.6 Age is commonly considered a 
non-modifiable risk factor for the disease. CHD has strong age gradients, and the disease is rare 
under 30 years of age, but increasingly common above the age of 60.7  
There are also strong socio-economic gradients with premature death rates being up to 
threefold higher in deprived groups compared to more affluent groups, making CHD and stroke key 
targets for reducing inequalities.5 
CHD prevalence generates a substantial disease burden to society, and more than 3 million 
people in the UK currently suffer from CHD.6 Total annual UK costs for CHD exceed £10billion, with 
recent NHS costs of £3.2 billion and still rising. An additional £1 billion was recently spent on NSF 
initiatives, like promoting a healthier lifestyle, providing statins in the secondary and primary 
prevention setting, improving the delivery of key services like acute revascularization and cardiac 
rehabilitation.5,8  Substantial indirect costs also are incurred each year, mainly related to productivity 
losses (2006: £3.9 billion) and informal care (£1.8 billion).8 
2.3.2 Global Burden 
Coronary heart disease mortality rates for both men and women vary substantially between 
different countries (figure 2-1). For example, in Europe, men in former Soviet Union Republics like 
the Ukraine have CHD mortality rates that are about 7 times higher than rates observed in France or 
Japan, countries with some of the lowest mortality rates in the World. 
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Figure 2-1 CHD mortality rates in selected countries (year 2000, rates per 100,000) Source: WHO 
mortality database 
 
The Global Burden of Disease Study (GBD) estimated in 2004 that about 7.2 million deaths 
were attributed to CHD, comprising 12% of total deaths. This effectively ranked CHD as the most 
common cause of death globally, in high and medium income countries. In low-income countries, 
CHD is the second most common cause of death, after lower respiratory infections. However, about 
80% of the CHD burden now happens in low and middle-income countries. 9 
Because age is a major factor associated with CHD mortality and morbidity, the burden of 
disease is expected to increase globally -particularly in low and middle-income countries- simply 
because of population ageing. Therefore, CHD will continue to be the leading cause of death in 2020 
and even 2030.9 Interestingly, despite the current decline in CHD Mortality rates in high income 
countries, current GBD projections still considers CHD as the leading cause of death in the next 3 
decades. 
CHD is amongst the leading six causes of death and disability when taking into account age at 
death and age effects on disability in a metric known as DALY (disability adjusted life years), and the 
second cause in middle and high-income economies. Thus, major increases are also expected in low-
income countries, as their population ages.9  
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2.4 CONCLUSIONS 
Coronary heart disease is an important disease for low, middle and high-income countries. 
This burden is increasing in part because of the progress in the control communicable diseases and 
injuries, leading to an increased life expectancy. Treating and managing the disease is consuming an 
increasingly large amount of resources both directly and indirectly, and causing a significant impact 
on individuals, their families and the society.  
Unravelling the biological basis of the atherosclerotic process has helped us to better 
understand the complex clinical presentations of the disease.  In the next section, I will briefly 
consider the aetiology of coronary heart disease, perhaps one of the most studied diseases in human 
history, with over a century of accumulating scientific evidence. The development of the risk factor 
paradigm has been essential to understand the causes and potential control strategies for CVD, as I 
will discuss in the next chapter.  
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3 THE RISK FACTOR PARADIGM FOR CVD CAUSATION 
 
 
3.1 INTRODUCTION 
During the 20th century, we acquired considerable knowledge about causation of coronary 
heart disease.  As discussed in chapter 2, the main pathophysiological phenomenon is vascular 
atherosclerosis, the progressive narrowing of arteries by the atherosclerotic plaque. This plaque is a 
complex structure, the result of endothelial dysfunction, blood lipid accumulation and the 
subsequent host inflammatory and thrombotic responses.2  
Many factors are causally related to the development of arterial atherosclerosis (Figure3-1), 
and the landmark Framingham study identified most of them.10  The major biological risk factors are 
causally proximal to events. However, important determinants of disease including diet or 
socioeconomic circumstances are more distally related and influence CHD risk by indirect pathways 
through the more proximal risk factors, and also by direct links to events. 
There is also a growing body of evidence that links early life developments, childhood and 
adolescent trajectories and adult levels of risk factors. This suggest that the causation of coronary 
disease develops over the life course, but that early ages are particularly important.11  
Furthermore, evidence of atherosclerosis has been found in autopsies of teenagers and young 
adults3, suggesting that the atheromatous process ending in clinically apparent coronary events  
might take decades to develop.12,13 
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Figure 3-1 Causal pathways in coronary heart disease 
 
 
 
3.2 MAJOR ESTABLISHED RISK FACTORS 
The idea of cardiovascular risk factors developed over the mid 20th century, particularly after 
a landmark paper from Framingham by Kannel et al.14 This initial insight was widely confirmed with a 
host of subsequent observational and experimental studies.  
The Framingham study started in 1948 to explore the causal relationship between several 
physical and biochemical traits and cardiovascular disease. This was a cohort study recruiting 5209 
men and women aged 30 to 62 from the town of Framingham in Massachusetts, United States. The 
participants were followed up and the occurrence of CVD events was recorded, with detailed clinical 
and biochemical examinations conducted every two years.  Initially, this study identified raised blood 
cholesterol, raised blood pressure, and tobacco use as major risk factors for CHD.14,15 
During the 1950s, the Seven Countries Study studied the relationship between biological and 
lifestyle risk factors in a wider set of populations, by conducting 16 cohort studies in seven countries, 
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in four regions of the world (United States, Northern Europe, Southern Europe and Japan), and 
addressed the important question of replicating the association of risk factors with CVD outcomes in 
other settings. This study included countries with high and low mortality rates, confirming the 
relevance of the Framingham risk factors, but suggesting a variable importance of the associations.16 
This study was also the first to identify important dietary patterns, and how the adoption of less 
healthy diet can result in increased CVD risk.16 Later studies, like the Nurses’ Health Study, a large 
cohort study of nurses in the United States have helped to confirm the importance in women  of the 
already identified major cardiovascular risk factors, particularly regarding obesity, physical activity, 
diet and hormonal factors.17 
Later, during the 1980s and 1990s, the MONICA Study using carefully designed protocols and 
methods and exquisite attention to detail, was able to explore more precisely the contribution of 
risk factors and treatments to mortality trends in over 20 diverse populations.18,19 The MONICA 
Project goals were to measure the trends in cardiovascular mortality and coronary heart disease and 
cerebral-vascular disease morbidity and to assess the extent to which these trends are related to 
changes in known risk factors, daily living habits, health care, and major socioeconomic features 
measured at the same time in defined communities in different countries. Their main findings were 
that about one third of the change in CHD mortality rates could be attributed to health care and two 
thirds to changes in risk factors. I will discuss later in more detail their results (see chapter 4).19,20  
The concept of risk factor for cardiovascular disease is firmly rooted in the way causal factors 
are  addressed in epidemiology, using guiding principles like those developed by Bradford Hill.21 
Using these criteria, an association is considered causal if it is strong and shows a biological gradient, 
it is found consistently over a range of contexts, it is specific and the exposure precedes the 
outcome, and it is not due to chance. Finally and crucially it has to be unconfounded and verified 
experimentally.  
Recent adaptations of these criteria have simplified the concept. First, we should obtain direct 
evidence from experimental or observational studies showing that a probabilistic association 
between intervention and outcome is causal and not due to chance or bias, preferably supported by 
an experiment or trial. This is further supported by evidence of a dose-response and the strength of 
the association, when experimental evidence is not available. Second, one requires evidence of a 
clear biological mechanism linking the alleged causal web that links the putative risk factor and the 
outcome. Finally, parallel streams of evidence supporting the causal hypothesis suggested in one study, 
with comparable studies in various contexts showing similar results.22  
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The large cohort studies I have discussed before provided most of the evidence necessary to 
assert causality within this framework. This was later confirmed when experimental evidence 
available at the time of the development of interventions to decrease risk factors levels started to 
emerge.23,24  Subsequent support came by similar findings across a range of populations and settings, 
using a variety of observational approaches.25-27 
Understanding the evidence base for CVD causation is essential, firstly for knowing what 
drives trends in the disease burden of disease and secondly to provide evidence for disease control 
policies. In the following sections, I will briefly describe the evidence to understand the causation of 
CVD for the major risk factors (summarized in Table 3-1 and 3-2). 
3.2.1 Smoking 
The report from the US Surgeon General in 1964 suggested that smoking was a clear risk 
factor for lung cancer and chronic bronchitis, but was less emphatic in describing its relationship 
with CVD risk, suggesting that although risk increases in smokers, the association has not been at 
that time, to be proved causal.28  
However, over the years from that report a large body of evidence linking tobacco smoking to 
changes in inflammatory and thrombosis markers and with subclinical markers of atherosclerosis 
was accrued.29 This body of evidence suggest a clear link between smoking and basic atherosclerotic 
disease mechanisms. 
Previous US Surgeon general reports have summarized the extensive body of evidence linking 
tobacco smoking with CHD, increasing its risk by  almost twofold.30 They also confirmed its harmful 
effects in women and demonstrated a dose-response relationship.29  
 
  
Table 3-1 Summary of the evidence base for the major modifiable biological risk factors for coronary heart disease 
Risk Factor Effect Size 
Temporal 
relationship 
Strength 
Dose-Response 
relationship 
Experiment References 
High Blood Cholesterol 
1 mmol/L lower total cholesterol 
was associated with reductions in 
coronary heart mortality ranging 
from about 50% in men and 
women aged 40-49 and 17% in 
those 70-79 , across the range of 
cholesterol 
Observational 
and RCT 
evidence 
Observational 
and RCT 
evidence 
Observational and 
RCT evidence 
Blood lipid reduction 
therapies RCTs showed 
that reducing blood 
lipids levels is 
associated to a 
reduction in fatal and 
non fatal CVD events 
Lewington 2007, 
26
; Law 2003
24 
High Blood Pressure 
A difference of 20mmHg in SBP 
was associated to more than 
twofold differences in stroke 
mortality and two fold 
differences in ischemic heart 
disease mortality 
Observational 
and RCT 
evidence 
Observational 
and RCT 
evidence 
Observational and 
RCT evidence 
Antihypertensive 
treatments RCTs 
showed that reducing 
blood pressure levels is 
associated to a 
reduction in fatal and 
non fatal CVD events 
Lewington 2002 
25
;He 1999
31
 
Smoking 
Between 2.5 to 3.3 times 
increased risk in smokers 
compared to non smokers. 
Observational 
evidence 
Observational 
evidence 
Observational 
evidence 
No 
US  Dept of Health 
2004
29
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Table 3-1 (continued) 
Risk Factor Effect Size 
Temporal 
relationship 
Strength 
Dose-Response 
relationship 
Experiment References 
Diabetes Mellitus 
increasing risk by 2.4 times in 
men and 5.1 times  in women 
Observational 
evidence 
Observational 
evidence 
Observational 
evidence 
Observational 
evidence, RCTs showed 
effects on nonfatal MI 
events but not on 
stroke or mortality 
outcomes. 
Wilson 
1998
32
;Kannel 
1985
33
 
Obesity 
Independent effect small, most of 
its effects is mediated through 
other risk factors. 
Observational 
evidence 
Observational 
evidence 
Observational 
evidence 
No 
The Emerging Risk 
factors 
collaboration 
2011
34
 
Lack of physical activity Increase risk 
Observational 
evidence 
Observational 
evidence 
Observational 
evidence 
No Warburton 2006
35
 
 
2
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More recently the INTERHEART study, a large international case control study including 50,000 
participants with incident acute myocardial infarctions (AMI), reported that the risk of AMI among 
smokers was 3.3 in young adults and 2.5 in older adults.27 The health effects of passive smoking have 
been also solidly established, with a relative risk for CHD of 1.26 to 1.65.36,37 More importantly, data 
from systematic reviews in tobacco cessation studies after MI, showed marked reductions in risk, of 
almost 40% within two years.38,39 
In conclusion, the association between smoking and cardiovascular disease is strong, graded 
and unconfounded.  
3.2.2 Blood Lipids 
More than a century ago, Virchow first suggested the association of blood lipids and 
atheromatosis. This was supported by animal feeding experiments conducted by Anitschcov early in 
the 20th century. Observational evidence from migrant studies, the Seven Countries study 16 and the 
Framingham study14,15 found the association in humans, confirmed later in MRFIT40, PROCAM41 and 
ARIC42 studies. The development of lipid reduction therapies, particularly HMG-CoA Reductase 
inhibitors (statins) provided experimental evidence of causality, not without some controversy.24,43  
Total cholesterol is clearly associated with CHD risk, as summarised in the Prospective Studies 
Collaboration systematic review and meta-analysis, a large systematic review summarizing 61 
cohorts consisting of almost 900,000 adults without previous disease, with nearly 12 million person-
years of follow-up, and more than 50,000 vascular deaths. In this study, a 1 mmol/L lower total 
cholesterol was associated with reductions in coronary heart mortality ranging from about 50% in 
men and women, aged 40-49 and 17% in those 70-79 , across the range of cholesterol levels  in most 
developed countries, and showing a linear relationship, with no evidence of a threshold.26 
Statins effectively reduce cholesterol levels between 1.8 and 2.8 mmol/l (depending on drug 
and dose) and this translates into cardiovascular event reductions. Reductions of 1 mmol/l are 
associated with a reduction of ischemic heart disease risk by 11% in the first year of treatment, 24% 
in the second year, 33% in years three to five, and by 36% thereafter, clearly indicating that 
substantial reductions in events can happen very quickly. 24 
High-density lipoproteins (HDL) represent another important lipid sub-fraction; they are 
protective and have a strong inverse association with CHD events. Thus, increases of 1 mg/dl are 
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associated with 2-3% reductions in total CVD risk.44 Interestingly, randomized clinical trials of novel 
drugs aimed to increase HDL levels have thus far failed to show any reduction in CVD risk.45   
Triglycerides have been associated to CVD risk, but their levels tend to reciprocate HDL 
concentrations. Their role as an independent risk factor remains controversial, and current control 
strategies only target them in special cases.46 
Dietary saturated fats are the main determinants of blood lipids levels, particularly total 
cholesterol.47 However, not all dietary fats are harmful. Mono-unsaturated fatty acids, (olive oil), 
poly-unsaturated fatty acids (marine omega 3 fatty acids) and plant-based omega 6 fatty acids, are 
associated to lower CVD risk, particularly when replacing saturated or trans-fats.48-50 
3.2.3 Blood Pressure 
Numerous observational and experimental studies have linked high blood pressure with 
adverse cardiovascular outcomes over the last decades.  Moreover, the link between endothelial 
dysfunction, vascular remodelling and hypertension with subsequent atherosclerosis progression 
has been clearly defined at the metabolic and functional levels.51,52 
Diastolic blood pressure (DBP) has been identified as an independent, graded and important 
predictor of CVD risk in large, prospective cohort studies and randomized clinical trials.53-55 However, 
later studies focused on exploring the association of systolic blood pressure (SBP) and risk, which 
resulted in even a stronger association compared with diastolic blood pressure. The Prospective 
Studies Collaboration systematic review produced a good summary of the evidence.25 This was a 
large systematic review involving 61 prospective studies observing 12,7 million person-years at risk 
and with 56,000 vascular deaths. For each difference in 20mmHg, SBP was associated with almost a 
threefold difference in stroke mortality and a twofold difference in ischemic heart disease mortality. 
Interestingly, the relationship was linear down to a SBP as low as 115mmHg.  Although the risk 
attenuated in those 80 years and older, the absolute difference in event rates was biggest in older 
ages.  Reduction of blood pressure and crucially SBP significantly reduce vascular events and deaths 
in people free from vascular disease. The CVD and CHD risk associated with blood pressure has been 
also found in many other populations.56 
In a systematic review and meta-analysis, He and Welton31 found a statistically significant risk 
reduction of 21% in CHD events and deaths, and a reduction of 27% in CHD mortality. 
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Antihypertensive treatments reduce stroke risk more substantially, with a 37% reduction in total 
events and a 36% reduction in fatal strokes.  Similar findings have been reported by Law et al.23  
Dietary Salt intake is a major determinant of blood pressure levels.57,58 Furthermore, a large 
body of evidence suggests that salt consumption is probably the single most important factor in 
determining blood pressure levels. The biological mechanisms has been explored in animal studies, 
and epidemiological evidence has been found in ecological studies like INTERSALT59 or INTERMAP60 
and in the prospective cohort study EPIC-Norfolk.61 The INTERSALT Study was a standardized, 
worldwide epidemiologic study of large sample size (n = 10079 men and women aged 20-59 y from 
32 countries) that studied both within- and cross-population ecological association between 24-h 
sodium excretion (a proxy for salt intake) and blood pressure. The estimated effect of a sodium 
intake higher by 100 mmol/d was higher blood pressure by approximately 3 to 6 mmHg of SBP and 
to 0-3 mm Hg of DBP. This relation prevailed for both men and women, for younger and older 
people, and for participants without hypertension.59 The INTERMAP study, with improved exposure 
and outcomes measurements, confirmed the association at the individual level with greater detail, 
although for a more limited set of countries.60 The EPIC-Norfolk study was a large cohort study 
conducted in Norfolk, UK, recruiting 30,000 participants with the aim of looking at the association 
between diet and lifestyle risk factors and cancer, but with the secondary aim of looking to 
cardiovascular outcomes. They found that individuals with salt intakes below 5 g per day halved their 
risk of developing high blood pressure compared to those at high intakes (10 g per day or more).61 
Interestingly, they also found that high intake of dietary potassium was associated to lower blood 
pressure.61 
Experimental evidence supporting the causality of the association of SBP and salt consumption 
came from population-based intervention studies.  Forte et al  tested the effect of an educational 
campaign on salt intake in two matched communities in Portugal.62 In the intervention community 
average blood pressure fell by 3.6/5.0 mmHg at one year and 5.0/5.1 mmHg at two years. Although 
other community interventions trials failed to observe changes in salt consumption, they also 
reported lack of change in blood pressure levels.  
More interestingly, the effect of salt on cardiovascular outcomes has been explored in RCTs. 
The THOP I and II studies63 randomized about 3000 participants  to a sodium reduction intervention 
or a control, and followed up to 15 years after the termination of the studies. They found that a 
reduction of salt intake resulted in a SBP fall between 1.2 and 1.7 mmHg and a 25% risk reduction in 
cardiovascular events over 10 to 15 years.  
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The focus on salt reduction initiatives across entire populations has been probably one of the 
most important drivers in decreasing blood pressure levels in many populations.57,58,64  
3.2.4 Obesity 
Obesity and overweight are conditions associated with an imbalance in energy intake and 
expenditure. The current physical, cultural and marketing environments are a powerful determinant 
of the continuing increases in obesity prevalence reported in the late 20th century and early 21st 
century.65 
Adipose tissue is metabolically active and can release a host of mediators that control body 
weight homeostasis and insulin resistance. Crucially, it also influences inflammation and thrombotic 
pathways leading to endothelial dysfunction and atherosclerosis.66 Not surprisingly thus, obesity is 
strongly associated with CVD risk factors and diabetes67, and is associated with excess mortality, 
mainly attributable to CVD and several common cancers.68-70 
However, the independent effect of obesity is probably small34, suggesting that most of its 
associated risk is mediated by more proximal risk factors, like systolic blood pressure, elevated 
cholesterol and diabetes.  
3.2.5 Diabetes Mellitus 
Diabetes mellitus (DM) is a risk factor for CHD, increasing risk by approximately 2.4 times in 
men and 5.1 times in women.32,33 It also has been identified in the early stages of atheroma 
formation in young ages71, and negates the low risk otherwise experienced by pre-menopausal 
women.72  Patients with diabetes have similar rates of events as patients with CHD but without 
diabetes.73 All levels of abnormal glucose metabolism are associated with cardiovascular disease, 
primarily by diabetes induced arterial macro-vascular atherosclerotic disease.74 
The mechanisms leading to enhanced development of atherosclerosis in diabetic persons are 
complex, and likely involve endothelial dysfunction, inflammatory mediators and modification in 
lipid metabolism.75 
Hyperglycaemia has also direct endothelial toxicity, leading to atherosclerosis.76 This direct 
mechanism is compounded as diabetic persons tend to have also higher levels of other risk factors, 
particularly obesity and hypertension, that continue to have an independent effect.77 Not 
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surprisingly, cardiovascular events are the main cause of death in adult diabetic persons, with 80% of 
them attributable to CVD, 75% of which are CHD.78 
However, there is still substantial uncertainty about the effects of controlling diabetes on 
cardiovascular risk. Epidemiological evidence suggests that diabetes it is an important, strong and 
independent risk factor. Yet, the results of randomized controlled trials on intensive glucose control 
strategies showed no effect on stroke outcomes or mortality, only a decrease in non-fatal 
myocardial infarctions.79,80 This is interesting, as diabetes in considered to confer the same level of 
risk as those with established CHD73, but this is probably because many diabetic patients when 
diagnosed already have advanced atherosclerotic disease.  
The evidence for diabetes prevention appears rather different. A growing body of evidence 
based on randomized clinical trials suggest that diabetes incidence could be halved relatively quickly 
with multiple interventions including lifestyle and dietary changes.81 Metformin has also been 
associated with a 31% reduction in the risk of diabetes in the Diabetes Prevention Program study, 
albeit smaller than the 58% risk reduction observed in the diet and lifestyle arm.82 
These findings highlight the importance of preventing diabetes, thus focusing attention higher 
up in the causal web leading to diabetes and CHD outcomes.  
3.2.6 Physical Activity 
Physical inactivity has been recognized since the 1950s to be associated with total mortality 
and cardiovascular risk; however, most of the evidence base is observational. This body of evidence 
suggests reduction in total mortality and CVD risk of about 20-30%, often showing a graded 
response, and with benefits in other outcomes also, like diabetes, certain cancers and 
osteoporosis.35 
Physical activity epidemiology is a difficult field, with controversies regarding exposure 
measurement and the complex causal pathways. However, most primary prevention guidelines 
recommend periods of moderate to intense physical activity as an effective intervention to reduce 
cardiovascular risk.83 
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3.2.7 Dietary patterns and other nutritional factors  
I discussed above how some nutrients like salt or dietary fats are associated both with the 
levels of risk factors and with global CVD risk.  Other dietary factors and diet patterns are also 
important.  
There is substantial evidence to support the concept of cardio-protective nutrients and dietary 
patterns.84 (These are summarised in Table 3-2) 
A systematic review found strong evidence, by complying with most Bradford Hill criteria, for 
the beneficial effects of the intake of fruit and vegetables, nuts and “Mediterranean” or similar high-
quality dietary patterns on CHD, confirming also the detrimental effects of trans-fatty acids and 
foods with high glycemic index. 85 The “Mediterranean diet pattern” and the DASH diet have shown 
beneficial effects confirmed in randomized controlled trial.84 An analysis of diet patterns in the 
INTERHEART case control study has found that higher levels of a “prudent diet” (rich in fruits and 
vegetables) were inversely associated to the risk of a first acute myocardial infarction, across 
participants in 52 countries.86 In general, dietary patterns are associated to high levels of 
cardiovascular protective individual nutrients and low content of detrimental factors.84 
Among nutritional risk factors, industrial trans-fats merit special attention. These are artificial 
fats used mainly in processed food for commercial reasons and considered not to have any 
nutritional value. They have a profound effect on increasing CHD risk. Replacing 1% of energy from 
trans fat with unsaturated fats reduces CHD risk by approximately 12 % (5.5% to 18.5%).48 Several 
countries have successfully implemented the complete removal of industrial trans fats from human 
food.87 
In summary, certain dietary patterns have established cardio-metabolic benefits and are 
higher in dietary fibre, healthy fatty acids, vitamins, antioxidants, potassium, other minerals, and 
phytochemicals; and lower in refined carbohydrates, sugars, salt, saturated fatty acid (SFA), dietary 
cholesterol, and trans fat. The role of other dietary supplements, micronutrients and vitamins is 
complex and remains less than clear.85 
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Table 3-2  Evidence base for the association between diet and nutritional factors with cardiovascular 
disease 
Nutrient Intake Level and effect on CVD 
outcomes 
Strongest Evidence Level*  
Fruit Increase, protective Prospective observational studies on clinical 
endpoints 
 
Vegetables Increase, protective Prospective observational studies on clinical 
endpoints 
 
Whole Grains Increase, protective Prospective observational studies on clinical 
endpoints 
 
Fish and shellfish Increase, protective RCT 
 
Nuts Increase, protective Prospective observational studies on clinical 
endpoints 
 
Dairy Products Decrease, protective Prospective observational studies on clinical 
endpoints 
 
Vegetable Oils Increase, protective Prospective observational studies on clinical 
endpoints 
 
Fats Decrease, protective RCT  
Hydrogenated fats and oils Decrease, protective Prospective observational studies on clinical 
endpoints 
 
Processed meats Decrease, protective Prospective observational studies on clinical 
endpoints 
 
Sugar sweetened beverages and 
foods 
Decrease, protective Prospective observational studies on clinical 
endpoints 
 
Alcohol Decrease, protective Prospective observational studies on clinical 
endpoints 
 
*References available in Mozzafarian et al. 
84
 
 
 
3.2.8 Alcohol 
The relationship between alcohol intake and CHD risk is complex. The relationship has been 
described as “J” shaped, with risk increased at high alcohol consumption or with no intake, and 
lower risk for low to moderate intake88,89; or as “L” shaped, where a protective effect was observed 
for alcohol consumption at low to high levels but not for no consumption.90,91 There is greater clarity 
about increased levels of mortality with increasing alcohol consumption for stroke.91-93 
A consumption of alcohol between 2.5 to 14.9 g/day was associated to a risk reduction of 
about 14% to 35% for cardiovascular disease mortality, and for incidence and mortality for CHD and 
strokes.91,92   
The intake of ethanol seems to be the most important factor, rather than any specific 
components of the alcoholic beverage.94,95  
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However, the drinking pattern is more important. Regular, low to moderate intake seems to 
be protective94-97, while episodic immoderate alcohol intake confers a considerable risk of incident 
MI and totally mortality.96,98 
Furthermore, heavy alcohol intake might have mass consequences, as illustrated by the huge 
temporal variations in cardiovascular disease mortality rates seen in Russia and other ex socialist 
soviet republics after the breakdown of the union in the 1990s.99 It is clear now that this 
phenomenon is not caused by misclassification of the causes of death.100 Although causality has not 
been established with experimental data, current guidelines in most countries recognize that while 
low to moderate intake of alcohol CVD risk are beneficial, higher intakes are harmful. Alcohol 
consumption is thus not recommended by the British Heart Foundation, National Heart Forum  or 
American Heart Association.101 
 
3.3 OTHER RISK FACTORS: SOCIAL DETERMINANTS, LIFE COURSE INFLUENCES AND 
GENETIC FACTORS 
3.3.1 Social determinants 
The Socioeconomic determinants of health are usually assessed as social gradients in mortality 
or morbidity. 
In the United Kingdom, these patterns are readily visible, with mortality gradients by 
socioeconomic levels or geographically across a North-South divide. For example, the mortality rate 
ratio between the most deprived quintile and the more affluent is 1.5 for both men and women, and 
almost 2 if we consider only those deaths happening under 75 years of age.6 In the USA, persons 
without  a high-school education lost almost three times more life years than more educated people, 
and cardiovascular diseases accounted for about 35% of this difference (coronary heart disease itself 
explained 11%).102 
These gradients are also evident in the distribution of cardiovascular risk. For example, in the 
USA,  there are major differences in risk factor prevalence and combined cardiovascular risk by 
ethnicity103,104 and other measures of socioeconomic status.105 In several European countries, 
persons in the lower socioeconomic strata are more frequently current smokers, have higher BMI, 
higher intake of alcohol and lower intake of fruit and vegetables.106 
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Worse childhood socioeconomic conditions are frequently associated with increased CVD risk 
in adulthood.107,108 This is possibly mediated by early life and childhood trajectories in risk factors, 
predicting young adulthood cardiovascular risk factors levels.11,109 
3.3.2 Life-Course influences 
Social influences in childhood may also have an important effect on CVD risk in adulthood. The 
timing of other exposures starting intrautero -and even transgenerationally- are also important.110 
Perhaps the first evidence on early life influences on adult coronary heart disease risk was provided 
by Forsdahl, who found that early 20th century infant mortality rates were strongly correlated with 
CHD mortality rate seven decades later111, suggesting that early childhood nutrition or perinatal 
phenomena might be linked to CHD risk. 
The “developmental origins” of coronary heart disease hypothesis, as stated by Barker et al112, 
suggest that many measures of foetal growth, as a proxy for the womb environment have shown 
that intrautero events are related to adult life CHD risk.113,114 
 Perinatal and early childhood influences also are linked to later , pre adulthood risk factor 
levels.109,113 Moreover, cholesterol, body mass index, systolic blood pressure measured in childhood 
or adolescence predict CHD risk 50 year later.113 
However, the scale of life-course effects on CHD causation remains unclear. Not least because  
such influences operating on individuals would be expected to operate, at the population level, as 
cohort effects.115 However, the declining CHD epidemics in most high income countries can be 
explained better by period effects rather than cohort effects, (intriguingly, Singapore and Norway 
offer apparent exceptions).116 
3.3.3 Genetic factors 
Genetic factors play a causal role in coronary heart disease. The Framingham Offspring Study 
suggests that heritability may be an important factor for premature coronary heart disease. 
Participants with familial history of premature CHD (defined as history of CHD in first-degree 
relatives before age 55 in men and 65 in women), have twice the risk compared to those who not, 
even adjusted for classical risk factors.117 Single gene association and several candidate loci and gene 
sets has been identified in linkage and  genome-wide association studies, usually associated with 
metabolic pathways related to lipid metabolism.118  
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However, in general, the potential candidates have small effect sizes119, low predictive power 
and low population impact measures119 compared to classical risk factors.120  
The rapid changes over time within countries and the marked differences in CHD mortality 
observed between countries , as discussed in chapter 2, (all of which I will further discuss later), 
powerfully indicate a major role of environmental factors and make very implausible to attribute 
such trends to changes in the distribution of genetic determinants.121 Moreover, the classical studies 
of migrants, particularly among Japanese populations, suggested that the risk of CHD and stroke 
increase substantially when exposed to Western dietary environments.122,123 
The interaction of environmental factors with particular genetic risk profiles may also be 
important in CHD.  Thus, for example, APOe e4 high risk alleles might not affect CHD risk in absence 
of smoking .124 Although Mendelian genetics or even genome wide association studies fail to explain 
a substantial proportion of the burden of coronary heart disease, heritable and non-heritable 
epigenetic changes might occasionally play an important role in individual cases.125 
 
3.4 “TRIGGERS” 
An often neglected issue when discussing coronary heart disease incidence is the concept of 
“triggers”. Triggers are exposures that will precipitate clinical events in persons who already have 
developed atherosclerosis. Although not strictly causal factors of atherosclerosis, they are important 
in determining short-term temporal patterns of incidence rates, measured as the occurrence of 
clinical events including death.  
Several factors have been proposed as potential triggers for the acute forms of CHD, like air 
pollution, traffic exposure, alcohol consumption (binge drinking pattern), cocaine use or infections, 
sudden stress, and extreme exertion. For some of them, the case for biological plausibility is solid.126 
However most of the evidence came from observational studies (time series), so there is still 
potential for significant confounding effects and biases.   
Triggers also are described of having a “harvester effect”.127 Triggers essentially precipitate 
events that will occur anyway in a few hours, days or weeks, by depleting the high-risk pool of 
individuals.  
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In any population, the incidence rate is the weighted average of the high-risk pool and the 
low-risk pool of individuals. When the population is exposed to the trigger, the most vulnerable will 
have events at a higher rate, creating a “spike” of mortality.  
However, as the high-risk pool is depleted, the low-risk pool make a larger contribution to the 
incidence rate, resulting in lower than average rates for a period. Finally, as the high-risk pool 
recovers, the incidence rate returned to its usual levels. 
Nevertheless, triggers offer a potentially interesting explanation in terms of mass exposures 
that can have a noticeable effect on event trends. For example, the population attributable fractions 
for several trigger candidates have ranged from 1% (cocaine and marijuana use) to 7% (air pollution 
or traffic exposure).128 
Some of these triggers might also have long-term effects, and perhaps at this point, they 
might be better considered alongside the mayor risk factors discussed previously. For example, 
cohorts studies exploring the risk associated to particulate air pollution have found a 10% increase in 
all cause mortality per 10 ug/m3 in long term average exposure (follow-up times ranging from 2 to 
30 years).129 Risk related specifically to CVD appears to be similar 129 and are the major component of 
the increase in total mortality. However, potential for substantial residual confounding exists, as 
these studies did not control extensively for other disease risk factors.  
 
3.5 EVIDENCE FOR STROKE 
The term cardiovascular disease comprises a range of diseases, including coronary heart 
disease, stroke and peripheral vascular disease. Although a very heterogeneous category, the 
ischemic forms of cardiovascular disease are the predominant ones and share most of their 
determinants. My emphasis on CHD is therefore hopefully justifiable since in the majority of 
countries it is the most important disease of this group in terms of burden of disease.  
However, some differences exist within the umbrella term cardiovascular disease.  I will 
therefore briefly consider stroke, as an example of another disease included with the CVD category.  
37 
 
Stroke is a heterogeneous disease, but is mainly composed of ischemic and hypertension 
related hemorrhagic strokes. However, the main burden is related to ischemic, which comprise 
about 80% of the disease burden.130 
Most of the risk factors for coronary heart disease are also risk factors for stroke, but the 
strength of the association is different.  If we consider total stroke, hypertension is significantly more 
important for stroke than for CHD (PARF 35% vs. 18%) as well as the ratio of Apo B/A1 (PARF25% vs. 
49%).131 
As I discussed before, heavy alcohol intake increases the risk of stroke, although there is still a 
more complex effect on CHD outcomes.  
Certain heart conditions are specific risk factors for stroke, like atrial fibrillation or dilated 
cardiomyopathy. Both conditions increase the risk of cerebral embolism, a cause of ischemic stroke. 
Risk factor for stroke have been found to be independently associated to stroke in high income and 
low income countries participating in the INTERSTROKE study.132  
 
3.6 THE EFFECT OF THE MAJOR RISK FACTORS IS UNIVERSAL 
This is an important question when trying to understand trend determinants globally. The 
assumption usually made is that they are universal, e.g. that the direction and size of the risk factor 
effects is similar across populations. 
The studies trying to replicate the Framingham findings consistently showed that the classical 
risk factor levels are useful to grade risk in Western and non Western populations, although 
calibration is an issue across different populations.10,133 The international case control study 
INTERHEART, and the  prospective studies collaboration and Asia Pacific collaboration have also 
suggested that the risk conferred by the classical risk factor is similar across Western and non 
Western populations.25-27,56  
However, Countries like France or Japan show low CHD mortality rates with relatively high 
levels of risk factors. This situation, often described as “the French Paradox” or the “Japanese 
Paradox”, might jeopardize the idea of “universality of risk factors effects”. However, these 
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paradoxes have been variously explained in terms of mortality misclassification the existence of 
additional protective risk factors, or by lag times which have been ignored.13,134 
The vast amount of data showing the association of risk factors with cardiovascular outcomes 
in many countries, populations and different time periods suggest that assuming that risk factor 
effects are essentially universal is based on solid grounds.  
 
3.7 THE MAJOR RISK FACTORS EXPLAIN MOST OF THE OCCURRENCE OF CORONARY 
HEART DISEASE 
As I have discussed, the evidence base for establishing the causation of cardiovascular 
diseases is broad and deep, solidly based on a combination of biological, observational and 
interventional evidence that mostly fulfil Bradford Hill criteria. However, the list of confirmed and 
potential risk factors for CHD and stroke exceed that of the “classical” ones. Candidates are 
thrombotic and inflammatory biomarkers, lipid sub-fractions and endothelial function measures. A 
huge body of literature and current research is focused in finding novel risk factors for CHD. 
This quest has been fuelled by the claim that only half of CHD incidence can be explained by 
the classical, major biological risk factors, promoting a frantic search for new ones. However the 
source of this statement is difficult to locate, as discussed by Magnus & Beaglehole  in a key paper in 
2002.135 
The debate is essentially about finding new targets for intervention.  For this reason, it is 
easier to claim the importance of the candidate novel risk factors based on relative risks. A better 
way to understand the impact of a risk factor can be summarized as the population attributable risk 
fraction (PARF), a variable that reflects both the risk factor frequency in the population and the 
strength of its association with CHD. One of the crucial assumptions of this concept is that the risk 
factor should be causally related to the outcome, because the PARF estimates the proportion of 
disease incidence that can be eliminated if the risk factor is completely removed from the 
population. For example, a weak risk factor but very prevalent will have a bigger impact compared to 
a stronger, but less common.  
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By using the PARF approach, the INTERHEART study estimated the population attributable 
fractions associated to lifestyle and diet related risk factors is about 90%, suggesting that there is 
little room for significant “novel” candidates, whatever strength they might have.   
From another perspective, a similar conclusion can be reached by examining the incidence of 
CHD in people at “low risk “ for CHD, defined in terms of people that never smoked and  have no 
diabetes, normal or low blood pressure and blood lipids.136,137 This group experienced extremely low 
cardiovascular disease rates.  
Another important distinction is to differentiate causal risk factors from the simple 
identification of earlier, preclinical phases of an already established pathological process. The 
distinction between a risk factor and a risk marker is thus important, mainly because some disease 
control strategy involves the identification of individual with subclinical disease.  
Describing the risk factors in terms of their prevalence and the strength of their association 
with CHD is then of paramount importance for public health.  
The place of a risk factor in a complex causal network is also important. Many risk factors 
distal to outcomes make them desirable intervention targets, as they will have downstream effects 
on more proximal risk factors. Therefore, it is perhaps better to talk about “Major causal pathways” 
to reflect better the complex web of causation of coronary heart disease (Figure 3 – 1).  
 
3.8 RECENT TRENDS IN CARDIOVASCULAR RISK FACTORS 
Global recent trends in risk factors showed a complex picture.  
The Global Burden of Disease has completed global regional and national estimates of trends 
between 1980 and 2008 for systolic blood pressure, cholesterol, obesity and diabetes, using the best 
data available and then conducting statistical multilevel modelling for inputting missing data on 
countries or years, “borrowing” information from neighbouring countries, regional estimates or 
information from previous trends.64,138,139 
BMI globally demonstrated increases about 0.4 kg/m2 per decade in men, and 0.5 kg/m2 per 
decade in women. The largest increases were observed in Oceania, but Western high-income 
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countries are amongst the countries with most marked increases. In contrast, countries in central 
and eastern Europe, Central Africa and South Asia showed predominantly flat trends.138 
Diabetes is increasing globally, in parallel with the increase in obesity seen almost worldwide. 
This increase is particularly important in low and middle-income countries.140 The Global Burden of 
Disease Study estimated that age-standardised adult diabetes prevalence was 9·8% (8·6—11·2) in 
men and 9·2% (8·0—10·5) in women in 2008, up from 8·3% (6·5—10·4) and 7·5% (5·8—9·6) in 1980. 
The increase was more marked in the USA compared to Western Europe.141 
SBP decreased globally by about 0.8 mmHg per decade in men and 1 mmHg per decade in 
women, with the largest decreases in Australasia, North America and Western Europe. However, 
countries in East Africa, Oceania and South and East Asia showed clear increases.64 
Cholesterol change very little globally over that period, falling less than 0.1 mmol/l per 
decade. This reflected conflicting trends, which cancelled out. Whereas cholesterol levels fell in 
Australasia, North America and Western, Central and Eastern Europe, they increased in East Asia, 
South East Asia and Oceania.139 
Smoking is decreasing in men in many countries, although often very slowly. In the USA, 
during 1998-2008, the proportion of U.S. adults who were current cigarette smokers declined 3.5% 
(from 24.1% to 20.6%).142 The UK also showed significant declines, however, in young adults, that 
decrease is slow or even stopped.6 
Smoking prevalence rates for most countries, but particularly for non-Western, low and 
middle income countries are still very high in men, and in women are often increasing from 
historically low levels. 143 
 
3.9 THE RISK FACTOR PARADIGM AND THE CONTROL OF CORONARY HEART DISEASE 
BURDEN 
There are many possible strategies to tackle the high impact of cardiovascular disease and in 
particular coronary heart disease. The main goal of these strategies is to decrease case fatality, 
reduce incidence and to improve quality of life and function.  
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3.9.1 Reducing case fatality rate, recurrence and improving functioning 
The explosion in the 1980s and in the 1990s of the availability of effective interventions to 
decrease CHD mortality and morbidity has been certainly one of the successes of Medicine in the 
20th century, and helped to establish the evidence based medicine paradigm. 
Treatments reduce dramatically the case fatality rates in high-risk situations like the acute 
coronary syndromes. The development of coronary care units, techniques aimed to unblock acutely 
occluded coronary arteries and the use of antithrombotic agents can together reduce case fatality 
rates by almost a third.144 
These treatments have not only reduce mortality acutely, and thus usually resulted in smaller 
infarct sizes, resulting in medium and long term benefits leading to a decrease in post-ischemic heart 
failure.145,146 
Major reductions are achievable by reducing case fatality rates in groups with larger numbers 
of patients or with the highest mortality risk. The treatment of the large and increasing pool of 
survivors of myocardial infarction and those who underwent coronary revascularization can reduce 
mortality substantially.144 The current strategies include the use of aspirin, statins, angiotensin 
converting enzyme inhibitors and rehabilitation.   
Patients admitted to hospital with heart failure experience a high mortality rate (about 50% at 
within 2 years), a mortality comparable with some common cancers.147 However the use of aspirin, 
angiotensin-converting enzyme inhibitors and spironolactone offered a substantial risk reduction of 
about 30%.144  
Although revascularization strategies are widely used and undoubtedly benefit individual 
patients, their contribution to population-wide mortality reduction is small.144,148,149 Moreover, only 
coronary artery bypass surgery [CABG] have shown definite mortality reduction effects, while 
percutaneous coronary interventions (PCI)  for revascularization in chronic angina has been proven 
not to be superior to adequate medical therapy.150  
Rehabilitation in CHD, both after acute myocardial infarction151 and in chronic settings 151,152  
showed a reduction of 20-30% in mortality, although in part the effect could be attributed to better 
use of other secondary prevention treatments and risk factor reductions.153 
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In modelling studies, the contribution of evidence-based treatments to the reduction in CHD 
mortality in many Western countries has ranged from 45 to 50% in the period 1980-2005.144,148,149   
3.9.2 Reducing CHD incidence 
Because of the comprehensive knowledge that has developed over the last 4 to 5 decades 
regarding CHD causation, reducing the risk of developing coronary heart disease in the first place is a 
primary goal to control disease burden. Prevention is important, since the reduction in case fatality 
rates achievable with evidence based therapies, still fail to substantially reduce the overall disease 
burden, as many people surviving myocardial infarction or living with heart failure has marked 
declines in their quality of life154 and consume a large proportion of health care resources.6  
Prevention will decrease the overall burden by not only decreasing mortality rates but also by 
prolonging the extent of life lived without disability.  
Two critical questions currently dominate the debate on prevention of cardiovascular disease: 
At which level of risk preventative interventions should be undertaken and at what age should it 
start? 
Prevention can be targeted at the individual level, by identifying those at high risk of coronary 
heart disease based on their age and the presence of risk factors. An assessment of the overall 
cardiovascular risk for an individual can be measured using risk functions. These are usually 
regression equations derived and validated in cohort studies, exploring the association of the major 
risk factors with CHD events and mortality.  Examples include the Framingham Risk Score, the 
EUROSCORE and Q RISK.155-157 
Once identified, these “high risk individuals” are selectively targeted to receive smoking 
cessation therapies, diet and physical activity advice, and specific medications, including anti-
hypertensive drugs and statins in certain situations.  
Although individual therapies have shown beneficial effects in high-risk individuals with 
hypertension or elevated lipids24,158, randomized clinical trials of multiple risk factor interventions 
have frequently shown disappointing results. Most programmes targeted at cardiovascular disease 
free participants failed to show reductions in events or mortality, or sustained improvements in the 
levels of risk factors.159 
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Another important limitation of these approach is the ability of the risk functions to 
adequately identify individuals at risk.160 Among Individuals classified at “high-risk” levels, an 
unacceptably large proportion of them may still not experience events. 161 Moreover, substantial 
residual risk might exist when only controlling risk factors levels with drugs, as generally the risk 
reduction achievable with successful blood pressure reduction or statins in primary prevention 
settings range from 15% to 25%.162,163 These strategies require substantial resource investments 
from the Health Services, and require patient compliance over the long term, and susceptible to the 
inverse care law.164 Is not surprising then that targeted intervention might result in an increase in 
socioeconomic inequalities.165 
The alternative approach is to attempt to reduce risk factor levels by shifting its distribution to 
lower levels across the entire population, a strategy championed by Geoffrey Rose.166 
This concept is based in the observation made originally by Wilhelmsen et al 167 that most 
cardiovascular events and deaths occur in individuals possessing risk factors levels near the 
population mean, and fewer events come from the relatively small numbers of individuals with high 
risk factor levels and corresponding much higher relative risks. This observation has been widely 
replicated, including in the British Regional Heart Study168, in Spain169 and in the Netherlands. 
(Monique Verschuren, personal communication)(Figure 3-2) 
Figure 3-2 Distribution of CHD risk, cases and cholesterol levels in the Dutch population (Verschuren 
M, personal communication)  
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The potential for reducing events by shifting the risk factor distribution is therefore 
substantial.  Emberson et al have looked at the potential gains for a shift in risk factor distribution of 
blood pressure, blood cholesterol or both as compared to only treating English persons with high 
levels of these risk factors, based on current guidelines.168 They found that if 6% of the population 
who is at ≥30% total CVD risk at 10 years is treated, a reduction of 11% could be achieved. 
Decreasing the threshold to ≥ 20%, it could reduce events by 34%, treating 26% of the population. A 
reduction of 10% in cholesterol and blood pressure, relatively modest, could achieve a 45% 
reduction in events.  However, an analysis by Manuel et al170 considered that the benefits from 
targeted strategies are higher than those achievable with the population approaches, in the 
Canadian population. They focused on cholesterol, and they found that targeting high-risk 
individuals would avoid 290 deaths per 100,000, while a population-wide, modest reduction in 
cholesterol will result in 42 per 100 000 fewer deaths. However, they modelled only a 2% reduction 
in population cholesterol levels, an extremely conservative goal. Far greater declines have been 
observed in Mauritius (15%) 171, and in North Karelia and Kuopio, Finland  (about 18%).172  
Shifting the population distribution of risk factors involves reducing mass exposure to risk 
factors or its determinants. For instance , governmental and Food Standards Agency actions in the 
UK resulted in a decline in salt consumption from 9.5 grams per day in 2000 to 8.6 grams per day in 
2008173. The US, Japan, Australia, Canada and Ireland achieved similar population wide reductions in 
salt intake.58 Furthermore, following the North Karelia project, Finland managed to substantially 
reduce population means of cholesterol and salt over a 30 years period.172,174 Similar progress have 
been achieved with tobacco legislation and taxation175, and by banning trans-fats.87 
Population level interventions, when correctly implemented, also have less potential to 
increase inequalities165, because they are not dependent on individual choice of more healthy or less 
risky behaviours. Population interventions are usually cost-saving and thus represent particularly 
good choices for resource-poor countries.176,177 
In terms of policy, the two options can be cost effective, even in low and middle-income 
countries, and probably complementary176,178, when resources are available. But in severely limited 
resource settings, population level interventions will probably incur in less direct costs and 
investment.178 
The polypill concept exploited the notion of achieving big reductions in disease burden by 
reducing risk in large subsets of the population at average risk. This concept, first introduced by Law 
et al in 2003179, consists in incorporating in a single tablet or capsule a combination of drugs to 
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reduce several cardiovascular risk factors simultaneously, each component with demonstrated 
efficacy in reducing risk factor levels and cardiovascular fatal and non fatal events in  randomized 
clinical trials. The concept has now been tested in clinical trials. Maleksadeh et al 180 found 
reductions in blood pressure and lipid levels, but with large attrition rates, with similar findings in 
the larger Indian Polycap study.181 However, none of these trials has looked at clinically important 
outcomes and both have a short duration [under a year].  Although these results are promising, the 
polypill strategy is still heavily dependent on choices made by practitioners and patients, and since 
its scalability is problematic, this may preclude its ability to reduce the burden of cardiovascular 
disease compared to population level interventions.  
3.9.3 Early start for preventative interventions 
The development of atherosclerosis is a long process, starting in the womb and ending with 
fatal vascular events. Multiple disease control strategies can be employed at different points in this 
timeline, but their potential to decrease morbidity and mortality necessary decrease as soon as the 
disease is clinically apparent. Preventative strategies thus have the biggest potential the earlier they 
are implemented, delaying or preventing the development of dangerously high levels of proximal 
risk factors in young adulthood.  
The concept of cardiovascular disease primordial prevention, pioneered by Strasser182 and 
championed by Labarthe183, is perhaps the earliest possible strategy to implement. Essentially, 
primordial prevention refers to strategies that preclude the development of adverse risk factor 
levels in the first place. However, this concept has not been widely adopted until recently, partly 
because now we have more evidence about the important of life course influences and early age risk 
factors trajectories as determinants of later life cardiovascular risk.  
 
3.10 CONCLUSIONS 
The causality of coronary heart disease has been comprehensively studied over the last five 
decades. The relationship of cardiovascular disease occurrence (mainly coronary heart disease and 
stroke) with diet, smoking and other lifestyle factors is now well established. The role of biological, 
downstream risk factors and their link with more upstream determinants has also been established 
with increasing confidence. As a result, many potential targets for intervention exist and now form 
the basis for modern cardiovascular disease prevention strategies. Furthermore, when deciding 
46 
 
actions to control the future disease burden, searching for new risk factors might be considered an 
activity of secondary importance  
The current paradigm in disease causation usually assumes that the development of clinical 
cardiovascular disease takes decades, as the atherosclerotic plaque slowly build-ups until it reaches 
a critical point when sudden occlusion (often the result of thrombotic and inflammatory changes in 
the plaque environment) leads to clinical events, including death. 
A corollary of this reasoning is that prevention might also take decades to reverse these 
processes, before showing any benefits. The timescales for change and the speed of change after 
any intervention are therefore of crucial importance from a public health perspective. Any public 
health strategy, either individual high-risk targeting or the population wide approach, might then be 
expected to deliver its benefits only over the long term. That concept will be further scrutinised later 
in this thesis. 
This knowledge of CHD aetiology has been developed while the Western world experienced a 
marked decline in cardiovascular disease mortality. This much acclaimed decline attracted a lot of 
attention, particularly in identifying the drivers of these changes.  This story is one of success and is 
very much celebrated. It has helped to understand and to refine the causal paradigm of 
cardiovascular disease and to drive attention to monitoring mortality trends as a measure of our 
understanding of the efficacy of interventions aimed to control disease burden.  
In the next chapter, I will review our existing knowledge regarding coronary heart disease 
mortality trends, and discuss their possible underlying drivers.   
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4 CURRENT TRENDS IN CHD MORTALITY: DETERMINANTS 
AND SPEED OF CHANGE 
 
 
4.1 INTRODUCTION 
Perhaps one of the most interesting epidemiological phenomena was the massive decline in 
CHD mortality observed in Western countries occurring since the 1960s. This is reflected in many 
opening sentences in cardiology research papers and textbooks, probably second only to the other 
statement emphasising the enormity of the CHD as a public health problem.  
In CHD epidemiology, the important question about to what are the drivers of the decline in 
CHD mortality has been asked in a meeting of the National Heart, Lung and Blood Institute held at 
Bethesda, USA in 1978.184 This conference debated extensively the contribution of changes in 
incidence (as a proxy of a change in disease determinants) or in case fatality (suggesting the effect of 
medical treatments) as explanations for the decline in CHD mortality. 
Although is assumed that incidence is the most appropriate outcome measure to use when 
looking for answers to the question asked by the Bethesda Conference, measuring it at the 
population level is a difficult task and only few studies have managed to  achieve this.  
Many studies relied on coronary heart disease mortality. Although not an absolute correlate 
of incidence, CHD mortality rates has been considered as a good proxies for it, particularly since our 
knowledge of risk factor effects and  the impact of medical treatments on population mortality and 
case fatality rates has been better understood.144 Moreover, is easier to measure than incidence, 
allowing examining trends over longer period of time using readily available data.  
Although mortality coding and changing definitions might add noise to these trends, the 
quality of its registration and coding has been substantially improved, particularly in the most recent 
decades and in high-income countries.185 
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4.2 ANALYZING AGE-ADJUSTED AND AGE-SPECIFIC TRENDS 
Classically, CHD mortality trends are analysed adjusting them for age, to remove the 
confounding effects of ageing (a risk factor that cannot be modified) and thus make the trend a 
better reflection of those other disease determinants that might be more responsive to intervention. 
However, much emphasis has been put on age adjusted rates as oppose to age specific ones, 
and also little attention has been paid to direction and pace of change, probably because the 
analysis has mostly focused on Western populations experiencing constant declines since the 1970s. 
The Russian mortality crisis 99, studies on Chinese CHD trends 186 and central European CHD mortality 
trends187 showed that decline is not necessarily a universal phenomenon.  
I have discussed that some risk factors are showing adverse increasing trends, particularly 
diabetes and obesity, while in some countries and particularly in the young, risk factors like smoking 
and systolic blood pressure are declining at a lower rate in recent years.  
Age, cohort and period effects are important considerations, since they might offer insights on 
changing exposures. Rose suggested that cohort effects are possible in connection to the Barker 
Hypothesis on early life origins of CHD (See chapter 3)188, or perhaps by later in life to cohort-
specific exposures. Moreover, Wilson et al suggested that recent cohort effects in young people 
can’t be excluded for young adults in an analysis of Australian CHD mortality up to 1992189. However, 
is difficult to find any other evidence of cohorts effects.116 The only exceptions are Singapore190 and 
Norway where the decline started earlier in younger cohorts.191 However, these papers looked at the 
periods around the peak of incidence of the epidemic (1970s-1980s). If these analysis are extended 
further in time, the evidence for cohorts effects disappear.116  
More recently, adverse age-specific effects have been identified.  Ford et al 192 recently 
described a flattening in CHD mortality in the US population, particularly in young adults, starting in 
2000, although based only in a couple of years of data. This is consistent with adverse risk factors 
trends in the younger age groups and is therefore of concern. 
The use of age-adjusted rate might conceal important age and gender specific trends that 
could shed light on ongoing changes in trends in disease determinants, highlighting the importance 
to observe in more detail those age specific effects.  
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4.3 TEMPORAL EVOLUTION OF THE CHD EPIDEMIC 
Geoffrey Rose developed the idea that the CHD epidemic is essentially the same epidemic in 
all countries 188, sharing the same determinants but happening at different times. It is possible then 
to describe CHD epidemics in terms of waxing and waning “rates increase” and “rates decline” 
phases.  
This concept can be better understood by considering the peak year of the epidemic as the 
starting point for the decline phase of the epidemic in a given country or defined population.  The 
decline of CHD mortality in the US started earlier in California, Maryland and the District of Columbia 
(towards 1960) than in the southeast states, were the decline started later (towards 1965).193  In 
most Western countries the CHD epidemic peaked during the 1970-1980s and then entered the 
decline phase whereas Central European countries, peaked later (1990s) and since then has shown 
dramatic declines. Some countries, particularly China and some former Soviet Socialist Republics still 
are in the “increase phase”, while low income and middle-income economies only experienced this 
recently. Some countries however, are in a “plateau” phase, were rates change little.194 
The pace of change can also be different, even in countries in the same phase of the epidemic. 
For example, Ireland showed faster rates of decline than the UK or Finland in the period 1985–
2006.195 Interestingly, risk factors contributions to the observed trend also varied across countries 
experiencing the same phase of the epidemic. For example, changes in risk factors exposure 
contributed the most to the observed decline in mortality in the Scandinavian countries (about 
70%)148,196 while in the UK and USA the contributions of risk factors and treatments were more 
balanced.144,149 
The value of studying trends in mortality thus resides in not only estimating the temporal 
evolution of coronary heart disease burden, but also in gaining insights on what is driving the 
epidemics in a specific population. 
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4.4 WHAT DRIVES THE TRENDS? INSIGHTS FROM OBSERVATIONAL AND MODELLING 
STUDIES 
Framingham is the paradigmatic study describing the relationship of the major risk factors to 
CHD incidence, and the Seven Countries Study showed that they are important in a range of 
populations, finding recently confirmed by the Asia Pacific Cohorts, the Prospective Studies 
Collaboration and the INTERHEART study.  
However not many studies have addressed the question of what drives these trend as raised 
by the Bethesda conference. Because this question cannot be practically addressed with randomized 
controlled trials, it has been mainly studied using observational designs and more recently, 
modelling studies.  
I will describe some of the major studies that provided evidence to explain what drives CHD 
mortality trends. One of them is the MONICA, a large international observational study and two 
modelling studies, the US CHD Policy model and the IMPACT model. Finally, I will discuss Finland, a 
country where both observational and modelling evidence is available.  
The MONICA Study20: 
Together with the Seven Countries Study and the Framingham Study, the MONICA Project 
(Multinational MONItoring of trends and determinants in CArdiovascular disease) helped to establish 
our current understanding of the epidemiology and control of cardiovascular disease. MONICA 
objectives  were first to observe the trends in CVD mortality and morbidity and second to evaluate  
the extent to which these trends were related to changes in known risk factors, including daily living 
habits, health care, and major socioeconomic features. The study was conducted in 38 populations 
in 21 different countries starting in 1980 and finalizing data collection by the late 1990s. They 
assessed the contribution of risk factors to CHD incidence rates by looking at the association 
between 10 year trends in major risk factors (smoking, blood pressure and blood cholesterol) and 10 
years trends in incidence (fatal and non fatal events). Careful biochemical measurements and strict 
event ascertainment and death certification procedures were key features of this exemplar study. 
They monitored almost 13 million people over 10 years, and more than 300,000 men and women 
were sampled and examined for risk factors. During the 10 year period they registered 166,000 
myocardial infarctions.  
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In the MONICA populations, CHD mortality rates fell 4% per year. About two thirds of the 
observed fall could be attributed to the fall in event rates, while one third could be attributed to a 
fall in case fatality20. However, they were unable to precisely quantify how much of these falls could 
be attributed to changes in risk factors18 or to evidence based treatments.19 The effect of individual 
risk factors on risk was lower than the observed in the cohort studies. In part, this can be attributed 
that to some extent, the analysis in the MONICA study are at the ecological level, and that they were 
not corrected for dilution regression bias. When the association in cohort studies is explored without 
taking into account this bias, the results are similar.148,197  
US CHD Policy Model198 
The US CHD Policy model is a state-transition, cell based model developed in the1980s.198 It 
was initially used to examine trends in CHD mortality199,200 and expected gains in life expectancy 
from risk factor modifications.201 This model was also used to evaluate the cost-effectiveness of 
specific medical interventions for primary and secondary prevention of CHD202-204, salt reduction 
policies205 and health promotion activities.206. The model showed that in the US population and for 
the period 1980-1990 risk factor changes contributed 50% to the mortality decline while treatments 
contributed 43%.  
IMPACT  
IMPACT is a cell-based model originally developed by Capewell and colleagues in 1996.5 Using 
a MS EXCEL spreadsheet, this model combines data from many sources on patient numbers, 
treatment uptake, treatment effectiveness, risk factor trends and consequent mortality effects. The 
deaths prevented or postponed (DPPs) over a specified period are then estimated. The model can be 
used to estimate the proportion of change in mortality attributable to specific treatments or risk 
factor changes. It can also estimate the future consequences of altering treatment strategies and 
changing population risk. The model also estimates life years gained and cost-effectiveness for 
specific interventions. 
IMPACT, an ongoing project, has been used to explore the contributions of risk factors and 
treatments in over 10 countries. In most of the studied countries (New Zealand, Scotland, England & 
Wales, Sweden, Italy, Spain, Iceland, USA and Canada) CHD mortality rates has been declining. The 
IMPACT model consistently found that about 40 to 72% of the fall in deaths could be attributed to 
risk factors changes and 23 to 55% to treatments.144 An interesting observation from IMPACT 
modelling related to the City of Beijing, were CHD trends were increasing, essentially driven by a 
52 
 
huge increase in cholesterol levels. This might be related to the rapid adoption of a “Westernized”  
diet, rich in saturated fats.186 
Particularly interesting are the recent findings in central European populations, were rapid 
declines in mortality has been observed after decades of increasing rates and linked to profound 
socio-economic changes resulting in substantial modification of the exposure to CHD risk factors.  I 
will describe in chapter 6 an analysis using the IMPACT model of the trend determinants for one of 
the most interesting countries in the region, Poland, which experienced a dramatic decline in CHD 
mortality since the 90s. I will also use the IMPACT model to study recent English trends by 
socioeconomic status (chapter 7) Methodological details of the model will be presented in the 
relevant sections and in appendices 2 and 4.  
Finland: Observational and modelling studies  
Finland experienced a marked decline in CHD mortality during the 20th century, associated 
with the implementation of nationwide, population level policies. Trends in mortality and in the 
major risk factors were then closely monitored. Thus detailed analysis of the period of sustained 
declined between 1972-2006 is available.207  
Serum cholesterol declined significantly in both men and women over that period. Blood 
pressure declined up to 2002, but levelled afterward. Smoking followed a more complex pattern, 
declining in men but increasing in women until 2002, and levelling off since then. BMI increase in 
men throughout the period and in women started to increase in 1982.  
Collectively, the changes in risk factors explained about 60% of the 80% observed decline in 
CHD mortality.  
The Finnish IMPACT model148 found similar contributions of risk factors to that observed by 
Vartianen et al. In this modelling exercise, risk factors explained 48 to72% of the observed fall in 
coronary heart disease mortality between 1982-1997, while medical treatments explained 23%, 
consistent with the observational data.148 
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4.5 CONCLUSIONS 
Although still there is not a definitive answer to the question posed at the Bethesda 
conference, insights coming from observational and modelling studies suggest that both risk factors 
and medical treatments contributed substantially to the observed trends in CHD mortality.  
The fact that the current epidemics across the globe are at different stages and that rates are 
increasing in many countries makes current study of these trends pertinent, especially given the 
alarming increases in obesity and diabetes.  
However, the current emphasis on monitoring trends using age-adjusted rates might present 
an incomplete picture of the state of the epidemic in individual countries, because this might 
conceal important differences in age-specific patterns that might mark the beginning of a new phase 
in the CHD epidemic.  
The decades long decline in age adjusted trends in the Western world convey the idea that 
trends are invariably longstanding, almost set in stone. In the next chapter, I will challenge this cosy 
concept, by studying recent changes in the pattern of the CHD epidemic in a variety of Western 
countries. 
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5 STUDIES ON RECENT TRENDS IN CORONARY HEART 
DISEASE MORTALITY RATES: ENGLAND & WALES, 
AUSTRALIA AND THE NETHERLANDS  
 
 
5.1 INTRODUCTION 
Most of our knowledge about the temporal evolution of the CHD epidemic was obtained from 
age-adjusted analysis of the CHD mortality rate. As discussed in chapter 4, emerging age-specific 
patterns are suggestive that this decline may not necessarily last forever. Detailed analysis of the 
temporal evolution of the rate of change of trends has been usually overlooked, or merely described 
as a relative change over a period and therefore assumed to be linear. However, trends can be more 
complex, and identifying periods where the trend change at a different speed might help us to 
better understand the underlying drivers.  
In the following section, I will discuss the main methodological approach used in analyzing 
temporal dynamics of CHD mortality trends. I will then use this method to study recent trends in 
England & Wales, Australia and the Netherlands. In the following chapters, I will examine trends in 
Poland, Scotland and England, focusing on the underlying determinants (drivers).  
5.2 METHODS: TREND ANALYSIS USING JOINPOINT REGRESSION  
This section describes the approaches I used for the trend analyses presented in this thesis. 
Details on specific issues relevant to each setting will be described in the methods section of each 
analysis.  
The key question to answer is whether the rate of change varies in different time periods.  
Most of the descriptive analyses on CHD trends have relied on simple qualitative trend 
descriptions. However, more formal trend analysis have rarely been done, except in the field of 
environmental CHD epidemiology129. Regression methods have been used to explain trends in terms 
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of risk factor contributions18; but the question of direction and speed of change in CHD epidemiology 
has not been formally addressed. In part, this can be attributable to the slow adoption of change-
point methods in cardiovascular epidemiology. This type of time series analysis look at trends trying 
to identify points where the trend change and is commonly used in fields like cancer epidemiology, 
econometrics and statistical process control.208  
One of these methods is the Joinpoint Regression Analysis approach.  This was developed by 
the U.S. National Cancer Institute with the purpose of describing change in cancer rates in terms of 
pace of change, direction of that change and statistical significance.209  
Joinpoint regression models explore the trend data to find points in time (“joinpoints”) 
defining segments where the trend has a constant pace of change. The method starts by assuming 
that there are no “joinpoints” thus, the entire trend has the same rate of change. Then, it iteratively 
adds joinpoints by performing a “grid search” (looking for points in time that minimize the error on 
the change of the rate) and thus identifying the years where the trend rate of change might vary, 
effectively identifying the “joinpoints”. Then, it formally tests whether these additional joinpoint 
creates segments with different rate of change. Statistical significance is tested using a Montecarlo 
permutation method. Permutation test method and the Bayesian Information criterion method offer 
two alternative goodness of fit approaches to select the optimal number of joinpoints. The 
Permutation test approach uses a sequence of permutation tests to select the number of joinpoint 
and controls the error probability of selecting the wrong model at a certain level (i.e. 0.05) using the 
Bonferroni multiple comparisons adjustment. The Bayesian Information criterion method (BIC) 
approach finds the model with the best fit by penalizing the cost of extra parameters, favouring 
trends with fewer segments. The models selected by BIC tend to fit the data well but are less 
parsimonious.  The PT approach has worked well for cancer incidence and mortality data, however 
little experience is available in the cardiovascular literature, although the results of both approaches 
are generally concordant (see appendix A1).  Information of the uncertainty around the rate of 
change and the time of the point of change in the trend can also be obtained.  
Identifying patterns in a trend is thus the main goal of the approach. Figure 5-1 and 5-2 
illustrate an example of this analysis. Figure 5-1 shows a rate plotted over time. The trend appears 
complex, with a period of decline that seems to have changed around 1988, continuing a slow 
decline or even a flat pattern. 
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Figure 5-1 An observed trend for a rate (simulated data) 
  
 
A joinpoint regression analysis on this data (Figure 5-2), found two distinct periods in the 
trend. The point of change has been located in 1991, with a 95% confidence interval of having 
occurred in 1987 or 1994. This point creates two segments of different rate of change. The first 
segment started in 1976 and ended in 1991 with an annual percent change of - 5.3% (95% CI -6.6% 
to -3.9%), statistically significantly different from a 0% rate of change.  
The last segment of the trend shows a “flat” pattern, starting in 1991 and ending in 2006, 
where the annual rate of change was 0% (-1.7% to 1.7%). Models with 0, 2, 3 or 4 joinpoints were 
rejected using the Bayesian Information Criterion (BIC) approach for model selection. The key 
strength of this technique is to avoid the detection of biased patterns when the trend is described 
subjectively using observer defined time intervals. The observer might bias in several ways the 
choice of periods for estimating summaries of the rate of change of the trend, based on prior 
knowledge or because the trend shows curious patterns. Joinpoint avoids this by essentially 
removing the observer from the selection process, instead using a formal and objective exploration 
of the time-series data space.    
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Figure 5-2 Observed and joinpoint modelled rates (simulated) 
  
 
In the next sections, I will use this approach to examine recent interesting phenomena 
observable in CHD mortality trends in a variety of different countries.  Flattening of previously falling 
CHD mortality rates has recently been reported among young adults in the US, perhaps reflecting 
changes in specific risk factors. Since young adults in many other Western countries are also now 
showing complex risk factor trends, a similar flattening in mortality rates patterns is distinctly 
possible.  
I will start by describing recent trends in CHD mortality in England & Wales, particularly 
amongst young adults, and then I will look for recent trend patterns in Australia and the 
Netherlands. Later I will examine recent trends in Poland and its determinants, and trends by 
socioeconomic status in Scotland and England.  
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5.3 CORONARY HEART DISEASE TRENDS IN ENGLAND AND WALES FROM 1984 TO 2004: 
CONCEALED LEVELLING OF MORTALITY RATES AMONG YOUNG ADULTS 
5.3.1 Introduction 
In the UK, mortality rates from coronary heart disease have continued to decline steadily since 
the late 1960s.6 Improvements in population risk factors and in medical treatments for CHD patients 
have both contributed substantially to the declines seen between 1981 and 2000.149 Nevertheless, 
coronary heart disease [CHD] remains the leading cause of death and exacts a heavy social and 
economic toll. Furthermore, concern has recently been expressed that in the USA the rate of decline 
in mortality from CHD has slowed during the 1990s compared to earlier decades.210  
Does the UK risk follow US trends? The increases in the prevalence of obesity and diabetes in 
the UK since the 1980s are potential warning signs that the hard fought gains in cardiovascular 
mortality improvements might be arrested or even reversed.211,212  Furthermore, the declines in total 
cholesterol concentrations during the 1990s have been modest,  even though prescribing of statins 
has escalated.213,214 Although tobacco use continues to decline, the adult prevalence of smoking still 
remains well above 20%; moreover, the large number of UK adults who are totally sedentary during 
leisure-time has probably increased since the 1990s.213 As a result of these conflicting trends in the 
various risk factors, the earlier falls in CHD deaths may soon be blunted.212  
Unfavourable trends in some cardiovascular risk factors have been particularly worrying 
among younger adults. Between 1993 and 2003, some of the largest relative increases in obesity and 
diabetes have occurred among adults aged less than 45 years. 213 Furthermore, mean concentrations 
of cholesterol dropped little or even increased among some of the younger age groups.213 Moreover, 
the previous decline in smoking rates may be levelling off among young adults, the smallest 
reduction have been seen in men aged 25-34.6 Thus, it is reasonable to hypothesize those adverse 
trends in CHD mortality rates may be detected first among young adults.  
Although previous reports have emphasized the continuing declines in the age-adjusted CHD 
mortality rate among UK adults6, trends in age-specific rates have received little attention. The 
objective of our study was therefore to examine trends in the age-specific rates for coronary heart 
disease among UK adults from 1984-2004, particularly among younger adults. 
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5.3.2 Methods 
Vital statistics data were obtained for the England and Wales. 6,211 We limited our analyses to 
people aged 35 years and older. The underlying cause of death from coronary heart disease was 
determined using the International Classification of Diseases (ICD)-9 codes 410-414 for 1984-1998 
and ICD-10 codes I20-I25 for 1999-2004. Population counts from the England and Wales census were 
used to calculate rates. We used census counts for the years 1981, 1991, and 2001 and inter-censal 
estimates for the other years. Age-adjustment was performed using the direct standardization 
method to the estimated England and Wales population of the year 2001.   
Plots of mortality rates were smoothed using 5-year moving averages.  A Joinpoint regression 
was fitted to provide estimated annual percentage change and to detect points in time where 
significant changes in the trends occur (JOINPOINT software version 3.0), and we used a Bayesian 
Information Criterion (BIC) approach to select the most parsimonious model that fits best the 
data.209,215  A maximum number of 3 joinpoints was allowed for estimations. For each annual 
percentage change estimate, we also calculated the corresponding 95% confidence interval (95% CI).  
5.3.3 Results 
The overall age-adjusted mortality rate for coronary heart disease declined from 1984 to 
2004, by 54.7% in men and 48.3% in women (Figure 5-3). The average annual rate of decline for men 
was 2.7% during the 1980s increasing to 3.7% during the 1990s (1.7% in women increasing to 3.5%). 
From 2000 through 2004, the average annual rate of decline was even greater, 5.4% for men (and 
4.2 % for women).  
The overall age-adjusted rates concealed striking differences in the age-specific rates, as 
shown in Figure 5-4 and Table 5-1.  Comparing the first and last period identified in the joinpoint 
regression analysis, the rate of decline has slowed for men aged 35-44 and 45-54 (reduction in the 
annual percent change of 35% and 47% respectively). Furthermore, for men aged 35-44, the annual 
percent change for the period 2000-2004 was not significantly different from 0, although is based on 
a period of 4 years .  For older men (aged over 55), the rate of decline continued to increase 
throughout the period. 
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Figure 5-3 Trends in age-adjusted mortality rates from coronary heart disease for England and Wales 
adults aged 35+ years, 1984-2004 
 
 
Among women aged 45-54, the annual percent change was reduced by about 39% in the 
period 1998-2004 (Table 5-1). Rates in the age group 35-44 apparently continued to decline however 
the numbers of events were very low. (Figure 5-5) 
Data on model fit and selection is presented in Appendix 1A1. Both the BIC and the 
permutation test approach identified similar periods and estimated annual percent changes. 
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Figure 5-4    Trends in age-specific coronary heart disease mortality rates and 5 year moving 
averages for men  aged 35+ years, England and Wales, 1984-2004 
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Figure 5-5 Trends in age-specific coronary heart disease mortality rates and 5 year moving averages 
for women  aged 35+ years in England and Wales, 1984-2004 
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Table 5-1  Joinpoint analysis: Trends in age-specific coronary heart disease mortality rates England 
and Wales 1984-2004 [adults aged 35+ years] 
  
Men 
 
Women 
  
Period EAPC 95%CI 
 
Period EAPC 95%CI 
35-44 
 
84-91 -3.7* (-4.8,-2.6) 
 
84-04 -3.2* (-3.6,-2.9) 
  
91-00 -6.9* (-7.91,5.8) 
    
  
00-04 -2.4 (5.9,1.4) 
    
         45-54 
 
84-87 -3.4* (-5.6,-1.1) 
 
84-90 -6.6* (-7.8,-5.3) 
  
87-94 -9.4* (-10.2,-8.5) 
 
90-95 -8.9* (-11.6,-6.2) 
  
94-99 -5.8* (-7.8,-3.8) 
 
95-04 -3.5* (-4.5,-2.5) 
  
99-04 -1.8* (-3.4,-0.2) 
    
         55-64 
 
84-87 -1.5* (-2.9,0.01) 
 
84-90 -1.6* (-2.7,-0.5) 
  
87-93 -4.8* (-5.5,-4.5) 
 
90-98 -6.6* (-7.6,-5.6) 
  
93-98 -6.4* (-7.8,-5.3) 
 
98-04 -11.3 (-12.9,-9.6) 
  
98-04 -9.5* (-10.2,-8.8) 
    
         65-74 
 
84-93 -3.8* (-4.1,-3.5) 
 
84-92 -2.8* (-3.3,-2.4) 
  
93-99 -4.8* (-5.7,-3.9) 
 
92-99 -4.5* (-5.2,-3.7) 
  
99-04 -8.3* (-9.4,-7.2) 
 
99-04 -8.3* (-9.5,-7.1) 
         75+ 
 
84-89 -4.6* (-5.8,-3.3) 
 
84-88 -3.5* (-5.5,-1.4) 
  
89-94 -1.3 (-3.2,0.5) 
 
88-93 0.9 (-3.1,1.2) 
  
94-04 -6.1* (-6.6,-5.6) 
 
93-00 -4.9* (-6.1,-3.7) 
      
00-04 -2.7* (-5.2,-0.1) 
         EAPC: Annual percent change 
* Significantly different from 0 
 
5.3.4 Interpretation 
Recent trends for coronary heart disease mortality in younger UK adults are disquieting. The 
previous falls in age-specific mortality rates appear to be flattening in men and women aged less 
than 55 years. Thus far, rates in older adults continue to decline.  These patterns are confirmed 
when formally examining the absolute annual changes in rates.  
As I discussed in chapter 4, changes in CHD mortality rates generally reflect changes in 
incidence rate and, to a lesser extent, case-fatality rate. 20 Unfortunately, unbiased data about CHD 
incidence in the UK are limited, especially in younger groups.  Studies using hospitalization rates 
represent a proxy that can be difficult to interpret. 216  However, population-based data from 
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Scotland and from the two UK MONICA centres reported substantial decreases in CHD incidence 
from the mid 1980s to the mid 1990s20,217,218 which continued beyond 2000.219 Case fatality following 
myocardial infarction has also improved since the mid 1980s. 20,220 
The flattening English coronary mortality rate trends during the 1990s among those aged 
under 55 years require explanation. These trends have occurred in spite of the increasing use of 
evidence-based therapies such as angioplasty, thrombolysis and angiotensin-converting enzyme 
inhibitors.149 This suggests that unfavourable recent trends in risk factors in young adults may 
explain these changes, specifically increases in obesity and diabetes compounded by stable 
cholesterol levels and a smoking prevalence stubbornly persisting above 25%.213 Material 
deprivation could be also an important factor in younger adults.  In this age group, deprivation is 
strongly associated with CHD mortality and could be understood as an upstream risk factor for 
coronary heart disease acting through the established risk factors as mediators (see chapter 3).221,222  
This is a potential target population for intervention, although it could be more effective to influence 
risk factor prevalence through population level interventions.223 
The flattening of the mortality trend in young adults I found in England & Wales is a recent 
phenomenon, and is consistent over 4 years. More evidence is needed, particularly to assess if this is 
a transient or an ongoing phenomenon. As we know that the phenomenon seems to be happening 
in the US, looking at trends in other countries could help to further understand it. The flattening 
trends in CHD mortality rates among younger adults, if continue, suggest that the cardiovascular 
disease epidemic is not being fully controlled. This is a crucial aspect that requires further attention.  
In the next section, I will discuss recent Australian trend data, where evidence of flattening 
was first suggested in the 1990s in the youngest adult cohorts. This provides a unique opportunity to 
explore if the flattening is a transient phenomenon or a more sustained population process.  
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5.4 THE DECLINE IN CORONARY HEART DISEASE MORTALITY IS ALSO SLOWING IN 
YOUNG ADULTS IN AUSTRALIA (1976-2006) 
5.4.1 Introduction 
Australia has been one of the countries that experienced the decline in coronary heart disease 
mortality in the last four decades. CHD mortality has been continuously decreasing116, as in most 
Western countries194,  with approximately 2/3 of the decline attributable to changes in risk factors 
and 1/3 to evidence based treatments.20,144,148,224,225 In Australia and New Zealand, a larger 
proportion of the decline has been attributed to changes in risk factors, about 80%.226,227 
 Nevertheless, because of population ageing, coronary heart disease will continue to exert a 
heavy burden for both developed and developing countries. 228,229 
 A slowing of the decline in coronary heart disease mortality is apparently occurring recently in 
young adults in the US192 and in the UK (section 5.3).  These changes probably reflect attenuation of 
declines, arrest or reversal of trends in major risk factors, since dramatic deterioration of medical 
care in this age group appears unlikely in developed countries.192,230,231  
However, the changes in the USA, England & Wales showed these changes in the rate of 
decline only recently and for a period of 2 to 4 years. This raises the question about whether this 
phenomenon is sustained or transient.  
In Australia, like in most Western countries, age-adjusted coronary heart disease mortality 
rates have also been declining over the last three decades. However, a report from Wilson et al 
suggested that the rate of decline for the most recent birth cohorts (aged 25-40 years in 1992) 
slowed or even ceased around the 1990s.189 
The aim of the following section is therefore to examine more recent age and gender specific 
trends in Australian CHD mortality between 1976 and 2006, to look for evidence of continuation of 
the flattening reported in the 90s. 
5.4.2 Methods 
Vital statistics data including population numbers were obtained from the General Record of 
Incidence of Mortality (Australian Institute of Health and Welfare) for the period 1976 to 2006.232 
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The underlying cause of death from coronary heart disease was determined using the International 
Classification of Diseases (ICD) 8 and 9 codes 410-414 for 1976-1996 and ICD-10 codes I20-I25 for 
1996-2006.  Age-adjustment was performed using the direct method to the estimated Australian 
population of the year 2001.  
We fitted a Joinpoint regression to provide estimated annual percentage change and to detect 
points in time at which significant changes in the trends occurred (Joinpoint Regression Program, 
version 3.4).215 We used a BIC approach to select the most parsimonious model that best fitted the 
data allowing a maximum of three joinpoints for estimations. 95% confidence intervals were 
calculated for each estimate of annual percentage change.   
5.4.3 Results 
From 1976 to 2006, the overall age-adjusted mortality rate for coronary heart disease 
declined by 73% in men and 70% in women (Figure 5-6). The average annual rate of decline over the 
entire period was 4.3% for men and 3.9% for women. The last ten years showed a slightly higher 
average annual rate of decline 5.8% for men and women. 
The age-adjusted rates concealed striking differences in the age-specific rates (Figure 5-7, 
Figure 5-8 and Table 5-2). The decline in mortality continued for men and women above 55 years. 
However, for men aged 25-34 years, the annual percentage change for the period 1991-2006 was 
not significantly different from 0 (95% CI:-1.6 to 1.6)(Table 5-2). 
For men aged 35-44 the decline in mortality rates started in 1992 and the annual percent 
change was 61% less, comparing 1992-2006 with 1976-92.  In men aged 45-54 years, the annual 
percent change was 44% less in 1994-2006 compared with 1976-94.  
A similar flattening was also seen in young women.  Among women aged 25-34 years, the rate 
mortality rate decline lessened from 1980 onwards, and the annual percent change was 97% slower 
in the period 1980-06 compared with the period 1976-80.  Furthermore, for both periods the rate of 
decline was not significantly different from zero. For women aged 35-44 years, the annual 
percentage change in 1988-2006 decreased by 82% compared to 1976-1988. For women aged 45-54 
years, the decrease in the average annual rate of change in the period 1991-2006 was 59% lower 
than in the period 1986-1991 (Table 5-2).  
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Figure 5-6 Trends in age-adjusted mortality rate from coronary heart disease for Australia,  adults 
aged 25+ years, 1976-2006 
 
5.4.4 Interpretation 
The overall decline in age-adjusted CHD mortality rates in Australia since 1980 conceals an 
important change in younger adults.  This recent slowing in the rate of mortality decline is occurring 
in both men and women aged below 45 years.  This mortality flattening first occurred in the 1980s in 
the youngest age groups, and started later around 1991-1994 for those aged 45 to 54 years.  
The attenuation in CHD mortality decline probably started in the early 1990s among male 
cohorts born between 1955 and 1964, as reported by Wilson et al189. The flattening in younger 
women was not initially apparent in this analysis. This probably simply reflects the different time 
periods analyzed by Wilson and in the way Joinpoint uses an unbiased statistical approach to best 
select the period of similar rate of change.  
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Figure 5-7 Observed and estimated trends in CHD mortality by age, Australian men 1976-2006 
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Figure 5-8 Observed and estimated trends in CHD mortality by age, Australian women 1976-2006 
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Table 5-2  Joinpoint analysis: Trends in age-specific coronary heart disease mortality rates in Australia 1979-2006 [men and women, aged 25+ years] 
Men 
 
Women 
Age Period EAPC Lower CI Upper CI 
 
Age Period EAPC Lower CI Upper CI 
25-34 1976 1991 -3.8* -5.2 -2.3 
 
25-34 1976 1980 -19.6 -36.4 1.7 
 
1991 2006 0 -1.6 1.6 
  
1979 2006 -0.5 -1.5 0.5 
             35-44 1976 1992 -5.6* -6.2 -5 
 
35-44 1976 1988 -9.4* -10.7 -8 
 
1992 2006 -2.2* -3.2 -1.2 
  
1988 2006 -1.7* -2.7 -0.8 
             45-54 1976 1982 -5.6* -6.6 -4.5 
 
45-54 1976 1986 -5.7* -6.8 -4.5 
 
1982 1994 -7.2* -7.7 -6.6 
  
1986 1991 -11.5* -17 -5.6 
 
1994 2006 -4.0* -4.5 -3.4 
  
1991 2006 -4.7* -5.7 -3.8 
             55-64 1976 1988 -4.7* -5 -4.4 
 
55-64 1976 1992 -5.1* -5.4 -4.8 
 
1988 2006 -7.0* -7.2 -6.8 
  
1992 2006 -8.9* -9.5 -8.3 
             65-74 1976 1985 -3.2* -3.7 -2.7 
 
65-74 1976 1980 -4.5* -5.8 -3.2 
 
1985 1997 -5.0* -5.4 -4.6 
  
1980 1987 -2.1* -2.8 -1.3 
 
1997 2006 -8.5* -9.21 -7.9 
  
1987 2000 -6.5* -6.8 -6.2 
        
2000 2006 -11.2* -12.4 -10.1 
             75-84 1976 1979 -5.8* -9.3 -2.3 
 
75-84 1976 1980 -4.4* -6.8 -1.8 
 
1979 1982 0.2 -7 8 
  
1980 1987 -1 -2.3 0.4 
 
1982 1995 -2.8 -3.1 -2.4 
  
1987 1994 -3.0* -4.3 -1.8 
 
1995 2006 -6.6 -7.1 -6.2 
  
1994 2006 -6.6* -7.1 -6.2 
             85+ 1976 1996 -1.3* -1.7 -1 
 
85+ 1976 1979 -5.7* -10.3 -0.9 
 
1996 2006 -3.2 -4 -2.4 
  
1979 1994 -0.3 -0.7 0.2 
        
1994 2006 -3.0* -3.4 -2.6 
CI: confidence interval. EAPC: Estimated annual percentage change. *significantly different from 0 
7
0 
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These results are also consistent with findings described in other populations. In the US, Ford 
and Capewell192 described a similar phenomenon in young men aged under 45 years, commencing in 
the 1990s, an in England & Wales trends as I described in section 5.3.  
The reasons for the attenuation of the CHD mortality decline in Australia, the US and England 
& Wales remain unclear. A marked deterioration of clinical care in these high-income countries 
seems implausible.  Indeed, in the US and the UK, the uptake of evidence-based treatment has been 
steadily increasing in recent decades, although there is room for further improvement.144,225 
Probably the most plausible explanation must be adverse changes in trends in major CHD risk 
factors, reflecting lifestyle changes in young and middle aged adults. As I discussed in section 4.4, a 
growing body of evidence suggests that 45%-70% of the recent decline in CHD mortality could be 
attributed to a decrease in risk factors.144,148,186,200,233 Furthermore it has been estimated in Australia 
and New Zealand, using a different methodology, that the decline in risk factors could explain 74% of 
the decline in CHD mortality in men`, and 84% in women.226,227 
Might age specific differences in risk factor changes therefore perhaps explain these recent 
differences in the rate of decline by age?  In Australia, risk factor trends over the last decades have 
shown a complex picture.  Blood pressure and serum cholesterol have all decreased across the 
entire population226 in men and women from 1990 to 2001. The proportion of energy consumed as 
fat has also been decreased significantly over the period.234,235 
Smoking reached a nadir of 16% during this period, but smoking in young adults continues to 
be a significant problem.236 However, diabetes mellitus increased significantly in Australia, between 
1991 and 2003, with the greatest increases (139%) seen in obese adults aged under 60 years.236 
Is this attenuation of the decline in CHD mortality simply an artefact of low rates?  It could be 
postulated that as rates progressively decline, a “background” incidence will be reached making 
further mortality reductions impossible.  However, our current understanding of CHD causation 
strongly suggests that this is not the case because far lower coronary heart disease mortality rates 
have been observed in the subset of individuals with low levels of risk factors in several large 
cohorts.136 I will discuss later (chapter 7) that the existence of socioeconomic differentials again 
suggest that this is a real phenomenon.237 Moreover, the log-linear relationship demonstrated 
between major CHD risk factors and CHD mortality suggests that any baseline threshold is very low 
indeed.238,239   
72 
 
This study has limitations. Since most of the trend changes were recent, the confidence 
intervals for their average annual percent changes were correspondingly wide. It is therefore 
important not to exaggerate the significance of these changes. The wide confidence interval 
encompassing zero means that a flat line is possible, but not 100% certain.  
There is also potential for disproportionate miscoding of mortality in the young.  However, 
Lozano et al.185 studied the proportion of ill-defined codes that could result in misclassification of 
ischemic heart disease deaths in several countries and calculated correction factors by age and 
gender. Globally, for those under 50 years of age, the correction needed is less than 5%.  
Furthermore, this study found that Australian observed rates were equal to the corrected ones 
suggesting that the quality of coding, particularly among the young, is high.185  
One of the strengths of the present study is the use of Joinpoint as an unbiased approach to 
detect points in time where a significant change in the annual percent change in mortality rates 
happened. Furthermore, our approach confirmed the earlier Wilson study that used a very different 
methodology.189  
Most evidence therefore supports the idea that coronary heart disease mortality rates in 
young adults can decline substantially further. These changing trends are clearly dynamic and need 
continuous monitoring.  Furthermore, as this cohort ages, they will reach a proportionately higher 
cardiovascular risk. We therefore need to explore and better quantify the exact relationship with 
mortality and risk factor trends in population subgroups defined by age, gender and socioeconomic 
status in order to determine optimal preventative strategies. These emerging data are therefore 
likely to further strengthen growing calls for more effective policies for cardiovascular disease 
prevention. Should we target specific age groups? Although this approach may appear superficially 
attractive, population-wide policies (such as smoke-free legislation, transfat eradication and 
reductions in the salt and saturated fat content of processed food), could be much more effective in 
reducing the risk across all age and gender groups, while reducing socio-economic inequalities in 
disease burden and actually saving costs.240   
The flattening of trends in young adults suggests that hard won gains can be rapidly lost. 
However, rates are not set in stone, they are dynamic and these changes could be as well reversed. 
In the next section, I will present evidence of flattening and a later recovery of the decrease in 
mortality in the Netherlands.  Its particular interest resides in the often overlooked speed at which 
the coronary heart disease epidemic can change course.  
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5.5 AGE-SPECIFIC PATTERNS IN THE NETHERLANDS 
5.5.1 Introduction 
The Dutch population experienced a decline in the age adjusted coronary heart disease 
mortality rates since the 1970s. As in other Western countries, the increased use of evidence base 
treatments and beneficial trends on physical activity241, cholesterol and dietary intake of fats242, 
were offset by adverse trends in diabetes and obesity.243 Little data on age specific risk factor trends 
is available, but as in many countries, smoking is still prevalent in young adults with modest declines 
compared to other age groups.244 
The aim of the analyses presented here was to explore recent coronary heart disease 
mortality trends in the Netherlands to verify if the flattening observed in some Western countries 
has also occurred in this country.  
5.5.2 Methods 
Data for all CHD deaths (1972-2007) were provided by Statistics Netherlands and grouped by 
year, sex and age. The eighth version of the ICD was used for the years 1972 to 1978 (ICD codes 
4100-4149), the ninth version for the years 1979 to 1995 (ICD codes 4100-4149) and the tenth 
version (ICD codes I20-I25) thereafter. Age adjusted rates were calculated using the European 
standard population.245 All analyses were performed in accordance with privacy legislation in the 
Netherlands.246 
A joinpoint regression was fitted to each age-sex-group to detect points in time at which 
significant changes in the trends occur.215 For every time period, we calculated the annual percent 
change, p-value, observed number of deaths, CHD mortality rates and the change in CHD mortality 
rate. 
5.5.3 Results 
Between 1972 and 2007, the age-adjusted coronary heart disease mortality rates decreased 
overall by 75.6% in men and 75.7% in women (Figure 5-9). The average rate of decline in men was -
1.65 (95%CI -2.0% to -1.2%) from 1972 to 1985, -4.0% (95% CI -4.3% to -3.6%) from 1985 to 1999, 
and for the period 1999 to 2007 -7.3% (95% CI -8.0% to -6.5%). For women, the average rate of 
decline was -1.5% (95% CI -3.1% to 0.1%) from 1972 to 1977, -3.0% (95% CI -3.2% to -2.8%) from 
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1977 to 1996, -5.3% (95% CI -6.8% to -3.8%) for the period 1996 to 2002 and -8.1% (95% CI -9.5% to -
6.6%) for 2002-2007. 
Figure 5-9 Age standardised coronary heart disease mortality rates in the Netherlands by gender, 
1972-2007 
 
CHD mortality rates varied between the different age groups (Figure 5-10 and Table 5-3). In 
men aged over 55 and women aged 55 to 84, the decline started in the mid 80s, with constant 
increases in the rate of decline. However, in both men and women under 55, the trend followed a 
different pattern.  After a decline started in both men and women around 1980, the rate of change 
flattened significantly  after 1993 in men (EAPC for 1993-1999: -2.5%, -5.0% to 0.0%) and after 1989 
in women (EAPC  for 1989-2000: -0.1%, -1.5% to 1.3%)(Table 5-3).  
At the beginning of the new century, both men and women under 55 years resumed the 
decline, with estimated annual percent changes of -7.6% (-8.7 to -6.4) for men and -7.3% (-9.5 to -
5.0) for women (Table 5-3) 
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Figure 5-10  5-years smoothed CHD mortality rate per 100,000 by age group, men and women, 
1972-2007 
 
  
Table 5-3 Coronary heart disease mortality trends by age in the Netherlands, 1972-2007 for men and women aged over 35 years 
Men 
 
Women 
Age Periods 
Number of deaths  
(min-max) 
Rates 
(min-max) 
EAPC 95%CI for EAPC 
 
Age Periods 
Number of deaths  
(min-max) 
Rates 
(min-max) 
EAPC 95%CI for EAPC 
             
35-54 1972 – 1980 1556–1898 95.2-128 -2.8* -4.0 to -1.5 
 
35-54 1972 – 1979 273-319 18.2-21.1 0.1 -2.3 to 2.6 
 
1980 - 1993 981-1556 45.2-95.2 -5.7* -6.4 to -5.1 
  
1979 – 1989 207-302 10.8-19.4 -5.7* -7.2 to -4.1 
 
1993 - 1999 918-1002 38.1-45.2 -2.5 -5.0 to 0.0 
  
1989 – 2000 200-280 9.8-12.0 -0.1 -1.5 to 1.3 
 
1999 - 2007 520-939 20.7-38.1 -7.6* -8.7 to -6.4 
  
2000 - 2007 156-244 6.3-10.2 -7.3* -9.5 to -5.0 
             
55-64 1972 -1985 2814-3220 431-564 -1.8* -2.4 to -1.3 
 
55-64 1972 -1985 714-932 101-131 -1.6* -2.3 to -0.9 
 
1985 -1998 1540-2949 206-483 -5.9* -6.5 to -5.3 
  
1985 -1996 476-771 64.9-106 -3.9* -4.9 to -2.8 
 
1998 - 2007 958-1541 93.5-206 -8.1* -8.9 to -7.2 
  
1996 - 2007 254-509 25.1-68.8 -8.0* -8.9 to -7.2 
             
65-74 1972 – 1985 4726-5265 1086-1285 -1.3* -1.8 to -0.8 
 
65-74 1972 – 1987 2095-2674 311-539 -2.2* -2.7 to -1.7 
 
1985 - 1999 3028-4794 559-1094 -4.4* -4.8 to -3.9 
  
1987 – 2000 1324-2095 205-311 -4.0* -4.5 to -3.5 
 
1999 - 2007 1501-3028 243-559 -9.6* -10.5 to -8.7 
  
2000 -2007 668-1324 99.7-205 -10.6* -12.0 to -9.2 
             
75-84 1972 – 1985 4177-4693 2113-2497 -1.1* -1.5 to -0.7 
 
75-84 1972 – 1985 3718-4421 1205-1635 -2.3* -2.7 to -2.0 
 
1985 – 1996 3730-4693 1581-2294 -2.8* -3.4 to -2.2 
  
1985 – 1996 3497-4426 820-1207 -3.4* -4.0 to -2.8 
 
1996 -2003 3157-3895 1079-1581 -5.2* -6.5 to -3.9 
  
1996 – 2003 2501-3497 529-820 -5.7* -6.9 to -4.5 
 
2003 - 2007 2412-3157 745-1079 -8.8* -11.0 to -6.4 
  
2003 - 2007 1831-2501 373-529 -8.7* -10.8 to -6.5 
             
85+ 1972 -1998 1371-1638 2665-4351 -1.7* -1.9 to -1.4 
 
85+ 1972 – 1977 1653-1958 3073-3311 -0.9 -2.5 to 0.7 
 
1998 - 2007 1266-1481 1875-2669 -3.9* -5.0 to -2.8 
  
1977 – 1980 1916-2083 2494-3077 -5.3 -11.9 to 1.8 
        
1980 – 1998 1932-2961 1747-2562 -2.0* -2.3 to -1.8 
        
1998 - 2007 2178-2879 1147-1747 -4.7* -5.3 to -4.1 
EAPC: estimated annual percent change 
*APC significantly different from 0% 
7
6 
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5.5.4 Interpretation 
The attenuation of the decline in CHD mortality among young Dutch adults in the 1990s is 
clearly evident and continued over several years. However, unlike the flattening described in the US, 
England & Wales and Australia, it was subsequently followed by a more recent period of decline. 
In contrast to the other countries that had shown evidence of the flattening of mortality rates 
over the 1990s, this is the first country where a further decline in CHD mortality rates was observed 
after a plateau in mortality, particularly amongst younger adults.  
The flattening in the Netherlands occurred despite the increasingly wide use of evidence 
based treatments, including lipid-lowering drugs247, and increased physical activity241,248, decreased 
cholesterol levels, and decreased dietary intake of saturated fat242 during this period. This suggests 
that adverse trends in unfavourable risk factors, especially obesity and diabetes, compounded by 
persistent smoking, may powerfully contribute to changes in CHD mortality rates.242,243.  
The recent period of resumed decline is more difficult to explain. Data on changes in risk 
factors in the Netherlands since 2000 are limited, but indicate that the prevalence of obesity may 
have stabilised.249 Furthermore, smoking prevalence250 further decreased after being relatively 
stable during the 1990s.251 These changes may have contributed to the more recent downward 
trend in CHD mortality.  
Crucially, the trends in the Netherlands along with other countries, suggest that a decline in 
CHD mortality rate trends can change very quickly.186,252,253 The pattern of flattening followed by 
resumed decline suggests that changes in the mortality rate can happen over relatively short periods 
of time, and an adverse trend can be turned into a favourable one rather quickly.  
There is growing evidence that such changes can occur very soon after alterations in risk 
factors. For example, in Poland steady increases in mortality due to coronary heart disease were 
succeeded by a rapid decline observed between 1991 and 1994. 252,253 This followed dramatic dietary 
changes in 1989 and 1990 with increases in the ratio of polyunsaturated fat to saturated fat, and in 
fruit consumption. Similar changes happened in neighbouring countries including the Czech Republic 
Hungary and East Germany.253 
78 
 
5.6 CONCLUSION 
The slowing in CHD mortality falls described in the USA, England and Wales and the 
Netherlands appears to be real, and probably not an artefact. Because clinical care over the periods 
studied improved, adverse changes in cardiovascular risk factors clearly represent the most plausible 
explanation for these patterns. 
In the next chapter, I will study the recent trends in Polish CHD mortality. Poland offers a 
potentially unique opportunity to gain insights into the drivers of one of the most dramatic reversals 
of an adverse CHD mortality trend, happening alongside a complex transition to a market economy 
from a heavily centralized and subsidized environment. 
I will then use the IMPACT model to formally explore and quantify the contribution of risk 
factors and evidence based treatments to the observed decline in Poland.  
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6 CHD MORTALITY IN POLAND: RECENT TRENDS AND 
POSSIBLE DRIVERS 
 
 
6.1 INTRODUCTION 
In this chapter, I will study an interesting natural experiment: the rapid decline in CHD 
mortality rates experienced by Poland since the 1990s. Substantial changes in CHD mortality 
happened in Poland after the transition to a market economy from a centralised, programmed and 
heavily subsidized society. As the Polish society becomes increasingly “Westernized” and integrated 
into the European Community, the trends in CHD mortality might eventually change their course and 
become more similar to rates observed in Western European countries. Continued monitoring of 
recent trends and understanding their drivers is therefore essential, not least to detect the first signs 
of any reversal of the huge gains achieved in this country.  
I will begin by studying recent trends in age adjusted and age specific trends with the aim of 
seeking evidence of a change in the pace of decline in age-adjusted and in age specific rates. Then, I 
will use the IMPACT model to explore and quantify the contribution of risk factor changes and 
treatment to the observed decline. 
 
6.2 ARE CHD MORTALITY RATES IN POLAND CONTINUING TO DECLINE?  
6.2.1 Introduction 
Poland experienced an interesting pattern in coronary heart disease mortality in the 20th 
century. During the Socialist era, coronary heart disease mortality rates increased at a steady pace.  
However, a marked and sudden decline in cardiovascular disease deaths started in the early 
1990s, paralleling the huge socioeconomic changes following the disintegration of the former Soviet 
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Union and the collapse of the communist economies in central Europe. Was this a coincidence or a 
causal association? 
This abrupt mortality fall has been attributed in an ecological study to contemporaneous 
decreases in the consumption of saturated fats (as a result of rapidly disappearing state subsidies) 
and the increase in fruit & vegetable availability, accompanied by the increase in imports of “exotic” 
fruits.252  
Poland in the 1990s can be viewed as a vast natural experiment, with reductions of key 
coronary heart disease determinants at a massive scale resulting in an abrupt change in direction of 
the mortality secular trend. 
I have previously discussed the recent phenomenon of the “flattening” of coronary heart 
disease mortality rates in several countries (England & Wales, Australia, United States of America, 
Netherlands), and the rapid resumption of the downward trend in one country (The Netherlands).  
Because Poland is becoming an increasingly Westernized country, my aim was to explore if the 
decline in mortality rates seen in the early 1990s has continued, or whether there is any evidence of 
a slowing in the mortality decline in specific age and gender groups, as elsewhere.  
6.2.2 Methods: 
CHD mortality rates for the Polish population were obtained from the Polish Central Statistical 
Office, for the period 1982-2006, and corrected by Jasisnki et al for the period 1991-2006. 254 This 
correction is needed because officially reported data showed a peculiar pattern. While 
cardiovascular disease rates declined since 1991, ischemic heart disease rates apparently increased. 
However, there was a substantial change in cause of death coding and certification in 1997 
(adoption of ICD 10 and regional coding by qualified coders). This resulted in an apparent increase in 
the number of ischemic heart disease deaths after 1996, but which was attributable to the frequent 
use of “atherosclerosis” as cause of death before 1996, primarily at the expense of specific ischemic 
heart disease and cerebrovascular disease codes.  
Jasinski et al therefore used a regression model to estimate the number of ischemic heart 
disease in the period 1991- 2006. Their model uses individual death records from the Central 
Statistical Office (CSO) and data from the WHO Mortality Database. It includes terms to reflect the 
coding error for two periods (before and after 1997) and terms for the time trend based on the 
cardiovascular disease rates trends. The level of underestimation of ischemic heart disease dates in 
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the uncorrected data, before 1996 is about 35%, compared to the figures obtained with the 
regression modelling, with errors more significant in those older than 75 years, where the error was 
between 50-72%, in men and women.  
I analysed the corrected, age- adjusted and age specific coronary heart disease mortality 
trends (using the Polish Population in 1982 as the population standard). I have used Joinpoint 
regression209 to indentify periods of time with similar annual percent change in the rate.  Model 
selection was performed using the Bayesian Information Criterion approach. Rates were smoothed 
using 3 years averages. 
6.2.3 Results: 
Age adjusted mortality rates:  
CHD mortality started to decline dramatically in 1991 (lower and upper estimate of change 
year: 1984-1992) in men and in 1992 (lower and upper estimates of change year: 1987-1994) in 
women. Since 1991, CHD mortality rates decline 34.4 % in men and 33.8% in women. Both in men 
and women the trend continued to decline, although in women at a slightly lower pace since 2002. 
(Table 6-1 and Figure 6-1)   
Table 6-1 Joinpoint analysis: Poland, men and women age adjusted  CHD mortality rates  
 Period  
Lower Endpoint 
Period 
 Upper Endpoint 
EAPC 
EAPC CI 
Lower CI Upper CI 
 
 Men 1982 1991 2.0* 1.6 2.4 
 1991 1999 -3.6* -4.6 -2.6 
 1999 2006 -4.4* -5 -3.9 
 
     Women 1982 1986 0.1 -1.2 1.4 
 1986 1992 2.1* 1.2 3.1 
 1992 1999 -2.0* -3.3 -0.8 
 1999 2002 -5.0* -8.8 -1 
 2002 2006 -3.2* -4.4 -1.9 
 
EAPC: estimated annual percent change 
*APC significantly different from 0 
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Figure 6-1 CHD Mortality rates in Poland, men and women aged 35+ 
 
 
Age specific rates showed a different pattern, with all age groups showing declines starting in 
the 1990s (See Table 6-2 and Figure 6-2).  
The coronary heart disease mortality rate for men under 54 years old rate changed abruptly  
in 1991 (1990-1992). The first period from 1982 to 1991 showed essentially an increasing trend, but 
since 1991 it showed a period of constant decline of 5.8% per year (95%CI 6.1-5.4). 
Men over 75 showed a more complex pattern, although the rate of change was not 
statistically significantly different from 0, but declining from 1993 onwards. In women a similar 
pattern is noted, with marked declines since 1991 in those under 75, accelerating towards the year 
2000. 
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Figure 6-2 Coronary heart disease mortality rates in Poland 1982-2006, by age and gender 
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Table 6-2 CHD mortality trends by age in men and women, Poland 1982-2006 (joinpoint analysis) 
Age Period EAPC 
EAPC 
Lower CI Upper CI 
      Men 
      <54  1982 1991 1.1* 0.4 1.8 
 
1991 2006 -5.8* -6.1 -5.4 
      54-75  1982 1991 0.4 0 0.8 
 
1991 2000 -2.8* -3.4 -2.2 
 
2000 2006 -7.7* -8.6 -6.8 
      75+ 1982 1984 -5.4 -10.7 0.1 
 
1984 1989 -0.4 -2.2 1.4 
 
1989 1993 5.7* 2.9 8.6 
 
1993 1996 -1.8 -6.9 3.7 
 
1996 2006 -6.2* -6.8 -5.6 
      Women 
<54  1982 1991 2.9* 1.9 3.9 
 
1991 2006 -5.5* -5.9 -5 
      54-75  1982 1992 0.9* 0.4 1.4 
 
1992 2000 -2.4* -3.3 -1.5 
 
2000 2006 -9.0* -10.1 -7.9 
      75+ 1982 1987 -4.4* -5.9 -2.9 
 
1987 1993 4.6* 3.1 6.2 
 
1993 1996 0.4 -5.8 7 
 
1996 2006 -6.8* -7.5 -6.1 
      EAPC: estimated annual percent change 
* APC significantly different from 0% 
 
 
6.2.4 Interpretation: 
Analysis of age-adjusted mortality trends confirmed the observation that the declining phase 
of the coronary heart disease epidemic in Poland started abruptly at the beginning of the 1990s, as 
described by Zatonski et al, and that this fall continues up to and including 2006, the most recent 
year studied. Men and women showed a period of marked decline in 1991-2006 in all age groups; 
but the speed of decline increased later on  in adults older than 54.  The oldest age group (75+) 
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appeared to start its decline a few years later. Furthermore, there was no evidence of a significant 
slowing down in any age group.  
The lack of striking age patterns regarding the start of the decline suggests that this is a strong 
period effect, showing effects of similar magnitude across the age ranges.  
Other countries in the region demonstrated similar changes in their mortality, and all 
experienced similar socioeconomic events in the same decade.187  
Although in the 1990s the access to evidence based therapeutic  interventions for coronary 
heart disease was limited compared to the Western world252, in recent years the uptake of those 
interventions have risen.255-257 Risk factor trends over the period of decline however showed a 
complex picture. While there were significant declines in total cholesterol, physical activity and 
systolic blood pressure (only in women), diabetes obesity and systolic blood pressure (in men) 
showed alarming increases.258-261 I will further assess the contribution of risk factors and treatments 
to the period of decline in the next section. 
In Poland, food was no longer subsidised after 1990; this caused big changes in relative prices. 
Consequently, the structure of food consumed by Polish citizens changed substantially. For example, 
between 1989 and 2008 yearly butter consumption decreased from 7 kg to 3.8 kg per capita, and 
beef consumption fell by 75%. At the same time availability and consumption of fruits increased 
markedly.252  Recent Food and Agriculture Organization food balance sheet data showed that the 
supply of fat from animal products (as a proxy for saturated fat supply) decline about 20% since 
1991, while the supply of fat coming from vegetable products almost doubled. (Figure 6-3) 
Interestingly, the change point in time for both the mortality rates and a proxy of the 
exposure of key determinants of coronary heart disease incidence are almost the same, 1991 (Figure 
6-3).  Since the effect of therapies is was small at that time (and increased thereafter), the changes 
in risk factors for the disease possibly triggered over a very short period of time(years), one of the 
most striking reductions in coronary heart disease mortality in the world.  
The changes in Poland and its neighbouring countries were revolutionary, quite unlike those 
observed in any Western European countries at this time. The socio-economic changes in Poland 
1991 and 2005 reflected substantial increases in GDP per capita. This increased four-fold in Poland 
(from 1 998 USD to 7 963 USD) but only two-fold in UK (from 18 387 USD to 36 084 USD, 
respectively).262   
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Figure 6-3 Fat supply quantities by origin (g/capita/day). Poland 1977-2007 (FAO, 2010) 
 
On the other hand, shortly after the democratic transformation, citizen’s purchasing power 
increased substantially, while inequalities increased modestly. 262,263 This might have resulted in an 
increased access to healthier foods. In Russia and Ukraine, by contrast, such inequalities increased 
sharply in the 1990s, and their mortality experience was crucially different.262 
These disparities among countries experiencing very different socioeconomic environments 
translating in different mortality experiences suggests that mortality trends are associated to 
changes in the socioeconomic environment. The association between socioeconomic status and risk 
factor levels and differential access to health care is well know, suggesting that both the speed, 
direction and magnitude of trend changes might be also socially patterned. For example, there is 
evidence that differences in the time of onset of the decline phase of the CHD epidemic can be 
explained by socioeconomic characteristics in the US. 264 I will further elaborate this topic in chapter 
7. 
The decline phase of the CHD epidemic has been studied exhaustively in Western countries, 
well after the peak year of the epidemic. Poland offers the unique opportunity to study the decline 
phase but almost from its beginning. In the following section, I will use the IMPACT model to 
estimate the contribution of risk factors and evidence based treatments to the abrupt decline in CHD 
mortality experience by Poland since the 1990s.  
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6.3 USING THE IMPACT MODEL TO EXAMINE THE ABRUPT RECENT DECLINE IN 
CORONARY HEART DISEASE MORTALITY IN POLAND 
6.3.1 Introduction 
In the previous chapters, I have examined the dynamism of CHD mortality trends in several 
settings. Trends can fluctuate over time, sometimes quite rapidly in the matter of a few years. I also 
discussed some compelling arguments suggesting that changes in risk factors rather than evidence-
based treatments might be the major drivers of these rapid changes.  
However, our current understanding of coronary heart disease causation suggests that 
coronary heart disease development is a long process, probably taking the entire life course of 
individuals. Correspondingly, a change in risk factors will be followed after several decades by a 
change in mortality. Consequently, the rapid trend changes I described so far seem to not fit 
adequately within this framework.   
Most of the research on the drivers of these trends in coronary heart disease rates has been 
conducted in Western countries, with longstanding declining trends. Generally, studies looked at 
trends well after the peak of the epidemic has been reached. For example, for the US studies this 
question was addressed over the period 1980-2000144,200, while the peak of incidence was observed 
in mid 1960s. Similarly, in most European countries, the onset of the decline was in the 1970s, while 
most studies have tended to focus on the last two decades of the 20th century. 148,149,265-267 
Do countries experiencing more recently the onset of the decline phase of the CHD epidemics 
have the same trend drivers as countries with longstanding declines? In countries with long 
established decline phases, risk factors explain about two thirds of the observed decline, while 
evidence based treatments explain about one third. However, the adoption of effective treatments 
happened towards the end of the century, and even then, treatment uptake levels in countries with 
strong health care systems were disappointingly low.265,268 Thus, bigger contributions from evidence 
based treatments are plausible in countries that started the decline phase of the CHD epidemic more 
recently, since the revolution in evidence base cardiology was firmly underway in the 1990s.  
As I described earlier in this chapter, Poland is a key Central European country in which to 
study the abrupt changes in rates. Cardiovascular disease deaths increased steadily through the 
seventies and eighties, continuing to the very end of the communist era. The dramatic 
socioeconomic changes then occurred during the transition to a market economy were accompanied 
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by sharp falls in mortality from 1991 onwards -one of the fastest declines in the world- resulting in 
substantial improvements in life expectancy, mainly attributable to decreases in cardiovascular 
mortality.269 Several countries in central Europe experienced equally dramatic political and 
socioeconomic changes in the nineties, including the Czech Republic, East Germany, Hungary and 
Romania.270  
I have already discussed the Zatonsky/Willett hypothesis that this might be related to dietary 
changes, as a consequence of the elimination of subsidies for animal fats during the socialist era, 
resulting in a fall in the consumption of saturated fats, whilst the intakes of polyunsaturated fats, 
fruits and vegetables all increased following the introduction of a market economy.187,252 
However, the potential contribution of treatments and other risk factors remains unclear.  For 
instance, smoking prevalence in men also fell significantly during that period.187,253 Indeed, changes 
in other cardiovascular risk factors might also have played a significant role on the observed 
mortality decline. Furthermore, improvements in evidence-based treatments for established 
coronary disease also became widely used in recent decades in Poland. This included therapies for 
acute myocardial infarction, CHD and heart failure, hypertension and hypercholesterolemia, as well 
as coronary bypass surgery, coronary angioplasty and stenting.  
My aim was therefore to explain the contribution of risk factor changes and evidence based 
treatments in the recent fall in coronary mortality observed in Poland since 1990. Such an analysis is 
potentially important, both for understanding past trends and for planning future strategies.  
6.3.2 Methods 
To explain the changes in cardiovascular mortality in Poland between 1991 and 2005 we used 
the IMPACT CHD mortality model.  This has been previously validated in the U.K., Italy, Sweden, 
Canada and the U.S.144,149,267,271  A detailed description of the model methods and data source is 
available in appendix A2.  
The model goal is to quantify what proportion of the coronary heart disease deaths prevented 
or postponed in the Polish population between 1991 and 2005 can be explained by risk factors and 
treatments. The model is comprehensive, incorporating all usual treatments for coronary heart 
disease and heart failure plus all major cardiovascular risk factors, including smoking, blood 
pressure, cholesterol, diabetes, obesity and physical activity.  
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All available Polish data sources were therefore systematically identified and critically 
reviewed as inputs in the Polish IMPACT model. The analysis was confined to adults aged between 
25 and 74 years.  Mortality and demographic data were taken from routine national statistics.  
Coronary heart disease patient numbers and treatments were obtained from cross-sectional 
national and local studies; country representative surveys (WOBASZ258, NATPOL260,261, Pol-
MONICA259), national registries (CABG registry257, acute coronary syndromes registry255,256) and 
hospital discharge databases.  Expert opinions were also elicited where objective data were 
deficient.  Data quantifying changes in the prevalence of cardiovascular risk factors were taken from  
national representatives surveys (NATPOL, WOBASZ,) as well as from the best regional and local  
epidemiological studies (Pol-MONICA and CINDI WHO272). More details on the data sources of the 
Polish IMPACT model are available in appendix A2.   
Calculating the number of deaths prevented or postponed to be explained 
Age and sex specific mortality rates for coronary heart disease were obtained from the Polish 
Central Statistical Office. Substantial changes in the coding of causes of death in Poland were 
introduced in 1997. I have discussed in section 6.2 the coding quality issues concerning polish 
cardiovascular mortality data  for the period 1991-1996, and the data used was corrected for these 
issues with the approach developed by Jasisnki et al.254  
The number of CHD deaths expected in 2005 if the 1991 mortality rates had persisted was 
then subtracted from the number of deaths actually observed in 2005 to produce the fall in 
mortality that the model needed to explain. 
We then estimated the proportions of the total number of deaths prevented or postponed 
(DPPs) which could be attributed to the use of treatments and to changes in cardiovascular risk 
factors.  
Estimating Treatment benefits 
The treatment arm of the Model includes the following populations of patients:  
-those hospitalized with an acute myocardial infarction (AMI),  
-Patients admitted to the hospital with unstable angina,  
-Community-dwelling patients who have survived an AMI, 
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-Patients who have undergone revascularisation procedure (coronary artery bypass 
grafting (CABG), or a percutaneous coronary intervention (PCI), with or without stent. 
-Community-dwelling patients with angina pectoris (no revascularisation) 
-Patients admitted to hospital with heart failure, 
-Community-dwelling patients with heart failure (no hospital admission). 
-Hypertensive individuals eligible for hypertensive therapy 
-Hypercholesterolemia subjects eligible for cholesterol lowering therapy  
For each of the groups, we estimated the number of DPPs that were attributable to various 
treatments. The size of each individual group was determined using data from hospital episodes 
statistics, disease registers and surveys (See appendix A2.) 
Data on the clinical effectiveness of each intervention and therapy were based on the most 
recent meta-analyses and large randomized clinical trials. Details on the magnitude of the risk 
reduction for each treatment and its uptake are available in appendix A2 
The number of deaths prevented or postponed as a result of each individual intervention in 
each group of CHD patients in the year 2005 was then calculated by multiplying the number of 
patients in each diagnostic group by their baseline case-fatality rate over 1 year, by the proportion of 
these patients receiving a specific treatment, and by the relative reduction in one–year case-fatality 
by the administered treatment.  
For example, in Poland, in 2005, approximately 12 230 men aged 55-64 were hospitalized with 
acute myocardial infarction.  Their expected age-specific 1-year case-fatality rate without treatment 
was approximately 5.4%.  From registry data256 96% of them were given aspirin or other antiplatelet 
drugs, interventions with an expected mortality reduction of 15%.  The number of deaths prevented 
or postponed for at least a year by the use of aspirin among men aged 55 to 64 were then calculated 
as:  
[Eq 1]                    12 230 x 0.054 x 0.96 x 0.15 = 95 fewer deaths 
This process was then repeated for men and women in each age group, each patient group 
and each therapy. Some adjustments were made to these basic analyses. Many evidence-based 
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therapies were not used Poland in 1991 (e. g. statins, or primary angioplasty in acute myocardial 
infarction).  However, in some cases the use of some drugs or procedures in 1991 was not negligible 
(for instance antihypertensive treatment or aspirin in acute myocardial infarction). In such cases, in 
order to obtain the net benefit, the number of deaths prevented or postponed as a result of the 
therapy as used in 1991 was calculated and subtracted from the number calculated for 2005. 
Compliance, (adherence, the proportion of treated patients actually taking effective levels of 
medication), was assumed to be 100% among hospital patients, 70% among symptomatic 
community patients and 50% among asymptomatic community patients.273 To avoid double 
counting of patients, it was necessary to identify potential overlaps between different groups of 
patients. For example, approximately half the patients having CABG surgery have a previous AMI220, 
approximately 25% of AMI survivors develop heart failure within 12 months274, and over 50% of CHD 
patients have a history of hypertension.275 
To quantify the relative reduction in case-fatality rate for individual patients receiving multiple 
treatments, we used the conventional Mant and Hicks cumulative relative benefit approach276:  
[Eq 2] Relative Benefit = 1 - [(1-relative reduction in case-fatality rate for treatment A) X (1- 
relative reduction in case-fatality rate for treatment B) X ... X (1- relative reduction in case-fatality 
rate for treatment N).  
 For example, considering appropriate treatments for AMI survivors, applying relative risk 
reductions (RRR) for aspirin, beta-blockers ACE inhibitors statins and rehabilitation then gives: 
[Eq 3] Relative Benefit = 1 - [(1 –aspirin RRR) X (1 - beta-blockers RRR) X (1 - ACE inhibitors 
RRR) X (1- statins RRR) X (1- rehabilitation RRR)] 
= 1 - [(1- 0.15) X (1-0.23) X (1-0.20) X (1- 0.22) X (1- 0.26)] 
= 1 - [(0.85) X (0.77) X (0.80) X (0.78) X (0.74)] 
= 0.70 i.e. a 70% lower case fatality 
This represents a 34% relative reduction (0.70/1.06) on the simple additive value of 106%. 
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Risk factor changes and mortality benefits 
We estimated the contribution of risk factors to the mortality decline by using two 
approached: the regression approach for continuous risk factors and the population attributable risk 
fraction approach for discrete risk factors.  
Regression approach 
Regression coefficients published in the literature were used to calculate the number of 
deaths prevented or postponed as result of change in systolic blood pressure, mean cholesterol 
concentration and body mass index (BMI).  The number of deaths prevented and postponed due to 
change in that risk factor was then calculated as the product of the number of CHD deaths observed 
in the baseline year (1991), the change in risk factor level and the coefficient quantifying the change 
in CHD mortality per unit of absolute change in that risk factor.  
For example, there were 2534 CHD deaths among women aged 55-64 years in 1991, the base 
year. Mean systolic blood pressure in this group decreased by 5.4 mmHg between 1991 and 2005. 
The largest meta-analysis demonstrates an age- and sex-specific reduction in mortality of 50 percent 
for every 20 mmHg reduction in systolic blood pressure, generating a logarithmic coefficient of –
0.035277. The number of deaths prevented or postponed was then estimated as:  
[Eq 4]  [deaths in 1991] * (1-EXP(coefficient*change) 
 = 2534 (1-EXP(-0.035*5.4)) = 436 fewer deaths 
Population attributable risk approach 
A population attributable risk fraction approach was used to assess the effect of changes in 
the prevalence of smoking, diabetes and physical inactivity, using the standard formula: 
[Eq 5]  ((P x (RR-1)) / (1+P x (RR-1)) , 
Where P = prevalence of the risk factor and RR = the relative risk for CHD mortality associated 
with that risk factor.    
To assess the decline in CHD mortality, the number of coronary heart disease deaths in 1991 
(the base year) was multiplied by the difference between the population-attributable risk fraction in 
1991 and that in 2005. 
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We assumed  that there was no further synergy between the treatment and risk factor 
sections of the model, or between the major risk factors because the regression coefficients and  
relative risks for each risk factor were each independent, being obtained from multivariate analyses. 
Deaths prevented or postponed as a result of risk factor changes were then systematically quantified 
for each patient group. Lag times between risk factor rate change and event rate change were not 
modelled. We assumed, as in other countries, that any time lag would be relatively unimportant 
over a period of fifteen years (1991-2005).278  
Model validation: comparison of estimated with observed mortality changes 
The model produces estimates of the total number of CHD deaths prevented or postponed 
attributable to each treatment and to change in each specific risk factor.  These estimates were then 
summed and compared with the observed changes in mortality for men and women in each specific 
age group. Any shortfall in the overall model estimate was then presumed to be attributable either 
to inaccuracies in our methodology or to other, unmeasured risk factors. 
Sensitivity analyses 
All the above assumptions were tested in a multi-way sensitivity analysis using the analysis of 
extremes method.279 This method consist in choosing for each model parameter, a lower and upper 
value using 95% confidence intervals where available, or otherwise using + 20% values (for patient 
numbers, treatment uptake, and compliance), and then recalculating the model outputs using these 
“extremes” values.  
An example of calculating lower and upper bound estimates for DPPs for treatment with 
aspirin among men aged 55-64 years who were hospitalized with an AMI is presented in Table 6-3. 
We used 95% confidence intervals from the Antithrombotic Trialists’ Collaboration meta-
analysis280 for relative mortality reduction; lower and upper bound estimates for the other 
parameters were calculated as minus or plus 20% [except for treatment uptake that was capped at 
99%]. Multiplying all the lower-bound estimates yielded the minimum [lower bound] estimate and 
multiplying the upper-bound estimates yielded the maximum [upper bound] estimate. 
This approach may be described as a “robust” for two reasons. 
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a) Maximum and minimum values for each variable were deliberately forced to provide a 
wider range rather than a narrower one, e.g. relative mortality reduction +20% rather than say, 
+10%. 
b) The resulting product, for instance the minimum estimate, was generated by assuming that 
the lowest feasible values all occurred at the same time, a most unlikely situation. 
Table 6-3. Example of sensitivity analysis 
 
Patient 
numbers 
Treatment 
Uptake 
Relative 
Mortality 
Reduction* 
One year case 
fatality 
Deaths 
prevented  or 
postponed 
 
A B C D (A x B x C x D) 
      Best Estimate 12 226 0.96 0.15 0.054 95 
Minimum estimate 9 781 0.77 11%* 0.043 36 
Maximum estimate 14671 0.99 19%* 0.065 179 
      * 95% CI from the Antithrombotic Trialists’ Collaboration meta-analysis280  
 
6.3.3 Results 
The large decline in CHD mortality rates since 1991 resulted in 26 200 fewer CHD deaths in 
2005.  The model explained approximately 23 715 (91%) of this mortality decrease.  
Approximately 37% of the mortality fall was attributable to treatments and approximately 
54% was attributable to changes in risk factors. A good agreement between estimated and observed 
number of deaths was generally observed across all gender and age groups. However, in middle 
aged men, the number of predicted deaths prevented or postponed was underestimated.   
Medical and surgical treatments 
Estimated numbers of CHD deaths prevented or postponed by medical and surgical treatment 
in 2005 are presented in Table 6-4. All treatments accounted for approximately 9 640 fewer deaths, 
representing approximately 37% of the mortality decrease.  
The largest reductions came from heart failure treatments in hospital and in the community, 
which resulted in approximately 3100 fewer deaths in 2005 (12% of the observed mortality 
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reduction).  Initial treatments for acute myocardial infarction or unstable angina (generated 
approximately 2450 fewer deaths, 9% of the observed fall). Secondary prevention therapies after 
myocardial infarction or revascularization explained approximately 1930 (7%) fewer deaths, 
followed by chronic angina treatments some 710 (3%), hypertension treatments approximately 580 
(2%) and statins for hypercholesterolemia in primary prevention some 880 (3%) fewer deaths.  
Risk factor changes 
Estimated numbers of CHD deaths prevented or postponed by changes in the exposure to risk 
factors are presented in Table 6-5.  Approximately 14,070 of the CHD deaths prevented or 
postponed (54%) were attributable to changes in risk factors, of which the majority, (41% of the fall 
in men and 33% in women) was attributable to large decreases in mean cholesterol concentration 
(declining by 0.4 mmol/L).  
The effects of changes in smoking and mean blood pressure in men and women were more 
complex. Smoking prevalence decreased in men by 15.7% explaining approximately 15% of their 
mortality fall. In women very little change in smoking prevalence was observed, which thus had 
virtually no effect on CHD mortality. Mean systolic blood pressure fell by 2.7 mmHg in men and by 
5.2 mmHg in women. After subtracting the effects of hypertension treatments, these blood pressure 
falls explained approximately 29% of the mortality decrease in women and an 8% increase in deaths 
in men. Increased leisure time physical activity explained approximately 10% of the decrease in 
deaths in the Polish population. 
However, these gains were partially offset by approximately 1810 additional deaths 
attributable to increases in body mass index (-4% and -5% for men and women respectively) and 
increasing diabetes prevalence (-1% and -8% respectively). 
Sensitivity Analysis 
Under the assumptions of the sensitivity analysis, the relative contributions of specific risk 
factor changes and treatment effects remained similar.  The extreme minimum and maximum 
numbers of CHD deaths prevented or postponed were 14 050 (54%) and 36 840 (141%) of the 
observed mortality fall.   
  
Table 6-4 Estimated coronary heart disease deaths prevented or postponed by medical and surgical treatments in Poland in 2005 
Patient groups & specific 
treatments§ 
Patients Eligible† Deaths Prevented or Postponed 
Number  † 
 
% of total mortality fall§ 
Best estimate Minimum Maximum 
 
 Best 
estimate  
Minimum Maximum 
     
 
   
Acute myocardial infarction 52 180 1 340 370 2 550 
 
5.1 1.4 9.7 
Unstable angina 105 920 1 110 550 1 850 
 
4.2 2.1 7.1 
Secondary prevention post-
myocardial infarction 
213 970 1 300 520 2 650 
 
4.9 2 10.1 
Secondary prevention post-
CABG/PCI 
100 890 630 260 1 310 
 
2.4 1 5 
Chronic angina 706 670 710 300 1 510 
 
2.7 1.1 5.8 
Heart failure with hospital 
admission 
18 330 1 470 700 3 550 
 
5.6 2.7 13.6 
Heart failure in the community 122 680 1 630 730 3 760 
 
6.2 2.8 14.4 
Hypertension treatments 8 488 520 580 -440 1 260 
 
2.2 -1.7 4.8 
Statins for primary prevention 
lipid reduction 
14 046 930 880 360 1 830 
 
3.4 1.4 7 
Total Treatments 
 
9 640 3 350 20 270 
 
36.8 12.8 77.5 
         
†reported numbers are rounded to nearest 10. 
§may not sum to total due to rounding. 
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Table 6-5 Estimated coronary deaths prevented or postponed as a result of risk factor changes in men and women in Poland 1991 - 2005 
Population risk factor 
Absolute level of 
risk factor 
Change in risk factor Beta 
regression 
coefficient 
RR 
Deaths  Prevented  or  Postponed 
Number of deaths† 
 
Percent of total reduction‡ 
1991 2005 
Absolute 
change 
Relative 
change (%) 
Best 
estimate§ 
Min§ Max§ 
 
Best % 
Estimate 
Min % 
Max 
% 
Smoking 
prevalence 
(%) 
men 55.8 40.1 -15.7 -28 
 
3.1 2980 2390 3580 
 
15% 12% 18% 
women 28.1 25.1 -3 -4 
 
4.2 -10 -10 -10 
 
0% 0% 0% 
  Systolic 
blood 
pressure 
(mmHg) * 
    men 140.1 137.4 -2.7 -1.8 -0.034 
 
-1720 -1250 -2380 
 
-8% -1% -12% 
women 136.6 131.5 -5.2 -3.4 -0.042 
 
1690 1100 2360 
 
29% 19% 40% 
  
Total 
cholesterol 
(mmol/l)§§ 
men 5.6 5.2 -0.4 -8.6 -0.95 
 
8390 6010 10340 
 
41% 29% 51% 
women 5.6 5.2 -0.4 -7.6 -0.91 
 
1920 1440 2200 
 
33% 25% 38% 
  Physical 
inactivity 
(%) 
men 64.6 38.7 -25.9 -40.1 
 
1.29 2000 1600 2400 
 
10% 8% 12% 
women 68.8 44.5 -24.3 -35.3 
 
1.35 630 510 760 
 
11% 9% 13% 
  
Body mass 
index 
(kg/m2) 
men 26 26.9 0.9 3.2 0.03 
 
-870 -480 -1340 
 
-4% -2% -7% 
women 25.7 26.6 0.9 3.2 0.027 
 
-290 -160 -450 
 
-5% -3% -8% 
  Diabetes 
prevalence 
(%) 
men 2.9 3.3 0.4 12.7 
 
2.47 -190 -130 -250 
 
-1% -1% -1% 
women 3.3 4.2 0.9 28.5 
 
3.4 -460 -310 -630 
 
-8% -5% -11% 
                
Total risk 
factors 
Men 
      
10 600 8130 12340 
 
52% 40% 61% 
Women 
      
3 480 2570 4230 
 
60% 44% 73% 
                RR: relative risk §antihypertensive treatment effects subtracted 
†reported numbers are rounded to nearest 10. ‡ may not sum to total due to rounding.  
§§ statin effects subtracted. 
9
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6.3.4 Interpretation 
There were 26,200 fewer coronary deaths in Poland in 2005 compared with 1991, 
approximately 55% being attributable to beneficial changes in risk factors and 37% to the increased 
use of evidence-based treatments. 
The major contributors to the mortality fall were large falls in total cholesterol, plus beneficial 
reductions in systolic blood pressure in women and decreased smoking in men.  Physical activity also 
contributed to the decline in deaths. Worryingly, adverse trends negated some of these benefits, 
specifically increases in the prevalence of obesity, diabetes and blood pressure levels in men and 
smoking prevalence in women.   
The most important treatment contributions came from therapies for heart failure, angina 
and secondary prevention.  
This is the first time the Impact model has been utilized in Central Europe, where many 
countries experienced a rapid decline in CHD mortality after the transition to a market economy.  
These included the Czech Republic, Slovakia, Hungary, East Germany and Romania. In contrast, 
mortality trends fluctuated in some other former communist countries that experienced more 
complicated pattern of mortality trends after the fall of communism, like Russia and Ukraine. For 
example in Russia, mortality initially fell rapidly for the first few years after the collapse of the 
former Soviet Union, but then began to rise following the economic crisis in 1998.281 Interestingly, 
the explanation for these more complex mortality trends is currently attributed to increases in heavy 
alcohol intake99,100, however, a more exhaustive analysis of trend drivers has not been conducted.  
The IMPACT model is a comprehensive tool that can quantify changes in mortality as a 
function of improving therapies and the major “downstream” risk factors (smoking, cholesterol level, 
blood pressure, obesity, diabetes and inactivity). Four of these six major risk factors reflect dietary 
habits; these in turn are powerfully patterned by “upstream” political and socio-economic factors. In 
our analyses, we observed a powerful effect of diet-related changes in cholesterol level on coronary 
heart disease mortality among both men and women. This is consistent with the earlier hypothesis 
that favourable dietary changes during the socio-political transition252,253 were the main reason for 
the sharp decline in cardiovascular mortality, changes that have been sustained throughout the 
period studied with the IMPACT model. In contrast, statins made a surprisingly small contribution to 
the overall cholesterol reduction.  
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Between 1991 and 2005, systolic blood pressure decreased substantially in women and young 
men; but increased in men aged over 55 years. This trend was consistently observed in three 
different sets of contemporary local and national studies. It generated over 1000 additional coronary 
deaths. However, it remains unclear why such important and worrying sex differences in blood 
pressure trends occurred. More research is needed, particularly around possible gender and socio-
economic differences in the intake of salt and other dietary factors. 
Increased physical activity resulted in some 2500 fewer coronary deaths. The main benefits 
came from increases in leisure time physical activity in Poland and are now well documented.282,283 
The uptake of evidence-based treatments for coronary heart disease increased markedly, 
mirroring other developed countries. However, these pharmacological therapies and invasive 
procedures together explained barely one third of the mortality decrease (37%).  This reflects a 
dynamic development in clinical cardiology in Poland in the late 20th century. Several new centres of 
invasive cardiology were created during this period demonstrating medical standards comparable to 
those in Western countries. However, at the start of the period, when the mortality trend started to 
change its direction, the level of uptake of most treatments was extremely low, suggesting that at 
that particular point in time, their contribution was even smaller. For example, the modern 
management of heart failure made the single biggest treatment contribution to the reduction in CHD 
mortality (12%). However angiotensin-converting enzyme inhibitors (ACEIs) uptake levels in the first 
half of the period were very low, and spironolactone was only introduced around the year 1999 with 
the RALES study,284 Therefore it seems plausible that most of the deaths prevented were actually 
achieved during the second half of the 20 year period, when the epidemic was already in a sustained 
decline phase. Although revascularization was available throughout the period, the mortality impact 
of invasive cardiology was modest (barely 4%). This suggest that risk factors changes at the start of 
the decline phase were more critical determinants of the trend  
This analysis is the first complex and quantitative analysis of the causes of sharp mortality fall 
in country experiencing a rapid transition from communism to democracy and market economy. The 
IMPACT model is comprehensive, and takes into account all known important downstream risk 
factors and all standard treatments. The model has been previously validated in many Western 
countries and its results are consistent with other analyses performed in the same settings. 
Several limitations should also be noted. In Poland, data for the initial analysis year (1991) was 
less complete and representative than in subsequent years. The model failed to explain 9% of the 
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overall reduction in CHD deaths: residual confounding in many of the risk factor effect estimates is 
likely and, furthermore, the model does not quantify all potential risk factors (e.g. psychosocial).27 
Our model results are generally consistent with other analyses conducted in Western Europe, 
the US and elsewhere.  However, interesting differences do exist. Thus, the contribution from 
population risk factor changes was even bigger in Nordic countries, probably reflecting more 
effective health policies at national and local levels.196 In contrast, in the UK, large reductions in 
smoking prevalence since 1980 had a large impact on reducing mortality whereas the dietary 
changes were far more modest.149  
 
6.4 CONCLUSIONS  
In conclusion, coronary heart disease deaths in Poland plummeted after 1990. Over half of the 
recent mortality reduction was associated with favourable changes in exposure to major risk factors, 
while approximately one third was attributable to modern therapies, probably acting towards the 
end of the study period.  
These results demonstrate the powerful effect of moderate changes in population level risk 
factors on CHD mortality.  The positive trends in risk factors most probably reflect beneficial changes 
in food prices and accessibility following economic transformation. These benefits were substantially 
greater than those from recent improvements in healthcare systems and medical therapy.  Crucially, 
all these changes happened in a very abrupt way and with almost no lag time in relation to the fall in 
mortality (see section 6.2).  
The rapid decline phase of the coronary heart disease epidemic in Poland is thus mainly 
attributable to decreases in major risk factors that can be linked to the substantial changes in dietary 
factors “forced” in the population during the socio-political transition to a democracy and a market 
economy.  The “natural experiment” which occurred in Poland now requires further support from 
evidence-based policy interventions. Furthermore, these analyses have implications for strategies to 
fight future epidemics of CHD. Effective legislation to control smoking, dietary salt and saturated fat 
consumption could be rapidly beneficial.   
Poland seems to have achieved a substantial socioeconomic transformation with only modest 
increases in inequalities. In both Poland and Hungary, all cause mortality rates decreased or 
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remained the same in all educational groups between 1990 and 2000; in Estonia and Lithuania, 
those with lower educational levels showed higher mortality, mainly attributable to cardiovascular 
disease and external causes.263 However, data on CHD mortality and risk factors trends is lacking for 
these latter countries, preventing further analysis of this crucial aspect. 
Substantial socio-economic inequalities exist in most developed countries. Intriguingly, many 
of these countries are showing evidence of slower pace of change in coronary heart disease 
mortality, after several decades of solid decline.  
Because of the social patterning of risk factors, differences in the pace of decline of CHD 
mortality trends by socio-economic status might further support the role of risk factors as the main 
driver behind the trend patterns. However, this is extremely difficult to study because few countries 
have detailed mortality, risk factors and treatment trends by measure of socioeconomic level. An 
exception in this regard is the UK.  
In the next chapter, I will therefore further examine potential socio-economic differences in 
mortality trends in Scotland and in England, both being countries demonstrating substantial 
inequalities and large coronary heart disease burdens.  
Thereafter, I will use an extended version of the IMPACT model to formally explore any 
socioeconomic differences potentially underlying these trends.  
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7 CHD MORTALITY TRENDS IN SCOTLAND AND ENGLAND 
BY SOCIOECONOMIC STATUS 
 
 
7.1 INTRODUCTION 
I have discussed in chapters 3 and 4 the role of risk factors in explaining CHD mortality rates. 
Furthermore, I also described the existence of important socioeconomic gradients in coronary heart 
disease burden and in the distribution of risk factors.  In Chapter 6, I discussed how Poland 
experienced a rapid decline in CHD mortality with relatively modest increases in inequalities, and 
with risk factors playing a major role.   
The known social patterning of risk factors suggests that any change in risk factors that show 
socioeconomic differentials should result in trend changes with similar socio-economic 
characteristics.  However, the causal web linking socio-economic circumstances and cardiovascular 
disease outcome is complex, and predicting the effects on mortality trends is therefore 
correspondingly more difficult. This is a very difficult topic to study, as data are very sparse. 
However, the UK situation in this respect is privileged and substantial work on the association of 
social determinants and CVD outcome has been undertaken in this country.  
In this chapter, I will analyse trends from two UK countries (first Scotland and then England), 
where data on CHD mortality trends by socioeconomic status are available. I will also use an 
extended version of the IMPACT model which takes into account socio-economic status, to further 
explore trend determinants in the English population.  
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7.2 RECENT LEVELLING OF CORONARY HEART DISEASE MORTALITY RATES AMONG 
YOUNG ADULTS IN SCOTLAND MAY REFLECT MAJOR SOCIAL INEQUALITIES 
7.2.1 Introduction 
Scotland has seen a halving of coronary heart disease mortality in the last two decades. 285  
However, this country still experiences some of the highest CHD mortality rates in Europe and 
globally .286 
In other countries with high but declining coronary heart disease mortality rates, several 
reports suggest that these trends may be changing. 189,192,227,231  Slowing or flattening of coronary 
heart disease mortality rates in young adults seems to recently happened in England & Wales, 
United States 192  Australia, the Netherlands and New Zealand.227 The pattern for major 
cardiovascular risk factor trends is also changing, with dramatic increases in obesity and diabetes in 
all industrialised countries287, flattening of blood pressure falls in US women288, and persistent 
smoking in young adults in the United Kingdom and elsewhere. 289 
Recent trends in cardiovascular risk factors among Scottish adults present a correspondingly 
complex picture. There was significant progress between 1997 and 2003, with decreases in physical 
inactivity, dietary intake of fat, salt, and smoking [which reached government targets sets for 
2010].290 However, recent and substantial increases in obesity and diabetes, particularly among 
young adults, raise concerns about adverse effects on their subsequent coronary heart disease 
mortality rates. 291   
Because most cardiovascular risk factors are powerfully associated with socio-economic 
deprivation292, I hypothesized that if there were any deterioration in mortality rates in the young, 
this might be seen particularly in those most materially deprived. I therefore examined recent trends 
and social inequalities in age-specific coronary heart disease mortality rates in Scotland, particularly 
among disadvantaged younger adults. 
7.2.2 Methods 
Mortality statistics 
Vital statistics data were obtained for the Scottish population for the period 1986-2006.  We 
limited our analyses to people aged 35 years and older. The underlying cause of death from coronary 
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heart disease was determined using the International Classification of Diseases (ICD)-9 codes 410-
414 for 1986-1998 and ICD-10 codes I20-I25 for 1999-2006.  
Age-adjustment was performed using the direct method , using the European standard 
population  as reference.293  
Socio-economic status data 
Area level socio-economic status was categorized using the Scottish Index of Multiple 
Deprivation (SIMD) 2006 quintiles.  The SIMD is the official Scottish Executive measure of area based 
multiple deprivation. It is based on 31 indicators in six individual domains [current income, 
employment, housing, health, education, skills and training and geographic access to services and 
telecommunications]. SIMD is calculated at data zone level (median population size of 770), enabling 
small pockets of deprivation to be identified. The data zones are ranked from most deprived (1) to 
least deprived (6505) on the overall SIMD index. The result is a detailed and comprehensive picture 
of relative area deprivation across Scotland. SIMD is reported here using quintiles, being the first and 
second quintile the least deprived and the fourth and fifth the most deprived. 294 Since the SIMD 
health domain for 2000-2004 includes a mortality indicator, the Comparative Mortality Factor (CMF), 
this risks a tautology.  We therefore repeated our analyses using only the income component of the 
SIMD index.  
We then obtained data on coronary heart disease mortality by age and sex for the period 
1986-2006, and SIMD data for the period 1996-2006.  
 Trend Analysis 
Plots of rates and plots of annual absolute changes in the age-specific mortality rates were 
smoothed using 3-year moving averages.  A Joinpoint regression was fitted to provide estimated 
annual percentage change and to detect points in time where significant changes in the trends occur 
(JOINPOINT software version 3.0)209. A Bayesian Information Criterion (BIC) approach was used to 
select the most parsimonious model that fits best the data.  A maximum number of three joinpoints 
was allowed for estimations.  For each annual percentage change estimate, we also calculated the 
corresponding 95% confidence interval (95% CI). We performed two Joinpoint regression analyses.  
The first covering the period 1986-2006 for age and sex specific coronary heart disease mortality 
rates alone;  and the second covering the period 1996-2006, for sex, age and deprivation specific 
coronary heart disease mortality rates, (the period was chosen because limited data on deprivation). 
To increase statistical power for these latter analyses, we then combined the deprivation data into 
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three groups: the two most deprived quintiles (3 & 5), the intermediate quintile (3) and the two least 
deprived quintiles (1 & 2). 
7.2.3 Results  
Age adjusted coronary heart disease mortality trends 
Between 1986 and 2006, the age-adjusted coronary heart disease mortality rates decreased 
overall by 60.9% in men and by 56.4% in women (Figure 7-1). The average rate of decline in men was 
-2.88% (95% CI -3.86% to -1.89%) from 1986 to 1993, and for the period 1993-2006, -5.03% (95%CI -
5.40% to -4.65%).  For women, the average rate of decline was -2.23% (95%CI -3.11% to -1.34%) in 
the period 1986-1993 and -5.04% (-5.37% to -4.70%).for 1993-2006. 
Figure 7-1 Age standardized coronary heart disease mortality rates in Scotland by gender, 1986-2006 
 
Age and sex specific coronary heart disease mortality trends 
Age specific rates revealed a more complex picture (Figure 7-2).  
Furthermore, the APC between 2004 and 2006 was not significantly different from 0, [point 
estimate for the APC +6.4%, -6.72 to 21.38 (Table 7-2].  
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In men and women aged up to 75 years, the APC was consistently smaller in the most 
deprived quintiles compared with the most affluent (Table 7-2 and 7-3).  Similar results were 
observed when the analyses were repeated using the SIMD income component alone.  
Figure 7-2  Age specific coronary heart disease mortality trends (Scotland 1986-2006, men and 
women). 
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Table 7-1 Coronary heart disease mortality trends in Scotland 1986-2006: Joinpoint analysis in men and women aged over 35years 
 
Age group 
[years] 
Periods 
Deaths, 
number 
(min-max) 
Rates*  
(min-max) 
EAPC 95%CI  
 
Periods 
Number of 
deaths 
(min-max) 
Rates** 
(min-max) 
EAPC 95%CI  
 
Men 
 
Women 
            35-54 1986 - 2003 434-955 60.3-157 -6.28*  -6.76 to -5.80 
 
1986 - 1989 197-223 31.5-35.6 0.14   -6.96 to 7.78 
 2003 - 2006 425-449 58.6-61.7 -0.55  -9.47 to  9.24 
 
1989 - 1995 139-198 20.3-30.6 -9.02*  -12.31 to -5.60 
 
      
1995 - 2006 102-154 13.2-21.8 -4.94*   -6.24 to -3.61 
            55-64 1986 - 1997 1227-2152 483-826 -4.78*  -5.35 to -4.22 
 
1986 - 1991 722-807 254-280 -2  -4.00 to 0.03 
 1997 - 2006 743-1129 244-439 -8.81*  -9.82 to -7.78 
 
1991 - 1999 387-612 137-217 -6.99*  -8.37 to -5.60 
 
      
1999 - 2006 245-369 78-130 -9.79*  -11.59 to -7.95 
            65-74 1986 - 1993 3003-3380 1523-1833 -3.72*  -4.57 to -2.86 
 
1986 - 1989 2127-2258 851-899 -1.28  -4.2 to  2.49 
 1993 - 1999 2190-2916 1106-1455 -5.54*  -7.13 to -3.92 
 
1989 - 1998 1342-1947 542-785 -4.81*  -5.70 to -3.92 
 1999 - 2006 1248-1946 599-978 -7.89*  -9.08 to -6.68 
 
1998 - 2006 724-1253 293-509 -7.38* -8.52 to -6.24 
            
75-84 
1986 - 1994 2835-2967 2763-3263 -1.77*  -2.74 to -0.79 
 
1986 - 1993 3047-3477 1830-2055 -0.27 -1.38 to 0.84 
 1994 - 2006 1692-1627 1492-2717 -6.59*  -7.20 to -5.97 
 
1993 - 2006 1560-2738 898-1706 -5.42* -5.92 to -4.92 
            
85+ 
1986 - 1998 710-941 4123-5696 -6.52*   -7.16 to -5.86 
 
1986 - 1998 1735-2200 3245-3913 -4.28*   -4.82 to -3.75 
 1998 - 2003 890-992 3931-4508 -2.21   -6.09 to  1.83 
 
1998 - 2003 1936-2177 3039-3394 -1.25   -4.36 to  1.97 
 2003 - 2006 895-918 895-3989 
-
11.14*  -17.10 to -4.74 
 
2003 - 2006 1756-1818 2581-2921 -6.76*  -11.72 to -1.52 
EAPC: annual percent change. *EAPC significantly different from 0%. ** rates per 100000 
1
07
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In both men and women aged over 55, the annual percent rate change increased from 1986 to 
2006. However, in men and women under 55, there were clear decreases in the annual percent 
change [APC].  Men aged 35-54 years showed recent, significant flattening of the trend since 2003. 
Furthermore, the APC for that period, -0.55% [95% CI -9.47 to +9.24] was not significantly different 
from 0%. (Table 7-1)  
 
Likewise in women aged 35-54, the APC was -9.02% from 1989-1995 decreasing to -4.94% 
from 1995-2006, suggesting that the rate of decline is slowing down significantly in young women %. 
(Table 7-1)  
 
Socioeconomic differentials in coronary heart disease mortality trends 
Six-fold socio-economic differentials were observed between coronary heart disease mortality 
rates in the most deprived and most affluent quintiles in the youngest groups (Figure 7-3) although 
these differences were smaller in older age groups and disappeared above 85years. (Figure 7-5 and 
7-6) 
Age-standardized mortality rates across most deprivation quintiles decreased between 1996 
and 2006 (Figure 7-3).  However, there was no narrowing of the relative inequality gap (Figure 7-4).  
Coronary heart disease mortality rates in men aged 35-54 in the two most deprived quintiles 
decreased between 1996 and 2004 [APC -5.62%, -6.88 to -4.34].   
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Figure 7-3 Differences in coronary heart disease mortality trends by deprivation and gender, 
Scotland 1996-2006 (age standardised rates). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7-4 Trends in coronary heart disease death deprivation rate ratios (European standardized), 
Scotland 1996-2006, both genders. (Reference category is the 3rd quintile) 
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Figure 7-5 Coronary heart disease mortality trends by age and deprivation (Scotland 1996-2006, 
men). 
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Figure 7-6 Coronary heart disease mortality trends by age and deprivation (Scotland 1996-2006, 
women) 
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7.2.4 Interpretation 
The overall decline in age standardized CHD mortality rates conceals a flattening in younger 
men and women in Scotland, England and Wales and the USA.  Furthermore, in Scotland between 
1996 and 2006, the rate of decline in young men and women aged under 54 years, was significantly 
slower in the most deprived groups.  
Moreover, substantial socio-economic differences in coronary heart disease mortality rates 
were seen in Scotland between 1986 and 2005. Social gradients were visible in all age groups up to 
the age of 85 years.  
This analysis has several strengths. The Joinpoint regression analysis is able to identify periods 
of similar annual percent changes; this avoids the need to pre-specify periods (which may then bias 
the way in which the trends are analysed). Moreover, because the maximum numbers of possible 
join points was deliberately limited in this study, each annual percent change estimate was based on 
more data points.  
However, such analyses also possess limitations. Since most of the trend changes were recent, 
the confidence intervals for their average annual percent changes were correspondingly wider.   It is 
therefore important not to overstate the significance of these changes. The point estimate suggests 
an increase in young men. However, the wide confidence interval encompassing zero simply means 
that a flat line is possible or even a decline, albeit at a slower pace.  This potentially important 
observation needs to be confirmed in other populations. Similar constraints apply when comparing 
rates of decline between social groups.  
Although the data quality for mortality registration can’t be assumed perfect, the potential for 
disproportionate miscoding of mortality in deprived areas over a short time appears very unlikely.  
Furthermore, a number of studies suggest that coding in coronary heart disease is good quality in 
the young, extending up to and beyond the age of 65 years.295-297   
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Table 7-2 Joinpoint analysis of coronary heart disease mortality trends by age and deprivation in 
Scotland 1996-2006: Men aged over 35years 
Age group [years] Deprivation Category periods 
deaths, 
number Rates EAPC 95% CI for EAPC 
   
(min-max) (min-max) 
         
35-54 1&2 (Most Affluent) 1996 - 1998 50-82 33-57 2.47 -14.87 to 23.35 
  
1998 - 2006 39-83 25-57 -6.46* -8.53 to -4.34 
 
3 1996 - 2006 69-116 47-82 -5.64* -7.80 to -3.42 
 
4 & 5 (Most Deprived) 1996 - 2004 87-210 65-167 -5.62* -6.88 to -4.34 
  
2004 - 2006 103-158 75-123 6.4 -6.72 to 21.38 
       
55-64 1&2 (Most Affluent) 1996 - 2006 72-152 131-313 -10.44* -11.59 to -9.27 
 
3 1996 - 2006 145-233 225-442 -9.65* -11.26 to -8.01 
 
4 & 5 (Most Deprived) 1996 - 2006 170-455 295-803 -5.58* -6.51 to -4.65 
       
65-74 1&2 (Most Affluent) 1996 - 2006 143-376 368-1028 -9.43* -10.24 to -8.62 
 
3 1996 - 2006 261-532 583-1279 -7.69* -8.79 to -6.59 
 
4&5 (Most Deprived) 1996 - 2003 411-704 959-1610 -3.98* -5.59 to -2.33 
  
2003 - 2006 309-430 727-1075 -8.58* -15.43 to -1.18 
       
75-84 1&2 (Most Affluent) 1996 - 2006 250-402 1204-2247 -8.29* -8.78 to -7.80 
 
3 1996 - 2006 373-560 1550-2804 -6.83* -7.94 to -5.72 
 
4&5 (Most Deprived) 1996 - 2006 366-603 1646-3080 -4.63* -5.75 to -3.50 
       
85+ 1&2  (Most Affluent) 1996 - 2004 144-214 3467-4658 -4.30* -6.43 to -2.12 
  
2004 - 2006 162-200 3164-3688 -13.3 -31.12  to  9.13 
 
3 1996 - 1998 187-207 4081-4698 -8.66 -24.09 to 9.90 
  
1998 - 2004 203-218 4166-4545 -1.22 -5.36 to 3.11 
  
2004 - 2006 145-183 3152-3500 -15.99 -31.91 to 3.65 
 
4&5(Most Deprived) 1996 - 2000 142-209 3633-4991 -8.49* -14.25 to -2.34 
  
2000 - 2004 145-200 3152-3500 1.24 -9.23 to 12.91 
  
2004 - 2006 145-179 3923-4501 -19.96 -37.21 to  2.00 
       
APC: annual percent change *APC significantly different from 0% 
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Table 7-3 Joinpoint analysis of coronary heart disease mortality trends by age and deprivation in 
Scotland 1996-2006: Women aged over 35years 
Age group [years] Deprivation Category periods 
deaths, 
number 
Rates EAPC 95% CI for EAPC 
   
(min-max) (min-max) 
  
       
35-54 1&2 (Most Affluent) 1996 - 2006 4-20 2-14 -6.54* -9.76 to -3.20 
 
3 1996 - 2006 15-28 10-20 -5.66* -9.11 to -2.07 
 
4 & 5 (Most Deprived) 1996 - 2006 25-57 17-42 -4.37* -5.95 to -2.75 
       
55-64 1&2 (Most Affluent) 1996 - 2006 14-60 21-117 -11.42* -13.14 to -9.66 
 
3 1996 - 2006 43-84 64-147 -8.49* -10.17 to -6.79 
 
4 & 5 (Most Deprived) 1996 - 2006 61-189 99-299 -6.22* -7.92 to -4.47 
       
65-74 1&2 (Most Affluent) 1996 - 2001 93-195 225-441 -7.52* -9.98to -4.98 
  
2001 - 2006 59-136 133-294 -10.85* -13.85 to -7.74 
 
3 1996 - 2006 142-312 275-604 -7.47* -8.85 to -6.06 
 
4&5 (Most Deprived) 1996 - 1998 346-458 611-814 1.49 -3.80 to  7.07 
  
1998 - 2001 488-394 488-721 -7.97* -13.16 to -2.46 
  
2001 - 2006 192-325 364-615 -3.59* -5.01 to -2.13 
       
75-84 1&2 (Most Affluent) 1996 - 2000 276-401 1045-1320 -4.18 -8.63 to 0.49 
  
2000 - 2006 221-368 719-1147 -7.74 -10.44 to -4.95 
 
3 1996 - 2006 314-527 867-1544 -5.66* -6.73 to -4.56 
 
4&5 (Most Deprived) 1996 - 1998 581-665 1496-1819 -5.67 -11.03 to  0.01 
  
1998 - 2002 512-589 1301-1649 -2.88 -5.90 to  0.23 
  
2002 - 2006 342-488 1019-1357 -6.45* -8.54 to -4.30 
       
85+ 1&2  (Most Affluent) 1996 - 2003 308-441 2548-3405 -2.48* -4.18 to -0.75 
  
2003 - 2006 276-432 2588-3308 -7.62* -14.02 to -0.74 
 
3 1996 - 2006 373-374 2267-3567 -2.55* -3.68 to -1.40 
 
4&5(Most Deprived) 1996 - 2000 389-453 2906-3713 -4.70 -10.73 to 1.73 
  
2000 - 2004 331-453 2854-3308 1.31 -9.08 to 12.90 
  
2004 - 2006 321-391 2588-2738 -11.67 -30.21 to 1.79 
       APC: annual percent change *APC significantly different from 0% 
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Measuring deprivation is a complex task. Although the SIMD might not be an ideal measure of 
socio-economic position, it is probably at least as good a deprivation measure as the Carstairs or 
Townsend indices. 298,299 Because the SIMD health domain included an indicator of the Comparative 
Mortality Factor (CMF) for 2000-2004, caution was necessary when analyzing mortality data lest a 
tautology occur. However, our results were essentially unchanged when the analyses were repeated 
using only the income component of SIMD as the deprivation measure.  Likewise, the SIMD 2006 
may not accurately reflect deprivation during the entire period of our analysis. 
A slowing of the rate of decline might simply reflect extremely low rates decreasing 
asymptotically as they approach zero. However, this would not explain the flattening in young men 
where rates were substantially higher than in women. 
Has this phenomenon been seen elsewhere?  Previous analyses of the flattening of mortality 
trends decline have mainly concentrated on age and sex effects in developed countries (England & 
Wales, USA and Australia). Surprisingly little attention has been paid to inequalities. Socio-
environmental factors, particular the income component, have been associated with the time of 
onset of the decline phase of the coronary heart disease epidemic in the USA in the 60s-70s.264 A 
comparison of mortality rates by educational level and occupational class in six European countries 
(Finland, Sweden, Norway, Denmark, England and Wales and Italy) showed that the decline in 
mortality among the socially disadvantaged was slower in the period 1983-1993.300  In the US, the 
rate of heart disease and stroke mortality decline among the least educated was slower, particularly 
in African Americans with low educational levels.301 In New Zealand, a cohort effect  has been 
suggested with flattening of the observed decline in mortality and a predicted major increase in 
burden for Maoris and Pacific Islanders,(both relatively deprived compared to Europeans).227 
Why might this mortality flattening remain confined to most deprived groups?  A number of 
possible explanations for the social mortality gradients should be considered.   Firstly, the 
distribution of major cardiovascular risk factors in the Scottish population showed marked 
socioeconomic gradients.291 These “downstream” biological risk factors such as smoking, cholesterol 
and blood pressure will in turn be strongly patterned by “upstream” socio-economic factors such as 
low educational attainment, poor housing and inadequate income.  
This also is consistent with the situation in Finland, where substantial decreases in 
cardiovascular mortality have been experienced in the last four decades, changes in risk factors are a 
stronger explanation for the mortality declines amongst the low socioeconomic groups as compared 
to the more affluent ones .302 
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Different levels and rates of change for cardiovascular risk factors in different socioeconomic 
groups may therefore make an important contribution to the continuing inequalities in coronary 
heart disease mortality. 292,303  In Scotland, the smoking rate in young adults is not declining as fast as 
in older groups. Furthermore, deprived groups continue to experience much higher smoking rates. 
291 A recent study on Scottish coronary heart disease risk factor trends have looked at socioeconomic 
differentials in risk factors trends. 304 Although there were reduction is most adverse risk factors for 
coronary heart disease, the socioeconomic differentials have not been reduced over a decade. Even 
more, there was a hint of widening albeit not statistically significant, meaning that in deprived 
groups risk factors trends might have decline at a slower pace. More importantly, Hotchkiss et al 
found that self-reported diabetes and hypertension increased in prevalence over this period for all 
the socioeconomic groups.  In the USA, although cholesterol and blood pressure improved in all 
socioeconomic groups, smoking and diabetes has actually increased amongst the more deprived.305 
Much more probably, these mortality changes reflect social gradients in unhealthy behaviour, 
lifestyle and circumstances resulting in poor diet and high tobacco consumption leading to 
unfavourable levels of major coronary heart disease risk factors.  These inequalities are persisting in 
spite of the widespread and constant health promotion and health prevention initiatives, which 
suggests substantial and continuing barriers to healthy changes. Increasing evidence suggests that 
younger and more deprived adults are less susceptible to preventative messages aimed at the 
general population.  For example, it has been shown that lower income, less education and lower 
self efficacy all increase barriers to health promotion interventions.303  Furthermore, marginalized 
minority and low-income groups may also receive less exposure to prevention messages on 
nutrition, exercise, and tobacco. 306  Although a role for decreased uptake of treatments among 
those most deprived groups cannot be discarded, this is probably modest, because the majority of 
premature coronary heart disease deaths occur outside hospital, half with no prior diagnosis of 
cardiovascular disease.307,308  
Cocaine cardio- toxicity might play a role. However, the scale of its burden cannot explain 
totally this phenomenon, even taking into account the substantial underreporting. Although cocaine 
related deaths (all causes) have been increasing in the UK, the peak in 2004 was 184 (1022 since 
1990). However only 36% of them were attributed to cocaine alone, and most happening in England 
& Wales.309 Furthermore, cocaine related cardiac deaths often occur in the context of established 
atherosclerosis310 and usually considered a triggering factor.128 
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Premature coronary heart disease deaths remain a potentially important contributor to social 
inequalities. Furthermore, the flattening mortality rates for coronary heart disease among younger 
adults may be the first warning signs of worsening lifestyle choices and behaviours rather than 
deterioration of medical management of coronary heart disease.  Unfortunately, large time series of 
risk factor prevalence measures are not currently available for this population. This represents an 
important priority for future research, in order to estimate the extent to which trends in major 
cardiovascular risk factors may explain inequalities in coronary heart disease mortality. A better 
understanding the complex interaction of causal risk factors and inequalities will also be crucial. 
Marked deterioration in medical management of coronary heart disease appears implausible. 
Thus, unfavourable trends in the major risk factors for coronary heart disease [smoking and poor 
diet], provide the most likely explanation for these apparent inequalities. 
This is the first country where socioeconomic differentials in the pace of change of coronary 
heart disease mortality rates were described. The most plausible explanation is the net result of 
diverse dietary and risk factor trends, rather than deterioration of medical care.   
In the next section, I will examine socio-economic differentials in coronary heart disease 
mortality rates in England, to explore whether the observed mortality flattening shows any evidence 
of socio-economic patterning similar to that in Scotland.  
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7.3 CORONARY HEART DISEASE MORTALITY TRENDS IN ENGLAND BY SOCIOECONOMIC 
CIRCUMSTANCES, 1982-2006  
7.3.1 Introduction 
England is an interesting setting for further exploring the relationship of socioeconomic level 
and coronary heart disease mortality trends, particularly because of the quality and similarity of the 
data to that available in Scotland. Thus, a comparison of the two countries might shed further 
insights regarding the drivers of the speed of change of these mortality trends.  
Recent flattening in mortality rates trends has been described both in Scotland and in England 
and Wales. In Scotland, the flattening is happening essentially amongst young deprived adults. There 
are no reports of age-specific socioeconomic trend differentials in England and Wales, although 
important socioeconomic differentials in mortality rates and risk factors has been described.6,106  
Our aim was therefore to analyze recent age, gender and socioeconomic specific coronary 
heart disease mortality trends in England during the period 1982-2006.  
7.3.2 Methods 
Data 
We used the Index of Multiple Deprivation 2007 (IMD) as our indicator of socioeconomic 
circumstances.311 The IMD is a measure of multiple deprivation at the small area level, the Lower 
Layer Super Output Area (LSOA), an area covering an average of 1,500 people. The overall IMD score 
is a weighted composite of indicators measuring seven domains of deprivation (income; 
employment; health and disability; education, skills and training; barriers to housing and services; 
crime; living environment). We grouped LSOAs into equal fifths of areas ranked by increasing IMD 
score. This IMD score remained fixed over the period of analysis Corresponding LSOA mid-year 
population estimates by five year age-group and sex for the period 2001-07 were provided by ONS 
(as ‘experimental statistics’)312. For 1981-2000, we estimated populations by extending previous 
work using a cohort-component model with outputs constrained to sum to the ONS sub national 
estimates for each year.313 All age-sex estimates were aggregated into the deprivation quintiles 
described above. 
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We obtained mortality data by year of registration of death for the period 1981 to 2007 from 
the Office for National Statistics (ONS). For each year, ONS provided counts of deaths aggregated up 
to 3-digit International Classification of Diseases (ICD) codes in five year age bands by sex for each of 
our five deprivation groups. We determined underlying cause of death from coronary heart disease 
by selecting on ICD-9 (ninth revision) codes 410-414 for the period 1981-2000 and ICD-10 (tenth 
revision) codes I20-I25 for 2001-07. We limited our analyses to people aged 35 years and older.  
Rates were standardised using the European standard as the reference population. To reduce the 
year on year variability in age-specific rates, we calculated rates for 10 year age bands (to age 85 and 
over) using three year moving averages. We quote just the central year to denote each three-year 
interval. 
Statistical analysis 
We used age-adjusted rate difference and rate ratio between the least and most deprived 
areas to quantify absolute and relative inequality.  We used Joinpoint Regression Programme 
(version 3.4.2, Oct 2009) to estimate periods with similar annual percentage change in mortality 
rates.  We used a Bayesian information criterion approach and allowed a maximum of three 
joinpoints (i.e. four segments).   In addition to the annual percentage change (APC) over each 
segment, Joinpoint also calculates a weighted average annual percentage change (AAPC) over the 
whole 25 years of the study. 
7.3.3 Results 
Overall change in age-adjusted CHD mortality rates 
Between 1982 and 2006, the age standardised rate for CHD mortality in England fell by 62.2% 
in men and 59.7% in women (see appendix A31A3) . Rates declined slightly faster for men than for 
women (averaging 4.0% and 3.7% per year, respectively).  However, absolute rates remained more 
than twice as high for men compared to women throughout the period. CHD mortality rates in men 
reached a similar level in 2006 (272 per 100,000) as those in women more than a decade previously 
(280 per 100,000 in 1992) 
The rapid decline in CHD mortality was observed in all deprivation groups.  Thus, the absolute 
gap in age-adjusted death rates between the most and least deprived groups fell by two-thirds for 
men (from 300 per 100,000 in 1982 to 190 per 100,000 in 2006) and almost halved for women (from 
161 to 87 per 100,000, respectively) (Figure 7-7). However, the narrowing of the absolute inequality 
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gap was accompanied by a significant widening in the rate ratio between deprived and affluent 
groups because rates fell more slowly for men and women living in the most deprived areas (3.3% 
per year for both) compared with the fall in rates observed in the most affluent areas (men 4.3% and 
women 3.9% per year) (Figure 7-8).  Even the differential pace of decline, the rate ratio for men 
therefore rose from 1.52 (95% CI: 1.50-1.54) to 1.94 (95% CI: 1.90-1.97); and for women, from 1.64 
(95%CI: 1.62-1.67) to 1.90 (95% CI: 1.86-1.94). Thus, over the quarter century, absolute inequality in 
CHD mortality has declined but relative inequality has increased.  
Figure 7-7 Age standardized CHD mortality rates by IMD, England 1982-2006 
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CHD mortality rates fell for all age groups and across all deprivation quintiles between 1982 
and 2006. Absolute inequalities therefore narrowed in each age and sex group (Figure 7-9). 
However, relative inequalities widened over the same period because death rates fell differentially.  
In 2006 there was a four-fold difference in rate ratios for men and a six-fold difference for 
women aged 35-44 (Figure 7-10 and 7-11). The rate ratio was largest for the youngest age groups 
and became successively shallower for older ages until by age 85 and over it stood at just a little over 
one, signifying only a small mortality disadvantage in the most deprived groups relative to the most 
affluent.  Not only were the CHD mortality rate ratios larger in younger ages, they also widened 
more over time (Figure 7-12). This was more clearly visible for men because rates for young women 
were particularly low in the least deprived areas (under 10 per 100,000 women from 1990 onwards 
in the age groups 35-44 and 45-54), and therefore subject to erratic fluctuations from one year to 
the next. Rate ratios drifted upwards over time because of the social gradient in the pace of decline 
in age-specific rates. Rates fell further in the more advantaged areas than in the deprived areas.  
Figure 7-8 CHD mortality rate ratios between most and least deprived groups, by gender.  England, 
1982-2006.  
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The social gradient in the Average Annual Rates of Fall (or AAPCs) was most marked between 
ages 55-64 to 75-84 where the majority of CHD deaths occur. Among those aged 85 and over, rates 
of fall were modest (about 2% per annum) and the pace of fall did not vary significantly between 
deprivation quintiles (Figure 7-9). As a result, the rate ratios for those aged 85 and over stood at just 
over 1 throughout the whole period despite rate difference in this age narrowing by about a fifth 
(Figure 7-12).  
The average annual rate of fall over the period was larger for men than women aged up to 54, 
but was higher for women than men aged 55 to 84 converging finally at age 85 and over (Figure 7-9). 
Time trend analysis - overall, by age, sex and deprivation quintile 
The annual rate of decline in CHD mortality in men for England was steeper in the most recent 
period from about 2000 onwards for most age bands above 45 years. (Table 7-4) The exact year 
when the rate of decline accelerated varied across different ages.  In contrast, for ages 35-44, the 
overall rate of decline for England slowed significantly from -4.7% per year (-4.6% to -3.3%) in 1994-
2000 to -2.9% per year (-2.0% to -3.9%) in 2000-2006.  
The average annual percentage decline in rates for women exhibited a similar magnitude and 
pattern of accelerated falls in the most recent period in the older age groups (Table 7-5).  Rates for 
the youngest age band (35-44) were very unstable with no clear pattern detectable in the most 
recent period (reflecting small numbers of events).  In the next higher age band (age 45-54) the 
overall pace of fall doubled in the most recent segment (from - 2.7% (-2.2% to -3.2%) in 1995-2002 
to -6.2%, (-5.2% to -7.2%) in 2002-2006. 
 In men , a similar flattening in the rate of fall in younger adults was seen in all quintiles except 
the third quintile.(Table 7-5)  In women, however, the APCs for the two most affluent quintiles 
flattened substantially (to 1.0% in quintile 1, not significantly different from 0% at the 95% 
confidence level) and actually reversed for quintile two with rates rising by about 5% per year 
between 2003-2006 (+4.9%, 1.0% to 8.9%) (Table 7-6) 
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Figure 7-9 Average annual percentage change (AAPC) in CHD mortality rates by age and deprivation, 
England 1982-2006 
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Figure 7-10 CHD mortality trends by age and deprivation, men, England 1982-2006 
 
Figure 7-11 CHD mortality trends by age and deprivation, women, England 1982-2006.  
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Figure 7-12 Trends in CHD mortality rate ratios between most and least deprived  groups by age 
group, England 1982-2006 
 
  
Table 7-4    CHD mortality trends by age and deprivation, men, England 1982-2006 
Age England By deprivation quintile 
Q1 (least deprived) Q2 Q3 Q4 Q5 (most deprived) 
year APC year APC year APC year APC year APC year APC 
 (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) 
35-44 82-91 -3.4* 
(-3.7 to -3) 
82-86 -1.1 
(-3.6 to 1.4) 
82-91 -3.9* 
(-4.5 to -3.2) 
82-97 -4.7* 
(-5.1 to -4.2) 
82-90 -3.3* 
(-3.8 to -2.8) 
82-85 -6.2* 
(-7.7 to -4.6) 
 91-94 -6.5* 
(-1.7 to -11) 
86-91 -4.4* 
(-6.8 to -1.9) 
91-94 -7.9 
(-15.6 to 0.5) 
97-00 -9.6 
(-20.9 to 3.3) 
90-00 -5.2* 
(-5.7 to -4.7) 
85-91 -0.8 
(-1.5 to 0.0) 
 94-00 -4.7* 
(-3.6 to -5.9) 
91-96 -9.5* 
(-12.3 to -
6.6) 
94-06 -4.3* 
(-4.9 to -3.7) 
00-03 1.9 
(-11.1 to 
16.8) 
00-04 -2.7 
(-5.7 to 0.4) 
91-95 -6.0* 
(-7.8 to -4.2) 
 00-06 -2.9* 
(-2 to -3.9) 
96-06 -4.0* 
(-4.9 to -3.1) 
  03-06 -6.4 
(-12.8 to 0.5) 
04-06 3.1 
(-3.0 to 9.6) 
95-06 -3.7* 
(-4.0 to -3.4) 
              
45-54 82-86 -3.7* 
(-3.1 to -4.4) 
82-87 -4.9* 
(-5.6 to -4.2) 
82-86 -4.1* 
(-5.0 to -3.2) 
82-88 -4.0* 
(-4.5 to -3.5) 
82-86 -3.9* 
(-4.7 to -3.1) 
82-85 -1.8 
(-3.9 to 0.4) 
 86-94 -6.7* 
(-6.4 to -7) 
87-93 -8.0* 
(-8.8 to -7.2) 
86-94 -7.1* 
(-7.5 to -6.6) 
88-93 -7.8* 
(-8.8 to -6.8) 
86-96 -5.8* 
(-6.1 to -5.5) 
85-95 -5.3* 
(-5.8 to -4.9) 
 94-03 -3.8* 
(-3.5 to -4.1) 
93-03 -4.7* 
(-5.1 to -4.3) 
94-02 -4.7* 
(-5.2 to -4.2) 
93-03 -4.3* 
(-4.6 to -4.0) 
96-03 -2.9* 
(-3.5 to -2.2) 
95-03 -2.7* 
(-3.5 to -1.9) 
 03-06 -6.1* 
(-4.6 to -7.6) 
03-06 -7.9* 
(-10.4 to -
5.2) 
02-06 -6.4* 
(-7.8 to -5.0) 
03-06 -6.0* 
(-8.1 to -3.8) 
03-06 -7.7* 
(-9.7 to -5.7) 
03-06 -5.7* 
(-8.8 to -2.4) 
              
55-64 82-85 -0.8 
(0 to -1.6) 
82-85 -1.4 
(-3.0 to 0.2) 
82-85 -1.1 
(-2.5 to 0.3) 
82-85 -0.5 
(-1.6 to 0.7) 
82-84 -0.1 
(-1.0 to 0.9) 
82-86 -0.4 
(-1.1 to 0.3) 
 85-93 -4.9* 
(-4.6 to -5.1) 
85-94 -5.7* 
(-6.1 to -5.3) 
85-91 -4.8* 
(-5.4 to -4.1) 
85-94 -5.4* 
(-5.7 to -5.2) 
84-92 -4.4* 
(-4.6 to -4.3) 
86-93 -3.9* 
(-4.3 to -3.5) 
 93-06 -6.5* 
(-6.4 to -6.6) 
94-04 -7.6* 
(-8.0 to -7.2) 
91-06 -6.8* 
(-7.0 to -6.7) 
94-06 -6.4* 
(-6.6 to -6.2) 
92-97 -5.2* 
(-5.6 to -4.8) 
93-98 -4.8* 
(-5.8 to -3.9) 
   04-06 -4.7 
(-9.9 to 0.7) 
    97-06 -6.4* 
(-6.5 to -6.2) 
98-06 -5.6* 
(-6.0 to -5.2) 
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Table 7-4 (continued) 
Age England By deprivation quintile 
Q1 (least deprived) Q2 Q3 Q4 Q5 (most deprived) 
year APC year APC year APC year APC year APC year APC 
 (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) 
65-74 82-84 0.0 
(1.9 to -2) 
82-84 -1.1 
(-5.9 to 3.9) 
82-84 -0.9 
(-3.6 to 1.8) 
82-84 -0.5 
(-2.5 to 1.6) 
82-85 -0.5 
(-1.9 to 1.0) 
82-84 1.0 
(-0.1 to 2.1) 
 84-94 -3.0* 
(-2.8 to -3.1) 
84-94 -3.5* 
(-3.9 to -3.0) 
84-96 -3.5* 
(-3.7 to -3.3) 
84-94 -3.1* 
(-3.3 to -2.9) 
85-94 -3.0* 
(-3.4 to -2.7) 
84-93 -1.8* 
(-1.9 to -1.7) 
 94-00 -5.7* 
(-5.2 to -6.2) 
94-98 -5.4* 
(-8.1 to -2.6) 
96-03 -7.4* 
(-7.9 to -6.8) 
94-99 -5.6* 
(-6.4 to -4.9) 
94-01 -5.2* 
(-5.8 to -4.6) 
93-02 -4.8* 
(-5.0 to -4.7) 
 00-06 -7.8* 
(-7.4 to -8.3) 
98-06 -8.5* 
(-9.2 to -7.8) 
03-06 -10.1* 
(-12.1 to -
8.1) 
99-06 -7.7* 
(-8.0 to -7.3) 
01-06 -7.8* 
(-8.8 to -6.8) 
00-06 -6.7* 
(-7.2 to -6.1) 
              75-84 82-85 0.2 
(1.3 to -1) 
82-94 -1.5* 
(-1.6 to -1.3) 
82-84 1.1 
(-2.1 to 4.4) 
82-84 0.7 
(-2.6 to 4.0) 
82-85 0.9 
(-0.7 to 2.5) 
82-85 0.9* 
(0.0 to 1.9) 
 85-94 -1.7* 
(-1.5 to -1.9) 
94-03 -5.3* 
(-5.5 to -5.0) 
84-93 -1.7* 
(-2.0 to -1.4) 
84-94 -1.5* 
(-1.8 to -1.3) 
85-94 -1.7* 
(-2.0 to -1.3) 
85-94 -1.5* 
(-1.7 to -1.3) 
 94-
2003 
-4.6* 
(-4.3 to -4.9) 
03-06 -7.4* 
(-8.6 to -6.1) 
93-04 -4.6* 
(-4.9 to -4.4) 
94-
2003 
-4.7* 
(-5.1 to -4.4) 
94-03 -4.2* 
(-4.5 to -3.8) 
94-
2003 
-3.9* 
(-4.1 to -3.7) 
 03-06 -6.9* 
(-5.6 to -8.2) 
  04-06 -8.2* 
(-11.6 to -
4.7) 
03-06 -7.3* 
(-9.1 to -5.4) 
03-06 -6.5* 
(-8.3 to -4.7) 
03-06 -5.7* 
(-6.8 to -4.6) 
              
85+ 82-92 -0.7* 
(-0.3 to -1.1) 
82-89 -1.4* 
(-2.0 to -0.9) 
82-92 -0.4* 
(-0.7 to -0.1) 
82-84 1.7 
(-4.3 to 8.0) 
82-92 -0.5 
(-0.9 to 0.0) 
82-84 3.6 
(-0.4 to 7.8) 
 92-
2003 
-2.5* 
(-2.2 to -2.8) 
 
89-92 1.7 
(-1.9 to 5.4) 
92-00 -2.8* 
(-3.2 to -2.4) 
84-92 -1.1* 
(-1.8 to -0.4) 
92-99 -2.9* 
(-3.8 to -2.0) 
84-92 -1.6* 
(-2.1 to -1.1) 
 03-06 -5.7* 
(-3.7 to -7.7) 
92-03 -2.9* 
(-3.1 to -2.6) 
00-06 -0.9 
(-3.8 to 2.2) 
92-03 -2.3* 
(-2.7 to -1.9) 
99-02 -0.7 
(-5.8 to 4.7) 
92-03 -2.8* 
(-3.0 to -2.5) 
   03-06 -5.5* 
(-7.0 to -4.0) 
03-06 -7.5* 
(-8.9 to -6.1) 
03-06 -5.7* 
(-7.9 to -3.3) 
03-06 -5.3* 
(-6.9 to -3.7) 
03-06 -5.1* 
(-6.7 to -3.4) 
              
Notes: * Trend significantly different from 0  
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Table 7-5    CHD mortality trends by age and deprivation, women, England 1982-2006 
Age 
England 
By deprivation quintile 
Q1 (least deprived) Q2 Q3 Q4 Q5 (most deprived) 
year 
APC  
(95% CI) 
year 
APC  
(95% CI) 
year 
APC 
 (95% CI) 
year 
APC 
 (95% CI) 
year 
APC 
 (95% CI) 
year 
APC  
(95% CI) 
35-44 82-84 
-7.9* 
(-1.7 to -13) 
82-85 
-12.7 
(-24.2 to 0.4) 
82-85 
4.7 
(-2.9 to 13.0) 
82-93 
-1.2* 
(-2.4 to 0.0) 
82-86 
-8.4* 
(-13.9 to -2.6) 
82-02 
-2.5* 
(-2.8 to -2.2) 
 
84-06 
-2.4* 
(-2.2 to -2.5) 
85-01 
-1.4* 
(-2.7 to 0.0) 
85-90 
-14.0* 
(-18.5 to -
9.4) 
93-96 
-12.0 
(-27.9 to 7.3) 
86-91 
2.7 
(-3.7 to 9.5) 
02-06 
0.2 
(-3.5 to 3.9) 
   
01-06 
-9.4* 
(-16.3 to -
1.9) 
90-93 
15.7 
(-3.6 to 38.9) 
96-00 
9.1 
(-1.0 to 20.4) 
91-95 
-10.4 
(-19.7 to 0.1)   
     
93-06 
-4.5* 
(-5.4 to -3.6) 
00-06 
-7.0* 
(-10.0 to -3.9) 
95-06 
-0.6 
(-2.1 to 1.0)   
             
45-54 82-84 
-2.8* 
(-0.5 to -5) 
82-94 
-7.9* 
(-8.7 to -7.1) 
82-93 
-6.3* 
(-6.7 to -5.9) 
82-85 
-1.1 
(-5.0 to 2.9) 
82-96 
-5.2* 
(-5.4 to -4.9) 
82-84 
0.6 
(-3.5 to 5.0) 
 
84-95 
-5.8* 
(-5.6 to -6) 
94-98 
2.6 
(-5.5 to 11.3) 
93-96 
-2.9 
(-8.9 to 3.5) 
85-88 
-9.2* 
(-16.8 to -0.9) 
96-99 
1.0 
(-5.5 to 7.9) 
84-97 
-4.4* 
(-4.7 to -4.1) 
 
95-02 
-2.7* 
(-2.2 to -3.2) 
98-02 
-8.7* 
(-16.2 to -
0.6) 
96-03 
-5.7* 
(-6.9 to -4.6) 
88-04 
-4.3* 
(-4.8 to -3.9) 
99-03 
-5.1* 
(-8.3 to -1.8) 
97-02 
-1.5 
(-3.2 to 0.3) 
 
02-06 
-6.2* 
(-5.2 to -7.2) 
02-06 
1.0 
(-4.9 to 7.2) 
03-06 
4.9* 
(1.0 to 8.9) 
04-06 
-12.1 
(-22.9 to 0.1) 
03-
Jun 
-10.5* 
(-14.0 to -6.9) 
02-06 
-8.0* 
(-9.8 to -6.2) 
55-64 82-85 
0.4 
(1.6 to -0.8) 
82-85 
-1.0 
(-4.2 to 2.3) 
82-91 
-3.3* 
(-3.7 to -3.0) 
82-84 
3.1* 
(0.5 to 5.8) 
82-85 
1.0 
(-0.5 to 2.5) 
82-85 
1.6 
(-0.2 to 3.4) 
 
85-90 
-3.8* 
(-3 to -4.6) 
85-93 
-5.0* 
(-6.0 to -4.1) 
91-95 
-10.1* 
(-12.4 to -
7.8) 
84-87 
-2.7* 
(-5.1 to -0.1) 
85-90 
-3.4* 
(-4.3 to -2.4) 
85-89 
-2.2* 
(-4.0 to -0.4) 
 
90-98 
-6.6* 
(-6.2 to -7) 
93-02 
-7.8* 
(-8.8 to -6.9) 
95-98 
-4.7 
(-9.9 to 0.9) 
87-95 
-5.5* 
(-5.8 to -5.1) 
90-97 
-6.0* 
(-6.6 to -5.4) 
89-98 
-5.3* 
(-5.8 to -4.8) 
 
98-06 
-8.4* 
(-8 to -8.9) 
02-06 
-10.7* 
(-13.9 to -
7.4) 
98-06 
-8.4* 
(-9.0 to -7.7) 
95-06 
-7.9* 
(-8.1 to -7.6) 
97-06 
-7.5* 
(-7.9 to -7.1) 
98-06 
-7.8* 
(-8.4 to -7.2) 
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Table 7-5 (continued) 
Age 
England By deprivation quintile 
year 
APC  
(95% CI) 
Q1 (least deprived) Q2 Q3 Q4 Q5 (most deprived) 
year 
APC  
(95% CI) 
year 
APC  
(95% CI) 
year 
APC  
(95% CI) 
year 
APC  
(95% CI) 
year 
APC  
(95% CI) 
65-74 82-85 
-0.1 
(1 to -1.1) 
82-84 
-0.7 
(-3.9 to 2.6) 
82-84 
0.5 
(-3.8 to 4.9) 
82-84 
0.1 
(-1.6 to 1.9) 
82-84 
2.9 
(-1.5 to 7.4) 
82-85 
0.8 
(0.0 to 1.5) 
 
85-94 
-2.8* 
(-2.6 to -3.1) 
84-94 
-3.4* 
(-3.7 to -3.1) 
84-94 
-3.4* 
(-3.8 to -3.0) 
84-94 
-3.0* 
(-3.2 to -2.8) 
84-94 
-2.3* 
(-2.7 to -1.9) 
85-93 
-1.6* 
(-1.8 to -1.4) 
 
94-00 
-6.3* 
(-5.8 to -6.9) 
94-01 
-7.2* 
(-7.8 to -6.5) 
94-98 
-6.2* 
(-8.7 to -3.6) 
94-99 
-5.4* 
(-6.1 to -4.7) 
94-02 
-6.2* 
(-6.9 to -5.5) 
93-03 
-5.5* 
(-5.7 to -5.3) 
 
00-06 
-8.8* 
(-8.3 to -9.4) 
01-06 
-10.3* 
(-11.5 to -
9.2) 
98-06 
-8.8* 
(-9.5 to -8.0) 
99-06 
-9.3* 
(-9.7 to -9.0) 
02-06 
-9.3* 
(-11.5 to -7.1) 
03-06 
-8.7* 
(-9.9 to -7.4) 
             
75-84 82-84 
0.5 
(2.9 to -1.9) 
82-85 
-0.1 
(-1.4 to 1.3) 
82-85 
0.0 
(-1.5 to 1.5) 
82-85 
0.0 
(-1.7 to 1.7) 
82-84 
1.4 
(-1.4 to 4.2) 
82-84 
0.8 
(-2.2 to 3.9) 
 
84-93 
-1.2* 
(-0.9 to -1.4) 
85-94 
-1.7* 
(-2.0 to -1.4) 
85-93 
-1.2* 
(-1.5 to -0.8) 
85-93 
-1.1* 
(-1.5 to -0.6) 
84-94 
-1.3* 
(-1.5 to -1.1) 
84-93 
-1.3* 
(-1.6 to -0.9) 
 
93-04 
-5* 
(-4.8 to -5.2) 
94-04 
-5.8* 
(-6.1 to -5.6) 
93-04 
-5.6* 
(-5.9 to -5.4) 
93-03 
-4.9* 
(-5.2 to -4.5) 
94-03 
-4.6* 
(-4.9 to -4.3) 
93-04 
-4.2* 
(-4.5 to -3.9) 
 
04-06 
-8.7* 
(-5.5 to -
11.7) 
04-06 
-8.8* 
(-12.0 to -
5.4) 
04-06 
-8.0* 
(-11.8 to -
4.1) 
03-06 
-7.0* 
(-9.2 to -4.8) 
03-06 
-7.5* 
(-9.3 to -5.7) 
04-06 
-7.0* 
(-11.2 to -
2.6) 
             
85+ 82-92 
-0.5* 
(-0.2 to -0.9) 
82-92 
-0.3 
(-0.7 to 0.1) 
82-92 
-0.5* 
(-1.0 to 0.0) 
82-84 
3.0 
(-2.2 to 8.5) 
82-93 
-0.6* 
(-0.9 to -0.3) 
82-92 
-0.8* 
(-1.1 to -0.4) 
 
92-00 
-3.3* 
(-2.7 to -3.9) 
92-00 
-3.4* 
(-4.0 to -2.9) 
92-04 
-3.0* 
(-3.4 to -2.6) 
84-92 
-1.0* (-1.7 to -
0.4) 
93-00 
-3.4* (-4.2 to -
2.6) 
92-99 
-3.9* (-4.5 to 
-3.2) 
 
00-03 
-0.8 
(4 to -5.4) 
00-03 
-1.4 
(-5.5 to 2.9) 
04-06 
-7.5* 
(-13.4 to -
1.3) 
92-04 
-2.6* 
(-2.9 to -2.3) 
00-03 
-0.6 
(-5.4 to 4.5) 
99-03 
-0.2 
(-2.3 to 2.0) 
 
03-06 
-5.9* 
(-3.5 to -8.2) 
03-06 
-6.4* 
(-8.5 to -4.3)   
04-06 
-6.4* 
(-10.9 to -1.7) 
03-06 
-4.6* 
(-7.0 to -2.1) 
03-06 
-5.6* 
(-7.8 to -3.4) 
             
Notes: APC: annual percent change * Trend significantly different from 0 1
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7.3.4 Interpretation 
Substantial social inequalities in CHD mortality persisted in England throughout the period 
1982-2006. This was despite dramatic falls in the incidence rates of CHD deaths. Age-adjusted CHD 
death rates rose progressively with increasing area deprivation for both sexes.  However, the rate 
difference (gap between the most and least deprived quintiles) closed year on year such that by 
2006 absolute inequalities were approximately half those in 1982. However, because the pace of fall 
was steeper in the more affluent areas, relative inequalities widened over the same period.  
The pattern was repeated consistently in both sexes and for all ages except in the oldest – 
thus, that over time absolute differences declined while relative inequalities increased. Relative 
inequalities were largest at younger ages with the gradient becoming progressively shallower and 
disappeared above age 85.  The larger the social gradient at the baseline, the more it widened over 
time. Thus, the youngest age groups for which the social gradients were already the largest in 1982 
became progressively wider over the 25 years of this study.  
This study adds more information to my previous reporting of the flattening observable in 
England & Wales. First, the flattening is still evident in the younger age groups after updating the 
time series, crucially by adding a few years at the end. This is particularly noticeable for men and 
women aged 45-54. In my previous analysis, these groups experienced a slowing down in the two 
last periods, starting in 1993.In this updated analysis the flattening is confirmed for the period 1993-
2003 (1993-2002 for women), but accelerated afterwards, a pattern that resembles the observed in 
the Netherlands. A recent analysis of the WHO health for all database, focusing in adults aged-
standardized rates for adults aged 35-44 , didn’t found this flattening in England & Wales, but 
confirmed the flattening periods in Scotland and the “speed up” observed in the Netherlands.314  
They looked at a similar time period as we did in this updated analysis, but instead defined “fixed 
periods” 1985-89 to 1995-99 and then for 95-99 to 2005-07, and calculated relatives declines. The 
results for England & Wales in that study showed that the average annual percent change in those 
periods decreased from 38.5% to 28.5%, suggesting nonetheless a slowing down of the rate in young 
adults. These findings highlights the need for constantly update the trend analysis using change-
point methods, as new information is available.  
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Interestingly, absolute differentials are observed across most quintiles. These strengthen the 
idea that the slowing down in CHD mortality rates is a real phenomenon, and not an artefact 
attributable to low or unstable rates.  
In the Scottish analysis we hypothesized that socioeconomic differentials in the rate of decline 
by age can be explained by socioeconomic differentials in risk factors. The English data showed some 
differences in the rate of decline by socioeconomic status.  For example, women aged 45-54 in the 
most affluent quintiles showed slower pace of decline compared to the most deprived quintiles, 
tough the general picture is that there is not a clear-cut pattern as the one described in Scotland.  
In other setting, socioeconomic differentials in the pace change have been observed, but 
without looking at age specific rates. Marked social differences, with widening of the inequality gap  
in coronary heart disease mortality rates has been described in six European countries.300 In the US, 
slower decline in CHD and stroke in the least educated was observed, particularly in African 
Americans with low educational attainment.301 And in New Zealand Maoris and Pacific Islanders, 
considered more deprived than Europeans, slowing of their CHD mortality rate of decline has been 
described.227  
Why there are no clear socioeconomic patterns in the pace of decline observed in England? 
Preliminary evidence on risk factor in England showed that trends by socioeconomic status are 
complex. Between 1994 and 2008, the prevalence of smoking, high blood pressure and raised 
cholesterol decreased in most deprivation quintiles. However, there are increasing inequalities in 
obesity, diabetes and cholesterol levels in older people, and high blood pressure in younger 
women.315 The net effect of these diverse trends on rates is therefore difficult to estimate, and 
might explain the lack of socioeconomics gradients in the trend pattern.  
This study is based on a larger population; therefore, the rates are more robust. This suggests 
that the lack of a clear socio-economic gradient in the pace of change is not due to lack of power.  
This study has limitations. Misclassification of cause of death in young adults and the elderly 
over time and by deprivation area is possible, although unlikely given the high quality of mortality 
registration in England, as in Scotland. Misclassification of socioeconomic level at the time of death 
is also possible, as we use only just one measure of socioeconomic level for the entire trend. This 
could also bias the comparison between the two countries if the misclassification rate in both 
counties differs systematically.     
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Substantial methodological difficulties might still hamper the comparison of socioeconomic 
mortality differentials between populations when using area-based measures of socio-economic 
position. For example, differential rates of concentration of more deprived areas (“polarization by 
selective migration or increasing pauperizations”)316 might result in areas at the same quintile 
deprivation level but with substantial differences in health. This might also operate within a 
geographically defined population, as people with poorer health move differentially across areas 
within the geographical boundaries. Furthermore, uncertainties in the way small area population 
structure estimation (needed to calculate deprivation and mortality rates by deprivations status) 
might bias the findings and the comparison between the two countries.  
The inclusion of the health and disability component of the SIM to analyze mortality rate 
might induced some circular inference, creating a dependence of the socio-economic classification 
on the health outcome we are analyzing. Reassuringly, removing these components tends not to 
alter the results of other analyses.  
An intriguing possibility is yet unexplained mortality differences between Scotland and 
England, the so called “Scottish Effect”.317 However, the higher mortality in Scotland is increasingly 
unexplained by socioeconomic factors317, even using approaches that take into account the life 
course socioeconomic position.318  One of the explanations offered is that Scots have higher levels of 
risk factors compared with their English counterparts at the same deprivation level. This might result 
in a different absolute risk for the same deprivation level and therefore a different trend. 
Furthermore, the deprived Scottish population might be at a slightly different phase of the epidemic 
compared to equally deprived people in England.  
In conclusion, overall trends represent the net result of diverse underlying treatment and risk 
factor trends, some favourable and some unfavourable, operating in the population over a defined 
period. I have discussed earlier that the observed recent trend patterns in many countries are 
probably related more to changes in risk factors than to changes in treatments. Poland offered an 
informative case study in Chapter 6.  Because risk factors frequently demonstrate strong 
socioeconomic gradients in the UK, their contribution to these trends might also vary by 
socioeconomic status. However, no studies quantifying the contribution of risk factors and 
treatments by socio-economic status have yet been conducted in the UK.  
In the next section I will therefore describe the first study to explore this issue in detail.   
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7.4 ANALYSING RECENT SOCIOECONOMIC TRENDS IN CORONARY HEART DISEASE 
MORTALITY IN ENGLAND, 2000-2007: A POPULATION MODELLING STUDY 
7.4.1 Introduction  
Since the 1970s, coronary heart disease (CHD) mortality in England has fallen by a remarkable 
60%, with accelerated reductions in annual age adjusted death rates since 2000. However, as I 
discussed in chapter 2, CHD remains the leading cause of mortality and is a major contributor to 
social inequalities in premature mortality in England. Moreover, UK death rates have fallen faster in 
the most socially advantaged groups compared to the most deprived, as I shown in the previous 
section. Thus, although absolute inequalities in mortality have fallen, relative inequalities have 
increased over the last decade.  
Previous country-level analyses have suggested that about 50%-70% of the dramatic falls in 
CHD mortality between 1980 and 2000 were explained by improvements in modifiable risk factors 
(mainly smoking, total cholesterol and blood pressure), with the remaining 30% -50% being 
attributable to improved uptake of evidence-based treatments.144,149,319  However, so far no study 
has examined the specific contribution of risk factors and medical treatments to the underlying 
social differentials in CHD mortality falls. This might help to shed further light on the different 
dynamics showed by CHD mortality trends across the socio-economic spectrum.  
The most recent IMPACT study in the UK modelled CHD mortality change in England and 
Wales between 1981 and 2000.149   However, since then several initiatives have been rolled-out to 
improve the delivery of health care in England. These notably include the National Service 
Framework for CHD (2000), and also the Qualities and Outcome Framework (2004) which aims to 
monitor and incentivise improvements in the quality of services provided for CHD prevention, 
diagnosis, treatment and rehabilitation.320,321  In addition, important population-wide public health 
measures to reduce risk factors across the entire population have been introduced since 2000. These 
included the ban on tobacco advertising (2003); comprehensive smoke free legislation (2007), and 
voluntary agreements to reduce salt and artificial trans-fats in processed food.322,323  Furthermore, 
reducing health inequalities was at the heart of New Labour’s health agenda when it came to office 
in 1997.  
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However, the target to reduce the inequality gap in life expectancy by 2010 was not met.324  
Moreover, the potential effect of population-wide interventions on reducing inequalities in CHD 
mortality (when compared with individual treatments) remains unclear.165  
Thus although the following analysis covers a relatively short period of time, the period 
included a range of measures specifically aimed to improve outcomes and reduce social inequalities. 
Furthermore, I have quantified the variation by socioeconomic circumstances (SEC) in the relative 
contributions of modifiable population-level risk factors and evidence-based individual treatments to 
the fall in CHD mortality during the period 2000 to 2007. To do this I used the widely- replicated 
IMPACT model, after colleagues had substantially extended the model to quantify socioeconomic 
inequalities concealed within the overall national trends.  
7.4.2 Methods  
IMPACTSEC model and data sources  
IMPACT is an epidemiological model used to explain the contributions of population-level risk 
factor changes (incidence reduction) and uptake of evidence-based treatments (case fatality 
reduction) to the change in CHD deaths between two points in time. This deterministic, cell based 
model has been described in chapter 6 and elsewhere.144,149 The extended IMPACTSEC model 
included all the major risk factors for CHD: smoking, systolic blood pressure, total cholesterol, body 
mass index (BMI), diabetes, physical inactivity, along with fruit and vegetable consumption; plus all 
45 medical and surgical treatments currently in use in nine patient groups. The model included the 
total population of England aged 25 and over in 2000 and 2007.  
Data sources specific to the England population were used to construct the IMPACTSEC 
model. When several sources were available, we chose the most up-to-date, representative dataset 
which we could link to a small-area deprivation index. Population estimates and CHD death counts 
(2000: ICD9 410-414; 2007: ICD10 I20-I25) by sex, five-year age bands to age 85+ and deprivation 
quintile were obtained from the Office for National Statistics. Emergency admissions for acute 
myocardial infarction were extracted from Hospital Episode Statistics and supplemented with data 
from the Myocardial Ischemia National Audit Project to disaggregate ST-elevated acute myocardial 
infarction and non-ST elevated acute coronary syndrome, and to apportion treatment uptake to 
each group. For heart failure admissions, the National Health Service (NHS) Heart Failure Survey was 
used to estimate in-hospital treatment uptake. The General Practice Research Database and the 
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Health Survey for England provided data on treatment uptake in the community. Risk factor trend 
data came from the Health Survey for England.  
Detailed information on the IMPACTSEC model, calculation methods and data sources are 
provided in Appendix A4 
Stratifying data according to socioeconomic circumstances  
Only the Health Survey for England consistently recorded individual socioeconomic position; 
but all data sources recorded individual postcode of residence. We therefore used a measure of 
relative area deprivation as a proxy indicator of the socioeconomic circumstances of individuals 
living in small areas (n=32,482; average population of 1,500). We used the Index of Multiple 
Deprivation 2007311 to rank all lower super output areas in England in ascending order of increasing 
deprivation and grouped them into equal quintiles. Based on postcode of residence, the data 
providers matched CHD deaths and treated patients to their corresponding deprivation quintile 
before releasing the data to us.  
Deaths prevented or postponed (DPP)  
The total number of deaths prevented or postponed (DPP) for each deprivation quintile were 
calculated as the difference between observed deaths in 2007 and expected deaths had age-, sex-
and quintile -specific CHD mortality rates in 2000 remained unchanged. DPPs explained by the model 
could be positive (i.e. deaths averted) or negative (i.e. additional deaths in 2007 relative to 2000). 
Any shortfalls between the DPP explained by the model and the total DPPs for each SEC were 
assumed to reflect either imprecision in our model parameters or omission of other, unmeasured 
risk factors.  
Mortality reductions attributable to treatment uptake  
The treatment component of IMPACTSEC included nine mutually exclusive CHD patient groups 
(Table 7-6). A total of 45 patient treatment-pairings were generated. To avoid double counting of 
patients treated for two or more conditions within the year (e.g. heart failure develops within 1 year 
after myocardial infarction in approximately 30% of survivors) we quantified overlaps between 
different groups and made appropriate adjustments (Appendix A4).  
The numbers eligible for treatment, uptake of specific treatment, one year case fatality rates, 
and relative risk reduction due to treatment, all stratified by age, sex and CHD subgroup, were 
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extracted from relevant data sources (See Appendix A4). Disease prevalence and treatment uptake 
were further stratified by deprivation quintiles.  
Deaths prevented by each intervention were then calculated by multiplying the numbers of 
patients in each diagnostic group by the proportion of those patients who received the treatment, 
the baseline case fatality rate, and the relative risk reduction of that treatment. To estimate the 
cumulative effect of relative risk reduction for patients on a combination of drug therapies, we used 
the Mant and Hicks correction.276  
Many of the treatments were already widely used in 2000. The net benefit of an intervention 
in 2007 was therefore calculated by subtracting the expected number of deaths prevented if 2000 
uptake rates had remained unchanged from the deaths prevented using 2007 treatment uptake 
rates.  
We assumed that adherence (i.e. the proportion of eligible patients actually taking 
therapeutically effective levels of medication) was 100% among hospitalised patients, 70% among 
symptomatic patients in the community, and 50% among asymptomatic patients in the 
community.144  
Mortality reductions attributable to risk factor changes  
We included seven risk factors in the model; both behavioural –smoking, physical inactivity, 
fruit and vegetable consumption, BMI – and physiological markers including systolic blood pressure, 
total serum cholesterol and diagnosed diabetes. To quantify the mortality benefits of an absolute 
change in each specific risk factor between 2000 and 2007, we used two approaches: a regression-
based approach for factors measured on a continuous scale (e.g. total blood cholesterol); and, a 
population-attributable risk fraction approach for dichotomous variables such as diagnosed 
diabetes. The independent regression coefficients of mortality benefit for a unit change in mean risk 
factor were obtained from published multivariate analyses (Appendix A4). Hence, the contribution of 
each risk factor to deaths averted was then calculated as the product of the deaths in 2000 (the base 
year), the absolute change in risk factor, and the associated relative risk reduction. For binary 
variables, we used relative risks from the Interheart Study (see Appendix A4)  
We assumed that there was no further synergy among risk factors nor between the treatment 
and risk-factor components of the model. Lag times between the change in cardiovascular risk factor 
levels and change in CHD mortality rates were assumed to be relatively rapid and were therefore not 
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specifically modelled. We used a different approach to estimate uncertainty for this version of the 
IMPACT model. We calculated 95% uncertainty intervals around the model output (i.e. DPPs) were 
calculated using Monte Carlo simulation. This involved replacing all fixed input parameters used in 
the model by appropriate probability distributions, and repeatedly recalculating the model output 
with values sampled from the defined input distributions (See Appendix A4). We used the EXCEL 
add-in Ersatz (www.epigear.com) to perform 1000 runs to determine using an bootstrapping 
approach the 5 and 95 percentiles of the resulting output distribution of DPPs values. These 
provided the 95% uncertainty intervals reported.  
7.4.3 Results  
Between 2000 and 2007, the age standardised CHD mortality rate in adults aged 25 and over 
fell from 229 to 147 deaths per 100,000; a decline of 36% overall or 6.1% per year (see appendix A3). 
In 2007, there were 74,174 CHD deaths, 56% of these were in men. Both death rates and the 
number of deaths were lowest in the most affluent quintile and the pace of fall was also faster: 
decreasing by 6.7% per year compared to just 4.9% in the most deprived quintile. This therefore 
widened relative inequalities over the period.  
Nationally, there were 38,070 fewer CHD deaths in 2007 than if 2000 mortality rates had 
persisted. This represents the total number of deaths prevented or postponed (DPPs). Despite the 
slower annual rates of fall in the most deprived quintile, their higher CHD mortality rates in the base 
year meant that the number of DPPs by 2007 were fairly equally distributed: about 6,560 fewer 
deaths in the most deprived quintile versus 7,355 in the most affluent.  
Overall, approximately half of the total CHD mortality fall (19,780 fewer deaths or 52%, 
minimum 15%, to maximum, 120%) was attributable to improvements in uptake of medical and 
surgical treatments (Table 7-6) with population-level risk factor changes accounting for 
approximately 14,250 (37%, 21% to 58%)fewer deaths (Table 7-7). The model could not explain 
some 10% of the overall mortality fall (i.e. a shortfall of 4,040 deaths) (Figure 7-14, Table 7-7). The 
contribution of medical treatments to the deaths averted was very similar across all quintiles, 
ranging from 50% in the most affluent quintile to 53% in the most deprived (Table 7-8). But risk 
factor changes explained a smaller proportion of deaths prevented in the most affluent quintile 
compared with the most deprived (approximately 31% versus 49%, respectively). As a result, about 
19% of CHD deaths prevented could not be explained by the model in the most affluent quintile. The 
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proportion not explained fell successively with increasing deprivation; the model predicted 115 
more deaths prevented (or -2%) than the total DPPs for the most deprived quintile.  
The most substantial contribution to deaths prevented by treatments came from statin 
treatment for hyperlipidemia (-14% of the total mortality reduction), management of chronic stable 
coronary artery disease (-13%) and secondary prevention following myocardial infarction or 
revascularisation (-11%) (Table 7-6). Uptake rates of statins and angiotensin-converting enzyme 
inhibitors (ACE inhibitors) or angiotensin receptor blockers (ARB) more than doubled for secondary 
prevention and the management of stable coronary artery disease (Table 7-9).  
Figure 7-12  Proportion of the CHD mortality fall explained by risk factors or treatments,  by 
deprivation quintile, England 2000-2007 
 
  
Table 7-6 CHD deaths prevented or postponed due to changes in treatment uptake between 2000 and 2007 in England and stratified by deprivation 
quintiles 
Patient Group Deaths Prevented or Postponed  By IMD: Deaths Prevented or Postponed 
Eligible  n Best,% Min,% Max,%  Most Affluent,n IMDQ2, n IMDQ3, n IMDQ4, n Most Deprived, n 
           
STEMI -130 -0.3 -0.7 -0.5  -6 -27 -28 -31 -38 
Thrombolysis -118     -22 -23 -21 -23 -29 
Aspirin 24     5 4 5 3 7 
B-Blocker 4     1 0 1 1 2 
ACE inhibitor or ARB 5     0 0 2 1 2 
Clopidogrel 65     12 14 14 13 12 
Primary PCI 139     30 28 28 27 25 
Primary CABG 1     0 0 0 0 0 
CPR in hospital -252     -33 -51 -57 -53 -57 
           
NSTEACS 295 0.8 0.1 2.1  57 59 62 53 65 
Aspirin and heparin 341     54 68 68 63 88 
Aspirin alone -114     -15 -24 -21 -21 -31 
PG IIB/IIIA inhibitors -1     -2 -1 0 0 2 
ACE inhibitor or ARB 44     6 8 9 10 10 
B-Blocker 27     5 5 6 5 6 
Clopidogrel 203     36 40 46 41 40 
CABG surgery 1     2 1 0 0 -1 
PCI 54     11 10 12 12 10 
CPR in hospital -259     -40 -48 -58 -55 -58 
           
Secondaryprevention post MI 3510 9.2 7.3 11.7  640 775 746 711 639 
Aspirin 351     65 69 76 87 55 
B-Blocker 862     158 197 194 167 146 
ACE inhibitor or ARB 903     166 200 190 175 172 
Statin 1303     241 280 269 268 245 
Warfarin 92     8 30 17 15 21 
Rehabilitation 0     0 0 0 0 0 
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Table 7-6 (continued)    
Patient Group Deaths Prevented or Postponed  By IMD: Deaths Prevented or Postponed 
Eligible  n Best,% Min,% Max,%  Most Affluent,n IMDQ2, n IMDQ3, n IMDQ4, n Most Deprived, n 
           
Secondaryprevention post MI 3510 9.2 7.3 11.7  640 775 746 711 639 
Aspirin 351     65 69 76 87 55 
B-Blocker 862     158 197 194 167 146 
ACE inhibitor or ARB 903     166 200 190 175 172 
Statin 1303     241 280 269 268 245 
Warfarin 92     8 30 17 15 21 
Rehabilitation 0     0 0 0 0 0 
           
Secondary prevention post revascularisation 590 1.5 1.2 1.9  112 121 128 117 110 
Aspirin 45     10 10 11 8 7 
B-Blocker 154     29 31 34 31 30 
ACE inhibitor or ARB 179     35 37 37 34 36 
Statin 174     31 36 38 37 32 
Warfarin 0     0 0 1 0 -1 
Rehabilitation (post CABG)b 0     0 0 0 0 0 
Rehabilitation (post PCI) 36     7 7 7 7 7 
           
Chronic stable CAD 4835 12.7 9.8 17.2  851 1007 1015 1006 955 
Aspirin in community 818     139 159 176 179 165 
Statins in community 2488     443 523 526 510 485 
ACE inhibitor or ARB 1292     241 281 268 261 241 
CABG surgery 236     27 44 45 57 63 
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Table 7-6 (continued)    
Patient Group Deaths Prevented or Postponed  By IMD: Deaths Prevented or Postponed 
Eligible  n Best,% Min,% Max,%  Most Affluent,n IMDQ2, n IMDQ3, n IMDQ4, n Most Deprived, n 
Heart failure - hospital 250 0.7 0.5 0.8  42 47 53 59 51 
ACE inhibitor 49     8 9 10 10 11 
B-Blocker 39     6 8 8 9 9 
Spironolactone 37     6 7 8 8 8 
Aspirin 126     21 22 27 32 23 
           
Heart failure - community 3335 8.8 7.3 10.6  564 689 732 711 641 
ACE inhibitor or ARB 737     125 158 171 146 137 
B-Blocker 1592     284 325 353 338 292 
Spironolactone 617     105 134 120 129 129 
Aspirin 389     50 72 88 97 83 
     
Hypertension treatment 1800 4.7 1.8 10.7  357 411 408 345 277 
           
Hyperlipidemia treatment (statins) 5300 13.9 5.3 30.8  1054 975 1305 1194 772 
           
A:Total treatment contribution 19780 52.0 41.4 70.8  3670 4055 4420 4166 3471 
Eligible patient numbers rounded to nearest 5. 
 
ARB: Angiotensin receptor blocker; ACE inhibitor: angiotensin-converting enzyme inhibitors; B-blocker: beta-blocker; CABG: coronary artery bypass graft; CAD: coronary artery disease; CPR: cardiopulmonary 
resuscitation; DPP: deaths prevented or postponed; IMD: index of multiple deprivation; NSTEACS: Non-STelevation acute coronary syndrome; MI: myocardial infarction; PCI: percutaneous coronary intervention; PG: 
platelet glycoprotein; STEMI: ST elevation myocardial infarction. 
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Table 7-7   CHD deaths prevented or postponed due to changes in risk factor prevalence between 2000 and 2007 in England and stratified by deprivation 
quintile 
 
 England: Deaths Prevented or Postponed  By IMD: Deaths Prevented or Postponed 
   Min Max  Most Affluent IMDQ2 IMDQ3 IMDQ4 Most Deprived 
 Number % % %  Number 
Current smoking 1440 3.8 -3.5 12.0  141 204 28 319 489 
Diabetes -3595 -9.4 15.4 -3.1  -467 -562 -681 -728 1159 
Physical inactivity 540 1.4 1.1 1.7  81 98 107 117 140 
Systolic blood pressure, mmHg 
a
 12475 32.8 19.5 45.3  2062 2407 2587 2672 2749 
Total cholesterol, mmol/l 
b
 2365 6.2 10.8 15.7  260 556 331 392 824 
Body mass index -705 -1.8 -3.3 -0.4  -120 -140 -147 -145 -149 
Fruit and vegetable consumption 1725 4.5 1.1 9.3  336 369 379 334 308 
           
Total risk factors contribution 14250 37.4 14.1 57.3  2293 2930 2864 2960 3202 
           
Total treatment contribution 
c
 19780 52.0 41.4 70.8  3670 4055 4420 4166 3471 
           
DPPs explained by the model 34030 89.4 72.7 107.6  5963 6986 7284 7126 6673 
           
DPPs not explained  4040 10.6    1390 1239 1065 458 -115 
           
Total DPPs 38070 100    7353 8225 8349 7584 6558 
a
 After subtracting deaths prevented or postponed (DPPs) due to hypertension treatment in primary prevention. 
b 
After subtracting DPPs due to statins treatment in primary prevention. 
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These two therapies together contributed some 6,340 DPPs (17%). In contrast, deaths averted 
due to changes in treatment uptake in hospital-based patient groups were relatively modest: 
contributing just 65 fewer deaths (-0.5%) amongst emergency admissions for infarction and unstable 
angina (ST elevation myocardial infarction (STEMI) and non-ST elevation acute coronary syndrome 
(NSTEACS), respectively). Improved heart failure treatments in the community resulted in approximately 
3,335 fewer deaths, with relatively modest gains (250 fewer deaths) in hospitalised patients. 
Furthermore, there were essentially no gradients in treatment uptake across deprivation quintiles for 
either hospital treatment or drugs prescribed in the community for secondary prevention and heart 
failure (Table 7-9).  
Of the deaths prevented due to population-level risk factor changes, the largest contribution 
came from the fall in systolic blood pressure amongst those not on hypertensive medications 
(approximately 12,475 fewer deaths, or 33%) (Table 7-7). On the other hand, gains from hypertensive 
medication were modest (approximately 1,800 fewer deaths, 5%) (Table 7-6). Blood pressure falls were 
twice as high in women (5.4 mmHg versus 2.5 mmHg in men) but were of a similar magnitude across all 
deprivation quintiles (Table 7-10). Both in terms of absolute numbers and proportions, more deaths 
were prevented due to blood pressure falls in the most deprived quintile than in the most affluent 
(Table 7-7 and 7-8). 
In contrast, the benefits attributable to statins lowering of total cholesterol levels were double 
those attributable to the fall in cholesterol levels in the population not on treatment (approximately 
5,300 versus 2,365 fewer deaths, respectively). Between 2000 and 2007, hyperlipidaemia treatment 
increased nine-fold across all social groups from 1% to 9% (Table 7-9). Amongst those not on statins 
treatment, total cholesterol levels fell marginally more in women than men and by a similar magnitude 
across deprivation quintiles (Table 7-10). Thus, while the proportionate fall in deaths attributable to 
cholesterol reduction in the general population was similar across quintiles, in absolute terms more 
deaths were prevented in the most deprived quintiles (Table 7-7).  
Mortality gains due to positive trends in smoking, fruit and vegetable consumption and physical 
activity risk factors were negated by increases in BMI and diabetes (together contributing 4,300 
additional deaths, equivalent to an 11% increase in mortality) (Table 7-7).  Favourable trends in smoking, 
fruit and vegetable consumption and physical activity were modest; together only contributing about 
10% of the overall mortality fall (Table 7-7). Smoking prevalence declined in men and women by a 
similar amount (4%); however, there was a clear social gradient with larger absolute falls in smoking 
prevalence in more deprived quintiles (Table 7-10). Furthermore, levels of smoking still remained twice 
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as high in the most deprived compared to affluent groups ( see Appendix 1A4). Physical inactivity fell 
more in men (7%) than women (4%) across all deprivation quintiles; however three in four adults 
remained classed as inactive in every quintile. 
 
Even over the relatively short period of this analysis, the social gradient in diabetes became more 
pronounced resulting in three times as many additional diabetes-related deaths in the most deprived 
quintile compared with the most affluent.  
Risk factors explained 23.0% of the fall in young men (aged 25-54) in the least deprived quintile, 
compared to 30.6% in the most deprived. Treatments explained 19.2% in the least deprived and 25.9% 
in the same age group. Similar patterns were noted in older men, although patterns in women are more 
difficult to interpret. Risk factors explained more of the decline in young affluent women, although the 
model consistently overestimate, because of the small number of DPPs expected in these age groups. 
(Table 7-11) 
Model fit and sensitivity analysis  
The percentage unexplained by the model varied by age, sex and socioeconomic circumstances. 
The model fit was generally good overall and in women and men living in the most deprived areas. 
However, the fit was less good in affluent areas, where the DPPs explained by the model were 
significantly lower than the observed DPPs (the 95% uncertainty intervals did not overlap the observed 
DPPs for IMDQ1. (See Appendix A4). Model fit also varied substantially by gender, being better for 
women than men (Appendix A4), and in older adults.  
 
  
Table 7- 8  Comparative percentage distribution of deaths prevented or postponed by deprivation quintile 
 England,% Most Affluent,% IMDQ2,% IMDQ3,% IMDQ4,% Most Deprived,% 
Treatments:       
STEMI -0.3 -0.1 -0.3 -0.3 -0.4 -0.6 
NSTEACS 0.8 0.8 0.7 0.7 0.7 1.0 
Secondary prevention post MI 9.2 8.7 9.4 8.9 9.4 9.7 
Secondary prevention post revascularization 1.5 1.5 1.5 1.5 1.5 1.7 
Chronic stable CAD 12.7 11.6 12.2 12.2 13.3 14.6 
Heart failure in the hospital 0.7 0.6 0.6 0.6 0.8 0.8 
Heart failure in the community 8.8 7.7 8.4 8.8 9.4 9.8 
Hypertension treatment 4.7 4.9 5.0 4.9 4.5 4.2 
Hyperlipidemia treatment (statins) 13.9 14.3 11.9 15.6 15.7 11.8 
Total treatments 52.0 49.9 49.3 52.9 54.9 52.9 
       Risk factors:       
Smoking 3.8 1.9 2.5 3.4 4.2 7.5 
Diabetes -9.4 -6.4 -6.8 -8.2 -9.6 -17.7 
Physical inactivity 1.4 1.1 1.2 1.3 1.5 2.1 
Systolic blood pressure, mmHg 32.8 28.0 29.3 31.0 35.2 41.9 
Total cholesterol, mmol/l 6.2 3.5 6.8 4.0 5.2 12.6 
Body Mass Index -1.8 -1.6 -1.7 -1.8 -1.9 -2.3 
Fruit and vegetable consumption 4.5 4.6 4.5 4.5 4.4 4.7 
Total Risk Factors 37.4 31.2 35.6 34.3 39.0 48.8 
       DPPs explained by model 89.4 81.1 84.9 87.2 94.0 101.7 
       DPPs not explained by model 10.6 18.9 15.1 12.8 6.0 -1.8 
DPPs Counts       
DPPs explained by model 34030 5963 6986 7284 7126 6673 
due to treatment uptake 19780 3670 4055 4420 4166 3471 
due to risk factor change 14250 2293 2930 2864 2960 3202 
DPPs unexplained by model 4040 1390 1239 1065 458 -115 
       Total DPPs 38070 7355 8225 8350 7585 6555 
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Table 7-9 Percentage treatment uptake rates in 2000 and 2007 for England and stratified by deprivation quintile 
Patient Group Eligible England Most Affluent IMDQ2 IMDQ3 IMDQ4 Most Deprived 
Patients 2000 2007 2000 2007 2000 2007 2000 2007 2000 2007 2000 2007 
STEMI 20,700             
Thrombolysis  77.2 56.7 79.4 58.6 77.9 59.5 75.4 57.1 76.2 56.0 77.4 52.5 
Aspirin  93.6 96.0 93.6 96.6 94.7 96.3 93.1 95.4 93.2 95.6 93.4 96.4 
B-Blocker  71.3 70.3 74.8 70.9 72.3 69.1 71.0 69.8 69.6 69.5 69.9 72.4 
ACE inhibitor or ARB  77.2 76.3 79.8 76.6 78.9 75.6 75.4 75.5 75.4 74.8 77.3 79.2 
Clopidogrel  27.7 88.5 26.9 88.7 25.7 87.7 28.0 88.4 28.5 88.4 28.9 89.2 
Primary PCI  3.9 23.7 2.9 24.2 3.4 21.8 3.8 23.3 4.3 24.5 4.8 24.8 
Primary CABG  0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.2 0.0 0.1 
CPR in hospital  11.4 6.6 9.9 6.5 11.6 7.1 11.7 6.3 11.8 6.7 11.6 6.3 
              NSTEACS 91,285             
Aspirin and heparin  64.0 79.7 67.1 79.7 65.0 80.3 66.7 79.9 65.7 80.2 57.9 78.8 
Aspirin alone  24.2 12.8 21.5 13.5 23.9 12.3 21.5 12.7 23.5 12.6 28.9 13.1 
PG IIB/IIIA  6.1 5.8 9.4 6.2 7.3 5.8 6.1 5.1 4.7 5.2 4.3 6.8 
ACE inhibitor or ARB  66.0 73.2 68.6 73.1 64.5 72.2 65.9 72.5 64.3 72.7 67.0 75.0 
B-Blocker  63.2 67.6 66.1 68.2 62.7 67.7 63.5 66.7 61.7 66.3 62.8 69.2 
Clopidogrel  44.3 86.6 43.5 87.1 44.2 86.9 42.3 86.8 45.6 85.9 45.4 86.3 
CABG surgery  3.0 2.6 3.5 3.4 3.2 2.7 3.2 2.6 2.9 2.3 2.5 2.1 
PCI  3.1 6.7 3.6 7.7 3.4 6.9 3.2 7.0 2.9 6.4 2.5 5.7 
CPR in hospital  5.3 2.3 4.6 2.3 4.9 2.2 5.3 2.1 5.6 2.5 5.8 2.5 
              Secondary prevention post  
revascularisation 
111,930             
Aspirin  64.3 76.5 58.8 73.5 63.5 76.2 62.5 76.5 65.7 76.1 71.2 80.0 
B-Blocker  30.7 55.7 29.2 52.7 30.5 55.6 29.8 56.4 31.7 56.9 32.3 56.9 
ACE inhibitor or ARB  30.1 64.2 30.8 63.9 29.2 63.0 29.5 63.9 30.9 63.4 30.5 67.1 
Statin  58.2 84.5 61.7 85.1 58.2 84.6 56.3 83.9 56.3 84.8 58.7 84.2 
Warfarin  7.4 6.7 7.9 7.2 7.3 6.6 6.7 6.5 7.1 7.1 7.9 6.1 
Rehabilitation (post CABG)  73.0 73.0 73.0 73.0 73.0 73.0 73.0 73.0 73.0 73.0 73.0 73.0 
Rehabilitation (post PCI)  10.0 20.0 10.0 20.0 10.0 20.0 10.0 20.0 10.0 20.0 10.0 20.0 
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Table 7-9 (continued) 
 Eligible England  Most Affluent IMDQ2 IMDQ3 IMDQ4 Most Deprived 
 xPatients 2000 2007 2000 2007 2000 2007 2000 2007 2000 2007 2000 2007 
Secondary prevention post MI 565,595             
Aspirin  59.7 74.4 56.4 72.4 60.0 74.3 59.2 74.5 58.8 74.8 63.3 75.8 
B-Blocker  32.6 53.4 34.0 54.0 34.0 54.6 31.6 53.3 32.2 52.9 31.7 52.4 
ACE inhibitor or ARB  31.3 62.0 32.3 62.6 32.5 62.3 31.0 61.6 30.6 61.2 30.5 62.5 
Statin  37.1 77.4 39.8 77.9 39.5 77.8 35.9 76.6 34.7 76.6 36.2 78.1 
Warfarin  6.6 8.1 7.7 8.3 6.7 8.9 6.5 7.9 6.2 7.7 6.2 7.6 
Rehabilitation  45.0 45.0 45.0 45.0 45.0 45.0 45.0 45.0 45.0 45.0 45.0 45.0 
              Chronic stable CAD 984,805             
Aspirin in community  42.9 62.4 38.7 57.2 42.6 61.4 44.7 64.3 42.9 63.4 45.0 65.3 
Statins in community  23.9 66.2 25.4 63.4 24.2 65.4 23.7 66.5 23.0 66.3 23.3 69.2 
ACE inhibitor or ARB  19.8 45.7 19.9 45.1 19.0 45.5 20.5 45.8 20.1 45.5 19.7 46.5 
CABG surgery  8.7 9.6 8.8 9.8 8.7 9.7 9.6 10.3 8.7 9.7 7.7 8.8 
              Heart failure - hospital 24,625             
ACE inhibitor  53.2 59.1 51.8 57.6 52.1 57.9 52.7 58.6 53.4 59.4 55.2 61.4 
B-Blocker  25.4 28.2 24.3 27.0 24.5 27.2 25.0 27.8 25.6 28.5 27.1 30.1 
Spironolactone  20.7 22.9 19.8 22.0 20.0 22.3 20.4 22.7 20.8 23.1 21.8 24.3 
Aspirin  59.2 73.9 56.6 71.9 59.8 73.3 58.6 74.1 58.1 75.3 62.2 74.4 
              
Heart failure - community 172,770             
ACE inhibitor or ARB  45.6 68.9 48.2 70.2 44.5 69.3 43.4 67.8 45.9 69.2 46.6 68.4 
B-Blocker  10.4 34.2 10.7 35.1 11.2 34.6 10.8 34.9 9.4 34.2 10.1 32.4 
Spironolactone  3.9 14.5 4.3 14.7 3.9 14.9 3.6 13.0 3.9 15.1 4.0 14.9 
Aspirin  38.1 50.4 37.9 46.3 38.3 49.9 37.3 50.3 37.0 51.8 40.0 52.7 
              Hypertension treatment 35,280,845 8.3 13.5 8.3 14.0 8.2 13.8 8.6 13.9 8.2 13.0 8.3 12.7 
              
Hyperlipidemia treatment 35,280,845 1.1 9.0 1.0 7.9 1.1 8.5 1.1 9.1 1.4 10.3 1.3 9.1 
1
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Table 7-10    Absolute change in risk factor levels between 2000 and 2007 for England and stratified by 
deprivation and sex. 
 
 Overall levels  Absolute change in percentage points, 2000 to 2007 
 2000a 2007a  England Most Affluent IMDQ2 IMDQ3 IMDQ4 Most Deprived 
Smoking prevalence (%) 
Male 27.2 23.6  -3.7 -2.6 -3.1 -3.6 -4.1 -4.8 
Female 23.4 19.9  -3.5 -2.5 -3.0 -3.4 -4.0 -4.6 
         
Diabetes prevalence (%) 
Male 3.7 6.5  2.8 2.4 2.7 2.8 2.6 3.6 
Female 2.9 4.8  1.9 1.6 1.4 1.6 2.1 2.8 
          
Physical inactivity (%) 
Male 80.9 74.0  -6.9 -6.9 -6.7 -6.8 -6.9 -7.2 
Female 82.4 78.1  -4.3 -4.3 -4.2 -4.2 -4.2 -4.4 
        
Systolic blood pressure (mmHg) 
Male 133.1 130.6  -2.5 -2.6 -2.6 -2.5 -2.5 -2.4 
Female 131.0 125.6  -5.4 -5.3 -5.5 -5.5 -5.5 -5.5 
        
Total cholesterol (mmol/L) 
Male 5.6 5.4  -0.1 -0.2 -0.2 -0.2 -0.1 -0.1 
Female 5.7 5.5  -0.2 -0.2 -0.2 -0.2 -0.2 -0.2 
          
Body mass index (kg/m2) 
Male 27.3 27.7  0.4 0.4 0.4 0.4 0.3 0.3 
Female 26.9 27.2  0.2 0.2 0.2 0.2 0.2 0.3 
        
Fruit & vegetable consumption (portions) 
Male 3.4 3.7  0.4 0.4 0.4 0.4 0.4 0.3 
Female 3.6 4.0  0.4 0.4 0.4 0.4 0.4 0.4 
Notes: See appendix A4 for weighted averages of risk factor levels for each deprivation quintile, 2000 and 2007 
 
  
Table 7-11   Comparative percentage distribution of deaths prevented of postponed,  by 
deprivation, gender and age. 
 
IMDQ1 IMDQ2 IMDQ3 IMDQ4 IMDQ5 
Model DPPs 
 
Dpps % Dpps % Dpps % Dpps % Dpps % 
          
Treatments 
         
           
M 25-54 36 19.2% 56 26.4% 40 21.7% 59 24.8% 72 25.9% 
M 55-74 549 33.5% 671 34.6% 609 29.1% 620 31.1% 643 34.0% 
M 75-84 759 46.1% 892 53.5% 880 49.4% 795 54.1% 663 54.8% 
           F 25-54 18 87.2% 17 62.6% 14 21.6% 24 38.4% 35 33.6% 
F 55-74 267 43.7% 356 43.0% 383 42.8% 431 47.3% 397 39.2% 
F 75+ 699 54.3% 682 52.2% 856 61.2% 923 68.8% 654 61.3% 
           
          
Risk factors 
         
           
M 25-54 44 23.0% 48 22.7% 52 28.1% 68 28.6% 85 30.6% 
M 55-74 726 44.2% 886 45.6% 973 46.4% 978 49.0% 1018 53.9% 
M 75-84 588 35.7% 610 36.6% 591 33.2% 603 41.0% 475 39.3% 
           
F 25-54 15 72.2% 19 69.6% 30 46.5% 38 60.4% 53 50.7% 
F 55-74 423 69.2% 555 67.1% 641 71.6% 671 73.7% 822 81.3% 
F 75+ 834 64.8% 1009 77.2% 1069 76.4% 1043 77.8% 909 85.3% 
Observed DPPs 
M 25-54 189 
 
213 
 
184 
 
236 
 
277 
 
M 55-74 1640 
 
1941 
 
2094 
 
1995 
 
1890 
 
M 75-84 1646 
 
1666 
 
1780 
 
1471 
 
1210 
 
 
3475 
 
3820 
 
4059 
 
3703 
 
3377 
 
           
F 25-54 21 
 
27 
 
64 
 
63 
 
104 
 
F 55-74 611 
 
828 
 
896 
 
911 
 
1012 
 
F 75+ 1288 
 
1307 
 
1400 
 
1341 
 
1066 
 
 
1920 
 
2162 
 
2360 
 
2316 
 
2182 
 
           M+F 5395 
 
5982 
 
6418 
 
6018 
 
5559 
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7.4.4 Interpretation 
Between 2000 and 2007, English coronary heart disease mortality rates fell by an 
impressive 36% resulting in approximately 38,000 fewer CHD deaths in 2007. However the 
relative mortality inequalities between rich and poor persisted and even increased slightly over 
this period. This is the first study to analyse the socioeconomic components concealed within 
the overall mortality reductions attributable specifically to risk factor trends and to evidence-
based treatments. By using deprivation scores for area of residence as a unified marker of 
socioeconomic circumstances across all relevant large databases of population health and 
health service use in England, the study had adequate statistical size to quantify the impact of 
changes in risk factors and treatments within socioeconomic groups, even over a relatively short 
period of seven years. Understanding these recent trends, and their socially divergent 
trajectories, will be crucial to planning the most effective and equitable future strategies to 
prevent cardiovascular disease and reduce inequalities.  
Approximately half the fall in CHD mortality was attributable to increased medical 
therapies. These benefits largely reflected a doubling of drug use for community patients with 
chronic disease (who represent the largest CHD burden). In contrast, the contribution of medical 
interventions in hospital was relatively modest. Firstly, because the numbers of patients with 
acute disease were much smaller. Secondly, because few new treatments were subsequently 
introduced other than clopidogrel and primary angioplasty. And thirdly, the uptake rates for 
existing treatments were already close to maximum levels in 2000. The age-specific prevalence 
of CHD is socially graded. With similar levels of uptake of treatments across socioeconomic 
quintiles in both base and final years, this meant that the benefits of increased treatment were 
distributed remarkably evenly across social groups, which suggests a fairly equitable distribution 
of therapies across the NHS.  
Reductions in major cardiovascular risk factors explained approximately half the fall in 
CHD mortality (49%). However, the net benefit much was much smaller (approximately 37%) 
because adverse trends in BMI and diabetes potentially increased mortality by some 10%.  
The single largest contribution to the overall CHD mortality decrease came from 
population falls in blood pressure  with relatively small gains from hypertension therapies.325 
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Furthermore, reductions were similar across social groups. This is therefore entirely consistent 
with recent UK population-wide reductions in salt intake64,326, and with recent encouraging 
trends in other wealthy counties. Small increases in fruit and vegetable consumption and 
physical activity were seen across all social groups. Furthermore, moderate declines in smoking 
levels were actually greater in deprived areas. This may reflect the benefit of cumulative 
tobacco control policies since 2000, reinforced by the targeting of cessation services in deprived 
areas.327  
However, after excluding the effect of statins therapy, the decline in cholesterol levels in 
the wider population was modest. This may well reflect a failure to implement more effective 
policies.328 Particularly worrying was the approximately 4000 additional deaths attributable to 
the continuing rises in diabetes and BMI. This is consistent with recent Foresight analyses and 
represents a further warning to policy makers.329  
The absolute gap in CHD mortality between the most affluent and most deprived groups 
narrowed over the period of our study, however relative inequalities widened. This was unlikely 
to be due to differential treatment of diagnosed patients because levels of uptake of evidence-
based therapies were similar for all groups. The pace of fall in mortality in the most affluent 
groups was faster; but changes in risk factor levels could not explain about 20% of this fall. 
Perhaps the most likely explanation for this is a social gradient in effect modification. Thus, the 
current model assumed that the mortality decrease per unit change in risk factor was similar 
across deprivation quintiles. However, the benefits of a specific decrease in blood pressure or 
cholesterol may be disproportionately higher in more affluent groups, perhaps reflecting 
synergy with other positive trends.27 A recent cohort analysis found that even if four classic risk 
factors– blood pressure, cholesterol, smoking and diabetes – were to be completely eliminated 
in middle-aged men, relative inequalities in CHD mortality between those in low and high 
employment grades would persist despite a 70% reduction in absolute mortality differences.330 
Furthermore we do not have many estimates of the cumulative benefit associated with a 
lifetime of low-risk. For example, the Finnish Public Sector Study found that a marked 
socioeconomic gradient in absolute risk of CHD mortality persisted even in a low-risk sub-group 
that had never smoked, were not obese or physically inactive and who consumed moderate 
amounts of alcohol.331  
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Alternative explanations for the fraction of the mortality fall unexplained by the model 
include the possible omission of more “upstream” risks such as psychosocial stress which might 
differentially benefit affluent groups.27,302 Differential levels of adherence to prescribed 
medications may also play a role: however, this is a relatively under-researched area without 
clear cut evidence to support or refute the existence of systematic social gradients.332-334 We 
also tested the impact of varying adherence rates differentially on the DPPS explained. We 
found that this had only a small effect on the gradient in the proportion unexplained. Finally, 
measurement error may contribute; Health Survey estimates of risk factor trends by deprivation 
quintiles may lack precision because of small samples and differential response rates.  
The social gradients by age were not very marked, although in general showed that in 
more deprived groups, risk factors and treatments explained more of the observed decline, 
particularly in those under 55 years. THE IMPACT model assumes a linear trend in mortality, so 
is not entirely appropriate to explain the trend pattern described in section 7.3, which are more 
complex.  However, the relatively shallow gradients by age in the proportion of deaths 
prevented or postponed are consistent with the lack of clear-cut age patterns in the pace of 
decline across deprivation quintiles. This also might be the result as well of the modest changes 
observed in powerful risk factors, like smoking or cholesterol.  
Compared with previous IMPACT analyses from a baseline of the 1980s144,149,196,266,271,335, 
models of more recent changes, for example in Ontario319, demonstrate the growing relative 
contribution from improved treatments to reductions in CHD mortality. However, country-
specific proportions attributable to risk factors or treatments are relative to the scale of the 
decline, and hence potentially misleading. Thus, although Nordic countries possess uniformly 
good health services, their larger absolute falls in coronary mortality mainly reflect particularly 
impressive decreases in major risk factors, mainly cholesterol, blood pressure and smoking, and 
also smaller adverse trends in obesity and diabetes.148,196 
The IMPACT model has been replicated and validated in diverse national populations. This 
is the first IMPACT study to quantify the socioeconomic components of the contributions of 
changes in treatment and risk factors to falls in coronary mortality. The main datasets used are 
reasonably representative of the socioeconomic distribution of the English population and large 
enough for reasonably accurate estimates of socioeconomic change.  
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A number of limitations should also be acknowledged. These include the use of area-level 
categorisation of socioeconomic circumstances. However, area deprivation correlates well with 
individual socioeconomic position and may also help to capture the contextual effects of living 
conditions.336,337 Approximately ten percent of the CHD mortality fall was not explained by the 
model. The model fit was also less good in men in affluent areas, as discussed earlier. However, 
the model fit was generally good overall and in women and in men living in the most deprived 
areas.  
Approximately half of the recent substantial CHD mortality fall in England was attributable 
to medical therapies. Benefits were relatively even across social groups. This is consistent with 
equitable service delivery across the NHS. Treatment uptake in hospitals was close to maximum 
levels over the entire period while follow up treatment of cardiovascular patients in the 
community substantially improved and was equitable. This suggests the Qualities and Outcome 
Framework which was being implemented in general practice during the study period was an 
effective incentive for an effective incentive for improving uptake overall.338  
However, the net gains from risk factor improvements were small, reflecting modest 
recent decreases in powerful cardiovascular risk factors such as smoking and cholesterol, and 
further eroded by continuing rises in BMI and diabetes. This throws a spotlight on recent UK 
policies for salt reduction and tobacco control (relatively effective) and healthier diets (relatively 
neglected). Elsewhere, the successful introduction of effective, powerful, rapid and cost-saving 
policy interventions have achieved substantial reductions in the saturated fat, trans-fats, sugars 
and calories hidden in processed food, takeaways and sweetened drinks.148,328  Mandatory 
interventions involving legislation, regulation, taxation or subsidies consistently appear more 
effective and cost saving than voluntary schemes.64,339,340  They also tend to be equitable165 and 
surprisingly rapid as I discussed in the Polish natural experiment in chapter 6. The UK now has 
an equally pressing need for population–wide policy interventions to effectively tackle 
persistent inequalities in cardiovascular mortality.  
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7.5 CONCLUSIONS 
Comparisons within and between countries can provide potentially  valuable insights into 
possible drivers of inequalities in coronary heart disease.  The differing results for England and 
Scotland are intriguing. These differences may be real or may reflect data artefact arising due to 
higher levels of selective health migration in deprived areas, misclassification of socioeconomic 
status or uncertainties in accurately estimating the population structure.  Furthermore, the 
complex interplay of risk factor and treatments trend might also explain the different mortality 
trend patterns by age and socioeconomic status. A future study to model socioeconomic 
differentials in trend drivers in the Scottish population would therefore be valuable. That might 
explore potential socioeconomic differences in the proportion of the trends explained by risk 
factors and by treatments.   
 
In the final chapter of this thesis, I will summarize the main findings, refine the most 
plausible hypotheses to explain the sudden and rapid changes in mortality now observed in a 
range of different populations and settings, and then briefly discuss the public health 
implications.   
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8 OVERALL CONCLUSIONS AND PUBLIC HEALTH 
IMPLICATIONS 
 
 
8.1 INTRODUCTION 
The main findings of my thesis suggest that trends in coronary mortality can demonstrate 
temporal patterns which are surprisingly dynamic. This is very different to the conventional 
view.  
The recent mortality flattening in young adults seen in countries that had previously 
experienced the decline phase of the epidemics suggest that favourable trends can change 
quickly. Happily, the rapid reversals observed in young age groups in the Netherlands and in the 
entire population in Poland suggest that recovery can also happen very quickly. There is a strong 
case to attribute these changes mainly to major cardiovascular risk factors, since simultaneous, 
substantial deterioration of medical care in these countries is implausible. The abrupt decline 
experienced in Poland from 1990 can be reasonably attributed to a great extent to beneficial 
dietary and lifestyle changes mediating downstream risk factor levels. The complex 
socioeconomic trend patterns observed in Scotland and England are also more plausibly 
attributed to changes in risk factors rather than a marked deterioration in treatment uptakes.  
These rapid changes however challenge some aspects of our current understanding of 
CHD causation, particularly suggesting that the temporal relationship between changes in risk 
factors and changes in outcomes are probably operating in shorter timescales (years rather than 
decades), with profound public health implications.  
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8.2 SUMMARY OF RESULTS 
Coronary heart disease can be attributed mostly to classical risk factors and their 
upstream dietary and lifestyle determinants.  
I have discussed in chapters 2 and 3 the evidence base that supports our current 
understanding of CHD causation. The wide variability observed in coronary heart disease 
mortality rates cannot be explained mostly by genetic differences, suggesting that 
environmental exposures during the lifetime are the major causative factors. The 
atherothrombotic process is well characterized, and the central role of cumulative plaque 
formation and the development of an active inflammatory and thrombotic environment have 
been linked to the development of the clinical phase of the disease. The atherosclerotic process 
has been clearly linked to the cumulative, life course exposure to harmful levels of the major 
biological risk factors; these are independently associated to coronary heart disease incidence, 
with clear biological mechanisms and showing consistent effects in different populations. 
Dietary patterns and specific nutrients are also powerful independent predictors of CHD events, 
and they might act independently or mediated by downstream biological risk factors.  The 
approaches to control the coronary heart disease burden are based on this risk factor paradigm. 
This in turn suggests that primordial and primary prevention activities may perhaps represent 
more powerful strategies that treating patients and reducing case fatality rates. Acute triggers 
might then play a role by precipitating events in patients with established atherosclerotic 
lesions. 
8.2.1 Rates are not set in stone: dynamics of coronary heart disease mortality rates in 
England, Scotland, Australia, the Netherlands and Poland 
The recent trends for coronary heart disease mortality in younger adults reported in the 
US, England & Wales, the Netherlands and Scotland UK are disquieting. In England & Wales, the 
previous falls in age-specific mortality rates appear to be flattening in younger men and women 
(aged under 55 years). Thus far, rates in older adults continue to decline. In Scotland, a recent 
period of flattening in young men is also evident. In Australia, the overall decline in age-adjusted 
CHD mortality rates in Australia since the early 1990s conceals an important change in younger 
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adults.  This recent slowing in the rate of mortality decline is occurring in both men and women 
aged below 45 years. Interestingly, my analysis of a longer series confirms an earlier observation 
by Wilson in 1995that hinted at mortality flattening in young Australians.  
The adverse trends in some in risk factors rather than deterioration of medical care are 
the most plausible explanations.  
The flattening of the decline in CHD mortality among young Dutch adults in the 1990s is 
evident. However, the subsequent further decline in mortality rates is reassuring and quite 
important, mainly because it adds support to the concept that the observed flattening is a real 
phenomenon and not an artefact of low rates or a trend based on only a few years. The limited 
data on risk factor trends suggest that they are probably linked to these changes.  However, 
more detailed analyses are urgently needed, and indeed, are currently being undertaken.  
The rapid decline in coronary heart disease mortality in Poland after 1990 was a massive 
natural experiment, with everyone experiencing this decline. The shouldering in Poland in 1990 
suggests that this was probably a strong period effect temporally associated with massive 
changes in diet and lifestyle. Interestingly, there was no evidence of any subsequent slowing 
down in mortality rates in any age group.  
8.2.2 Socioeconomic differences in the rate of decline and shape of the trend: an emerging 
issue 
 In the UK, premature coronary heart disease death rates can be three to six times higher 
in the most deprived groups. They therefore remain a major contributor to social inequalities.  
Furthermore, the flattening mortality rates for coronary heart disease among younger 
adults may represent an early warning sign. The decreasing absolute inequalities and the 
increase relative inequalities observed in age-adjusted rates suggest that deprivation has a 
significant role as a trend driver.  
In Scotland, the observed flattening in the trends is apparently confined to the most 
deprived groups.  As worse medical management of coronary heart disease in deprived young 
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adults appears implausible, unfavourable trends in the major risk factors for coronary heart 
disease, must provide the most likely explanation for these inequalities.  
However, the lack of clear socio-economic gradient in the flattening in young adults in 
England represents an interesting contrast, and merits further consideration.  Firstly, the risk 
factor trends in England have a complex socioeconomic patterning, and the net effect of these 
diverse risk factor trends might explain the discrepancy with Scotland.  Secondly, the CHD 
modelling in England showed less marked social patterning of the contribution of risk factor 
changes among young adults.  More detailed risk factor trend analyses using a modelling 
approach by socio-economic status are now urgently needed for Scotland, and for additional 
countries such as Australia and the Netherlands. 
8.2.3 Results potentially explaining the trend drivers 
Deaths from coronary heart disease in Poland have decreased rapidly after the great 
political, social and economic transformation commencing in 1989. This natural experiment 
offered a unique opportunity to examine the contributions of treatments and risk factors to the 
observed dramatic decline in mortality.  
The major contributors to the Polish mortality fall were large changes in total cholesterol, 
plus beneficial trends in systolic blood pressure in women and decreased smoking in men.  
Physical activity also contributed.   Together they explained about 55% of the observed 
mortality decline. Worryingly, adverse trends negated some of these benefits, specifically 
obesity, diabetes and blood pressure in men and smoking in women.   
Evidence-based interventions explained about a third of the mortality fall in Poland. The 
most important treatment contributions came from therapies for heart failure, angina and 
secondary prevention. However, it is reasonable to assume that these benefits accrued over the 
20 years period, while the abrupt change in diet and lifestyle was occurred within a very short 
period.  
The rapid decline phase of the coronary heart disease epidemic in Poland is thus almost 
certainly attributable to changes in risk factors that can be linked to the major changes in 
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dietary factors as a consequence of the socio-political transition to a democracy and a market 
economy.  
A modelling approach can also be used to try and help explained complex trends by 
socioeconomic status, by crudely quantifying the contribution of risk factors and treatments.  In 
England, the IMPACTsec model suggests that approximately half the CHD mortality fall was 
attributable to improved treatment uptake. This benefit occurred evenly across all social groups, 
which reflects well on the UK National Health Service.  Important gains were observed from falls 
in systolic blood pressure, probably reflecting population level policy interventions on salt. 
However, the contributions of other cardiovascular risk factors were smaller, reflecting modest 
recent decreases in powerful risk factors such as smoking and cholesterol. These benefits were 
then further eroded by continuing and substantial rises in obesity and diabetes prevalence.  
8.2.4 Could the rapid changes in CHD mortality simply be artefacts? 
These changes in coronary heart disease mortality could be due to artefacts. However, 
even brief reflection suggests that this appears very implausible.  The flattening is consistently 
seen in similar age groups, has extended over many years or even a decade, and, crucially, has 
been observed in many countries.  
Major changes in coding quality also appear implausible, as most of the countries where 
the flattening occurred have some of the best death certification systems in the world. The 
method use to correct rates in Poland was based on the trend observed in cardiovascular 
disease, usually a better quality level of coding, and similar to other approaches.185  Differential 
coding precision by age is possible; however this generally tends to occur more frequently in 
older adults341 , while the flattening has been observed mainly in younger adults.  
It can also be postulated that a low rate might show an asymptotic pattern as it 
approaches a certain “minimum threshold”. Although theoretically possible, any such a 
threshold must be very low for coronary heart disease based on observations of event rates in 
individuals with very low overall cardiovascular risk.135,136,342 A threshold based on cases 
exclusively based on genetically determined events is implausible, as most of the candidate 
genes and genome-wide association studies suggest that the gene-environment interaction is 
the main determinants of the expression of harmful phenotypes. 125  Moreover, the Scottish 
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data shows how rates in the same age-group by socio-economic status (and thus within a similar 
order of magnitude) might show different trend patterns. 
A further key issue is that the trend analysis method used is sensitive to the length of the 
time periods considered. Therefore, phenomena happening at the end of the time series can be 
very dependent on the robustness of the rate. However, in the countries where flattening was 
observed, the period was sustained over several years. Australia and England are interesting 
cases in this regards, where the flattening was first identified based on a few years’ observations 
and then persisted when the series were updated.  
I have based my observations on the underlying determinants of the trends in Poland and 
England using a modelling approach. Many assumptions of the model are simplistic, and 
probably ignore potentially important determinants like life course influences or more complex 
trends over time. The models also failed to explain all the estimated deaths prevented or 
postponed. In part this can be attributed to the inherent uncertainty in the model parameters. 
Reassuringly, sensitivity analysis suggests that the main outputs of the models are not heavily 
influenced by imprecision. The effect of risk factors is probably underestimated because we 
assume that their effects are independent. On the other hand, the effect of treatments could be 
overestimated, particularly because we use effect measures based on randomized clinical trials. 
Treatment efficacy might be lower in the real world. However, the IMPACT model explicitly 
takes into account the uptake rates for treatments. Finally, some of the ages specific results are 
based on smaller numbers and thus, model outputs for age and gender specific analysis are 
correspondingly less robust. 
In conclusion, the rapid changes in CHD mortality trends are therefore very unlikely to be 
artefacts. Although the role of evidence based treatments cannot be disregarded, the recent 
changes in mortality trends described in this thesis more plausibly mainly reflect changes in risk 
factors levels.  
However, the conventional understanding of the development of CHD involves a long lag 
time, spanning decades.  The rapid changes observed in recent CHD mortality trends therefore 
demand a better explanation.  
In the following section, I will postulate some hypotheses in this respect.   
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8.3 MORTALITY RATES DYNAMISM – THREE HYPOTHESES  
 
The rapid changes in mortality observed in the populations I have studied, can be the 
result of changes in the disease determinants. We do not know with certainty what is causing 
these changes. The causal framework for coronary heart disease is very well established.  
However, the temporal dynamics of these trends however does not fit very well into the 
accepted paradigm, so alternative explanations should perhaps be explored as competing 
hypotheses. 
 
8.3.1 Do these dynamic changes reflect a reduction in CHD case fatality rates achieved by 
modern evidence-based treatments? 
The explosion in evidence-based treatments for coronary heart disease impacting on 
mortality and morbidity started in the early 1980s. Furthermore, a few treatments were 
available earlier, such as coronary care units and medications for hypertension. They explain up 
to half the deaths prevented or postponed in many Western countries. They also have rapid 
effects, with most benefits achieved within a few months or years, and lasting over the longer 
term. However, such therapies cannot easily explain the sudden changes in mortality I have 
described.  
In most Western countries, the decline in CHD mortality has been well underway 
following their peaks in the 1960s and the 1970s. Most of the “breakthrough” discoveries in 
coronary heart disease treatments were achieved in the late 1980s and 1990s (thrombolysis, 
angiotensin converting enzyme inhibitors, spironolactone in heart failure), although their wide 
adoption lagged considerably. Thus even in 2000, the uptake levels of evidence based 
treatments in health care systems in highly developed countries, like the US or the UK were 
remained unacceptably low144,149, and substantial additional gains could be achieved by 
increasing their provision.228 268  
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The flattening in mortality in young adults US192 and the similar patterns observed in 
England and Wales, Australia, the Netherlands and Scotland were essentially all starting during 
the last decade of the 20th century, when the evidence based treatment revolution was well 
underway. Thus, is implausible to consider that medical care in those settings subsequently 
deteriorated significantly.  
In Poland, the abrupt decline in mortality cannot be solely attributed to a surge in 
evidence-based treatments. The trend was well underway in the first few years of the decline, 
continuing at the same pace over the period at the same time that the uptake of modern 
treatments increased from very low levels in 1991 to moderate levels in 2005.252 
 
8.3.2 Are these dynamic changes the result of “triggers”? 
As I described in chapter 3, triggers precipitate cardiovascular events by essentially 
harvesting from the high-risk pool in the population, generally detected as a “spike” in a longer 
trend. Shortly after that spike, the rate then briefly decreases to a subnormal low level,  and 
then later recovers to its “endemic” level, usually over a period of days or weeks at most.  This 
peak followed by a trough is sometimes termed the “harvesting” phenomenon.127 
An individual might progressively accumulate atherosclerotic lesions and reach a period of 
vulnerability.  Some of them will develop acute clinical events “triggered” by environmental 
factors acting in a short lag time scale, such as shovelling snow or peak pollution levels. If 
enough people in the population are in this period of vulnerability, sudden and rapid changes in 
the direction and speed of change might occur at the population level. In a declining trend, a  
“harvesting effect” – triggers causing events that would have otherwise happens a short period 
after exposure – might result in a slowing down or even a reversal of the declining trend for a 
period of time, and then the rate will catch up to its usual level .  
The pattern of coronary heart disease mortality trends I described might be consistent 
with certain triggers like alcohol binge drinking pattern or cocaine abuse, both more prevalent in 
the young. However, the relative long period of time of sustained flattening is not consistent 
with the usual short time frame when triggers usually exert their effects. Trigger effects 
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associated with cardiovascular disease are usually seen within very short time scales (hours , 
days or weeks).128  Furthermore, a recent study of myocardial infarction incidence and exposure 
to air pollution found evidence of a “harvesting effect”.343  In this time-series study, Bhaskaran 
et al observed an association between particulate air pollution exposure up to 6 hours after 
exposure but lack of association in longer time scales, measured in days.  Influenza can increase 
the risk of cardiovascular events particularly among older people or people at high risk344 and is 
generally considered a “trigger”345. However it follows a clear seasonal pattern with peaks in 
CVD admission rates lasting several weeks or months at most, and particularly noticeable in 
epidemic periods.  In conclusion, the short-term nature of trigger effects completely fail to 
account for the long periods encompassing years of sluggish or no change in coronary heart 
disease mortality rates described earlier in this thesis. 
Furthermore, any such trigger would need to demonstrate clear cohort effects or strong 
age specific effects, because the flattening of CHD mortality rates has been observed mainly in 
young adults. Cohort effects in coronary heart disease mortality trends seems to be rare, only 
reported in  Singapore and Norway116, thus cohort specific triggering events are likewise 
unlikely. 
Age specific effects are more plausible. Binge drinking has been considered a trigger for 
cardiovascular events128 , and is a common drinking pattern among the young.346 However, its 
effects are only noticeable when rates are analysed over time periods measured in days or 
weeks 347,348  An interesting example is the midsummer celebrations in Finland, short term 
changes are observable following this alcohol excess , with a limited period of about three days 
of higher risk for cardiovascular events.348 However, year on year cardiovascular disease 
mortality rates are decreasing in Finland.349 Thus, although such triggering effects may be 
distinct, they cannot explain longer term Finnish trends. This peak of high mortality over a short 
time period thus fails to explain sustained periods of slow changing rates. The association of 
heavy alcohol intake  has been implicated in rapid changes in mortality occurring over several 
years in the former soviet republics in adults100, but this pattern and association has not been 
described in other settings, particularly the countries I have studied.  
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The association of very heavy alcohol intake and rapid changes in cardiovascular mortality 
within years has been reported in adults in the former Soviet republics.100 However, this pattern 
has not been described in other settings, particularly the countries I have studied in this thesis.  
Acute cocaine abuse has increased significantly among young cohorts, and is associated 
with acute cardiovascular morbidity and mortality.350  However, most studies suggest a time 
window of some hours or one day at most.128  Chronic cocaine abuse is associated with 
cardiovascular mortality and morbidity, but mainly associated with cardiomyopathy.  Cocaine is 
also associated with smoking and chronic alcohol abuse310 acting over a longer time scale. 
Chronic cocaine abuse is thus more a risk factor rather than a “triggering effect”. 
The trigger hypothesis singularly fails to explain the dramatic decline in mortality in those 
Central European countries joining the European Union after the collapse of the Soviet Union, 
where the rate of decline in CHD mortality was sustained over several years, without any 
evidence of subsequent “rebound”.  
Perhaps the most critical flaw in the triggering hypothesis is the very short time scale 
required, which is simply not consistent with longer periods of more sluggish rate change. The 
trend patterns which I have described in several countries lasted several years in a row. This 
suggests that the drivers of these sudden, rapid changes are attributable to determinants 
operating in a time scale of years, not months or days. Furthermore, they are probably acting on 
the forces that determine the size of both the high risk and low risk pools (affecting incidence or 
case fatality or both).  
Because the causal paradigm for CHD has been extensively studied over the last six 
decades, a simpler explanation should take it fully into account.  
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8.3.3 Might risk factors operate over relatively short time scales?  Revising the classical CHD 
causal paradigm 
A key aspect of this causal paradigm is the lifelong time course of the disease extending 
over many decades.12  Challenging this assumption and allowing shorter lag times for risk factor 
effects might explain the trend patterns in a simpler and more elegant way. There might also 
then be profound public health implications.  
I have discussed in chapter 2 the basic disease mechanism of coronary heart disease. 
Most clinical features of the disease are caused by underlying atheroma, usually complicated by 
thrombosis which suddenly blocks a critical vessel.  I have also discussed the evidence 
supporting an early life origin, with atheroma streaks developing  in some teenagers and young 
adults, 3,4,351,352  and the substantial body of evidence to support the early developmental origins 
hypothesis.113,115,353  This supports the notion that CHD and CVD have a long natural history 
extending over many decades or more probably over a lifetime.   
Indeed, the traditional causal paradigm in the temporal relationship between risk factor 
changes and the corresponding changes in mortality previously favoured an “incubation period” 
lasting some decades. Geoffrey Rose suggested this was probably longer than 10 years12, 
whereas Law et al proposed a lag time period of some three decades to explain the “French 
paradox”, (whereby French CHD rates are much lower than UK rates in spite of similar current 
risk factor levels)13. The life course paradigm also lends support to the idea of long lag times in 
CHD.353  And most extreme, Kelleher et al suggested that CVD trends in the mid 20th Century 
might reflect socioeconomic circumstance trends a century before.354 
Reversibility of disease and reduction in risk has correspondingly been conventionally 
assumed to require decades. However, my results and other observations on the rapid changes 
in coronary heart disease mortality suggest that this paradigm needs urgent revision.  
As I discussed previously, in the second half of the 20th  century, most Western countries 
experienced sustained declines in age adjusted mortality rates, with consistent rates of decline 
over a period of several decades.355  
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However, the recent reversal of the decreasing trends in many countries in young adults I 
have described in this thesis (chapters 5 and 7)  suggest that the hard won gains of the past 
could also be lost, and this could happen within a short time horizon.  
Rates can also go up, like the rapid rise in CHD mortality rates in China in recent decades. I 
have also discussed examples of more complicated trends, like in Poland where after a period of 
steady rising, coronary heart disease mortality rates suddenly commenced a rapid decline in 
1990 which continues today (chapter 6).  
More rapid changes can also occur, when associated with major changes in environmental 
conditions.  Thus, CHD mortality rates rose steadily during the 20th century and peaked in the 
1970s and 1980s in the UK, Western Europe, and North America. However, close scrutiny of 
these national trends usually reveals a notch in the early 1940s. This disparity has been 
consistently attributed to sudden decreases in dietary intake of meat and animal fats because of 
rationing (as in the UK) or starvation (as in Holland and Norway) during World War II.356  
This dynamism of CHD mortality rates clearly requires that the causation of coronary 
heart disease should also operate over shorter periods. Kuulusma et al analyzed data from the 
MONICA study and found that the association between risk factors and mortality rates improved 
if a lag time of just 3 to 4 years was taken into account.224  Furthermore, data from randomized 
clinical trials of lipid or blood pressure reduction suggest that mortality reductions occur within 
the first few years of follow up.24,357 Randomized Clinical Trials on diet84 and dietary 
supplementation (GISSI PREVENZIONE)358 likewise suggest that benefits are also observed within 
a very few years. Very short-term changes  in CHD mortality have also been associated to 
particulate air exposure.359 Equally important, rapid reductions in acute coronary events have 
been consistently observed within months of implementing smoke-free legislation in diverse 
countries.  Thus, rapid reductions averaging 17% were recently reported following smoke free 
bans in Scotland and elsewhere.360  
Numerous “natural experiments” also suggest that change can occur rapidly.  I discussed 
the possible explanations for the abrupt decline in Poland following the break-up of the Soviet 
Union in 1989. Subsidies for meat and animal fats ended and consumption fell.  This, plus 
substantial increases in vegetable oils and fresh fruit and vegetables quickly led to a 26% 
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decrease in CVD deaths between 1990 and 1994. These changes continued well into the 21st 
century, and the pace of decline keeps constant. Similar changes have been reported for Eastern 
Germany and the Czech Republic.187,253  In this thesis, I showed that risk factors explained 
approximately 55% of the Polish decline in CHD mortality over the period, while evidence-based 
treatments only explained about a third. Furthermore, most of the treatment gains likely 
happened towards the end of the two decades period. Similar changes have been reported for 
Eastern Germany and the Czech Republic.187,253  
Elsewhere, legislation in Mauritius during the 1990s, mandated polyunsaturated oils as a 
substitute for highly saturated cooking oils. Blood cholesterol levels fell 15% (0.8mmol/l) within 
five years.361   Likewise, in Cuba, rapid CVD mortality falls followed a sharp and substantial 
reduction in calorie intake during the “special period” of the early 1990s.362  In New Zealand, 
inequalities in life expectancy and CVD mortality have fluctuated in line with socio-economic 
changes.  The lag time was consistently less than five years.227  In Japan, successful salt reduction 
community based programs resulted in significant systolic blood pressure declines and 80% 
reduction in stroke mortality within a decade.57  Even more rapid rises and falls in CVD mortality 
have recently been observed in Russia, partly reflecting the dramatic fluctuations in 
consumption of diverse forms of alcohol.99 
Although there is an important body of evidence supporting the long period of 
atherosclerosis build up in the arterial system (See Chapter 3), the emergence of the vulnerable 
plaque paradigm and our increasing understanding of the role of thrombosis and inflammation 
might bring light to the often rapid time course of cardiovascular disease events.  
Most acute coronary events happen in plaque that are less than 75% occlusive; this 
suggests that thrombosis and inflammation usually play a major role in both atherosclerosis 
build-up and also in precipitating acute events (by creating and exploiting vulnerable 
plaques).2,363  The inflammatory and thrombotic milieu is a very dynamic environment.  Changes  
can occur very rapidly (within minutes) and might in part explain the circadian variation in ACS 
occurrence.364,365  Furthermore markers of inflammation like leptins or interleukin-6 have been 
also associated on the long term (years) with CHD events, even taken into account short-term 
individual variation.366,367  
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Since the different pathologic processes leading to plaque development, instability 
rupture and occlusion act on different time scales, subsequent clinical events might reasonably 
be considered to reflect the complex interplay of causal risk factors acting on different time 
scales.  
Dietary and lifestyle risk factors can be linked to inflammatory and thrombotic 
mechanisms in the atherosclerotic plaque. There are strong links between metabolism and 
inflammation and thrombosis. 363 For example, the effects on inflammation markers may explain 
the enormous risk associated with transfat consumption368, or the increased production of pro-
inflammatory adipokines observed in patients with central obesity or diabetes.369  Furthermore, 
lifestyle factors like smoking370 and physical activity371 have been associated with specific 
thrombotic and inflammatory processes operating at plaque level.  
Diet and lifestyle are thus not only determinants of the classical risk factors, involved in 
the long term build up atheroma, but also might be associated with biological and thrombotic 
events happening over much shorter time scales.   The recent flattening in mortality observed in 
some Western countries and the natural experiments observed in Finland, Eastern Europe, Cuba 
and Mauritius provide population level observations compatible with this hypothesis.   
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8.4 PUBLIC HEALTH POLICY IMPLICATIONS OF RAPID CHANGES IN CHD MORTALITY 
RATES  
The rapid response of mortality trends to changes in risk factors, acting at the population 
level provides further support to the importance of preventative strategies to decrease the 
future cardiovascular burden.  
A pro-active public health approach also makes strong scientific economic sense.  Such 
measures might include increased tobacco controls, improving the contents of food products 
(re-formulation); controls on the marketing of energy dense, nutrient poor, high fat, salt and 
sugar processed foods; package labelling, taxation of junk food and subsidies for healthier foods.  
Making commercial markets more health promoting and boosting the affordability of healthier 
diet options could be substantially cost saving. 372 373 
These types of policies are difficult to evaluate with traditional research methods, and we 
may therefore gain insights on the potential benefits by using a modelling approach.  For 
example, in the UK, the National Institute for Clinical Excellence (NICE) recently commissioned 
detailed economic modelling. A spreadsheet model was developed which generated a relative 
risk of primary CVD across the entire England and Wales population of 50 million for each 
successive year. In brief, reducing mean population cholesterol or blood pressure levels by 5% 
could result in discounted annual savings of approximately £0.7 billion and £0.9 billion 
respectively.328  
Reducing population cardiovascular risk by even one percent might generate discounted 
savings of approximately £260millions per year. 328 Additional benefits to existing CVD patients, 
and the inevitable reductions in other diseases were not quantified. However, halving CVD 
events across the entire population might result in discounted savings of approximately £14 
billion per year.328  
As with any modelling exercise, ranges of usually conservative assumptions are made, 
with the general result of probably underestimate the true gains. For example, usually benefits 
are discounted, because in general future gains are valued at a lower level than present or 
short-term gains.   An important implication  for estimating future disease burden is that If lag 
170 
 
times operates over a time horizon of years instead of decades, these benefits are greater, since 
discounting  will be smaller.  
Of course, policy-based prevention strategies are challenging and many politicians would 
instead prefer to rely on voluntary agreements with industry or focus on individual 
responsibility. Moreover, if preventative strategies are expected to work only in the long term, 
urgent issues might compete for scarce resources, reducing the value of these policies for real 
world policy decision making. Policy makers thus need to overcome their natural reluctance to 
legislate mandatory action.  This becomes easier when the situation urgently demands it, for 
example, when the pace of change in mortality rates is not sufficient or when the “epidemic” of 
childhood obesity continues to increase, in spite of numerous well meaning but ineffective 
initiatives.329 
The accumulating evidence in my thesis that change in a hard outcome like population 
CHD mortality can occur rapidly after intervening on cardiovascular risk factors could also help 
when prioritizing different policy options. However, the timescales of policy maker’s decisions 
are usually short term. In the UK for example, the need to demonstrate impact within the 4 year 
political cycle and  the requirement to 'balance the books' within the annual commissioning 
cycle374, makes it difficult for planners to prioritise prevention when assuming the “long time 
scale paradigm”. However, the rapid changes I have described in this thesis may help them to 
remove such perceived but false barriers, and instead consider more radical interventions.  
Action is urgently required, because the global burden of non communicable diseases is 
rapidly increasing, as I discussed earlier.  The control of the CHD epidemic across communities 
and populations is not immune to “adoption delays”. The earlier start of the decline phase in the 
US started at the beginning of the 60s in California, Maryland and the District of Columbia but in 
the southeast states only started five years later.193  Globally, Western countries started in the 
1970s-1980s, while most middle income and low income countries still experiencing the rapid 
increase phase of their cardiovascular epidemics. 
In 2011, the first UN High level summit on the prevention and control of Non 
Communicable disease was held, looking to engage member countries in a concerted and 
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accountable effort to tackle one of the key challenges of the upcoming decades. Time will tell if 
this will be translated in decisive action.   
Our knowledge of what we need to do is thus already substantial, the proof of its efficacy 
is considerable, and the examples of the early adopters are now more widely known.  More 
effort should therefore be directed to increase the adoption of effective strategies by more 
communities.177 
In conclusion, population wide interventions aimed at the major diet and lifestyle 
determinants of cardiovascular disease can have large benefits. Furthermore, this could happen 
quickly, within a few years. This also makes strong economic and political sense. It seems that 
prevention of cardiovascular diseases could score big, and also fast, even within the electoral 
term of many politicians and policymakers.   
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8.5 FURTHER RESEARCH 
Linking trends in CHD mortality with trends in risk factors remains a research priority. 
Such studies are not easy to perform, as they traditionally require following large cohorts over 
years or decades. Furthermore, these studies often have issues related to generalisability.  
In contrast, modelling studies potentially offer the opportunity to study many of the 
trends in contexts that are more relevant for policy makers. To some extent, IMPACT and other 
CHD models have addressed this, but mainly for simple linear trends. More sophisticated 
modelling approaches are now indicated to explore complex multi-dimensional trends in 
mortality and risk factors for CVD, and for wider non-communicable diseases.  
Studies that provide population answers will ultimately have to rely on long time series of 
risk factors and mortality in representative samples. However, such data are not easily available 
for most populations. An important recent development in this regard is the methodology 
developed by the latest version of the Global Burden of Disease study, currently underway. They 
implemented a multilevel hierarchical approach to estimate risk factors trends for settings with 
few data sources.64,138,139,141  This type of data can be used in trend analysis studies within a 
multivariate, time-series regression framework like ARIMA.  These methods allow the use of 
covariates and could be helpful in studying and explaining the ongoing disease trends.   
The England and Wales analyses described earlier demonstrated mortality flattening 
without significant differences across socioeconomic levels. This may be partly explained by the 
complex pattern of risk factors trends in socio economic groups. The hypothesis that the 
mortality trends differentials can be attributed to risk factor trends differential is therefore not 
yet proved nor disproved. The effect of risk factors on mortality (as a proxy for incidence) is 
complex, and the net effects might depend in many other factors including baseline risk and 
changes in population structure over time. Alternatively, the socio-economic measures currently 
available may simply be inadequate to highlight socioeconomic differences in both mortality 
trends and risk factors trends. We have extended the IMPACT model to analyze trends by 
socioeconomic status, and performing analysis on England and Scotland, to further explore the 
relationship between socioeconomic differentials and trend drivers in CHD mortality. This 
approach may in future allow us to explore whether the observed mortality flattening in 
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Scotland which shows marked inequalities by socioeconomic status, is related to risk factor 
trends differential by a measure of deprivation.  
One of the issues limiting the approach I used to identify points in time where a trend 
showed a different pace of change is the “sensitivity” of mortality rates to change in the number 
of events, particularly when rates are low, and thus less robust. Although Joinpoint regression 
models provide ways of controlling the numbers of years that will be considered into estimates 
of periods of constant change, a trend based on few years could be still heavily dependent by 
unstable rates at the end of the period.  The way the trend analysis methods find out change 
points in the trend thus becomes important. Recently, Martinez-Beneito375 proposed a Bayesian 
approach to Joinpoint inference, that could to some extent address this issue. The originality of 
this approach is that it is possible to propose a “prior model” and then use the data to estimate 
a “posterior model”. In that sense, more flexibility for model selection can be achieved, instead 
of considering as the baseline comparison a model with no joinpoint (a linear trend).  
Other time series methods employ cumulative change. These are generally known as 
Change point methods; an example of these is the CUSUM approach using in statistical process 
control methods. They can offer some insights, but are usually more useful for applications 
involving continuous variables.  
Simulation modelling approaches could also help our approach to sensitivity analysis. 
Incidence models that synthesize data on population, risk factors trends and case fatality can be 
developed for this purposes, and explore different assumptions in terms of mortality trend’s 
shape, pace of change and absolute or relative changes.  Such models can also be extended to 
integrate information on long time series of CHD determinants acting on different time scales: 
life courses influences, biological established risk factors, and triggers.  We are therefore now 
developing a policy model called IMPACT2 as a generic modelling platform that could in future 
perhaps be used for this purpose. 376  
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8.6 LESSONS I HAVE LEARNED DURING THIS PHD WORK 
Time is a complex variable in every epidemiological analysis. The time dimension of the 
CHD epidemic is particularly challenging.  Useful insights are difficult to obtain with informal, 
descriptive analyses or simple, age-adjusted analysis. I therefore needed to identify and use 
more appropriate study methods, like time-series analysis techniques. Nevertheless, because 
time is important, continuing monitoring of rates is crucial to make sense of ongoing trend 
changes.  
The analysis of mortality rates is frequently seen as a limited exercise particularly when 
done in a simplistic way. Even more, they are often overlooked altogether, or used as “off the 
shelf” paragraphs to justify importance or relevance of the study. However, they remain an 
essential part of the epidemiologist’s work, and the recent changes in CHD trends and the 
challenges they pose to central tenets of the coronary heart disease causation paradigm can be 
exciting.  
I enjoyed explaining an unusual method (Joinpoint) to reviewers during the peer review 
process of my papers, and when helping colleagues wishing to analyse their own data. This 
experience showed me the vital importance of clear and succinct communication of complex 
issues, without simply referring to other work, or resorting to technical language. The general 
reader should be helped to clearly understand the essential features of the particular technique 
being used, in order to enable them to critically appraise your work.   
Finally, hypothesis generating analyses are potentially important studies, even though 
mainstream peer-reviewed epidemiological research may look at them with some suspicion. 
They do not have the solidity of hypothesis-testing studies and might understandably go 
unnoticed.  However, when the hypothesis is focused on important policy issues and explicitly 
addresses the implications for prevention and public health, editors, reviewers and readers may 
often welcome this type of analysis.   
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10 APPENDICES 
A1. Example of model selection with the Joinpoint regression technique. 
England & Wales coronary heart mortality trends  
Both the Permutation test method and the Bayesian Information criterion method (BIC) try to 
find the simplest trend that fits the data well. The simplest case is therefore the model with no 
joinpoints, e.g., a linear trend. The BIC approach finds the model with the best fit by penalizing the 
cost of extra parameters (e.g. more joinpoints) , although fitting well the data, they are less 
parsimonious . The k-joinpoint model with the minimum value of BIC(k) is selected as the final 
model.  
The permutation test approach test if the alternative hypothesis of a trend with more 
joinpoints can be accepted instead of the null hypothesis of a trend with fewer joinpoints, adjusting 
for multiple comparisons.  
For example, for men aged 35-44 the best model is the one with 2 joinpoints, with a BIC of -
13.98 (see table A1-1). The permutation test approach finds as well that the best model consist of 2 
joinpoints, with a probability of type I error <0.01 , adjusted for multiple comparisons.  
A comparison of both approaches is presented in tables A1-1 and A1-2.  
 
 Table A1-1    Model selection using a Bayesian Information Criterion (BIC) approach. Men, England & Wales 
 
Bayesian Information criterion 
 
Permutation tests 
Age 
[years] 
Model JP n P df Σ SE BIC 
 
Test  JP, H0 JP, H1 N, df D, df 
Permu- 
tations 
P** 
                
35-44 #1 0 21 2 19 1.7E-05 -13.7 
 
#1 0* 3 6 13 4500 0.026 
 
#2 1 21 4 17 1.2E-05 -13.8 
 
#2 0 2  * 4 15 4500 0.010 
 
#3 2 21 6 15 7.4E-06 -14.0 
 
#3 1 2* 2 15 4500 0.020 
 
#4 3 21 8  7.5E-06 -13.7 
  
      
 
Final Selected Model 2 Joinpoint(s) 
 
Final Selected Model 2 Joinpoint(s) 
                45-54 #1 0 21 2 19 1.6E-04 -11.5 
        
 
#2 1 21 4 17 4.7E-05 -12.4 
 
#1 0 3* 6 13 4500 0.000 
 
#3 2 21 6 15 1.6E-05 -13.2 
 
#2 1 3* 4 13 4500 0.000 
 
#4 3 21 8 13 9.8E-06 -13.4 
 
#3 2 3* 2 13 4500 0.024 
 
Final Selected Model 3 Joinpoint(s) 
 
Final Selected Model 3 Joinpoint(s) 
                55-64 #1 0 21 2 19 5.0E-04 -10.4 
 
#1 0 3* 6 13 4500 0.000 
 
#2 1 21 4 17 6.7E-05 -12.1 
 
#2 1 3* 4 13 4500 0.000 
 
#3 2 21 6 15 2.2E-05 -12.9 
 
#3 2 3* 2 13 4500 0.012 
 
#4 3 21 8 13 1.1E-05 -13.3 
        
 
Final Selected Model 3 Joinpoint(s) 
 
Final Selected Model 3 Joinpoint(s) 
                65-74 #1 0 21 2 19 5.2E-04 -10.3 
 
#1 0 3* 6 13 4500 0.000 
 
#2 1 21 4 17 6.0E-05 -12.2 
 
#2 1 3* 4 13 4500 0.010 
 
#3 2 21 6 15 3.4E-05 -12.5 
 
#3 2* 3 2 13 4500 0.083 
 
#4 3 21 8 13 2.7E-05 -12.4 
        
 
Final Selected Model 2 Joinpoint(s) 
 
Final Selected Model 2 Joinpoint(s) 
                75+ #1 0 21 2 19 1.8E-03 -9.1 
 
#1 0 3* 6 13 4500 0.000 
 
#2 1 21 4 17 5.1E-04 -10.0 
 
#2 1 3* 4 13 4500 0.001 
 
#3 2 21 6 15 1.9E-04 -10.7 
 
#3 2* 3 2 13 4500 0.778 
 
#4 3 21 8 13 1.8E-04 -10.5 
        
 
Final Selected Model 2 Joinpoint(s)   
 
Final Selected Model 2 Joinpoint(s)   
                BIC: Bayesian Information Criterion df:degrees of freedom JP: joinpoints n: number of observations  P: number of parametersΣ SE: sum of squared errors  
 N, df: numerator degrees of freedom D,df:Denominator degrees of freedom ** p : p value with multiple comparisons adjustment (Bonferroni) 
 
1
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Table A1-2   Model selection using a Bayesian Information Criterion (BIC) approach. Women, England & Wales 
 
Bayesian Information criterion 
 
Permutation tests 
Age 
[years] 
Model JP n P df Σ SE BIC 
 
Test  JP, H0 JP, H1 N, df D, df 
Permu- 
tations 
P** 
                
35-44 #1 0 21 2 19 1.7E-06 -15.7 
 
#1 
 
0* 3 6 13 4500 0.294 
 
#2 1 21 4 17 2.1E-06 -15.5 
 
#2 0* 2 4 15 4500 0.307 
 
#3 2 21 6 15 1.8E-06 -15.4 
 
#3 0* 1 2 17 4500 0.367 
 
#4 3 21 8 13 1.6E-06 -15.2 
  
      
 
Final Selected Model 2 Joinpoint(s) 
 
Final Selected Model 2 Joinpoint(s) 
                45-54 
 
0 21 2 19 2.3E-05 -13.4 
 
#1 
 
0 3* 6 13 4500 0.000 
  
1 21 4 17 5.8E-06 -14.5 
 
#2 1* 3 4 13 4500 0.103 
  
2 21 6 15 4.2E-06 -14.6 
 
#3 1* 2 2 13 4500 0.098 
  
3 21 8 13 3.7E-06 -14.4 
        
 
Final Selected Model 3 Joinpoint(s) 
 
Final Selected Model 3 Joinpoint(s) 
                55-64 
 
0 21 2 19 3.2E-04 -10.8 
 
#1 
 
0 3* 6 13 4500 0.000 
  
1 21 4 17 4.7E-05 -12.4 
 
#2 1 3* 4 13 4500 0.000 
  
2 21 6 15 1.2E-05 -13.5 
 
#3 2* 3 2 13 4500 0.086 
  
3 21 8 13 9.2E-05 -13.5 
        
 
Final Selected Model 3 Joinpoint(s) 
 
Final Selected Model 3 Joinpoint(s) 
                65-74 
 
0 21 2 19 3.2E-04 -10.8 
 
#1 
 
0 3* 6 13 4500 0.000 
  
1 21 4 17 3.6E-05 -12.7 
 
#2 1 3* 4 13 4500 0.001 
  
2 21 6 15 1.4E-05 -13.3 
 
#3 2* 3 2 13 4500 0.469 
  
3 21 8 13 1.3E-05 -13.1 
        
 
Final Selected Model 2 Joinpoint(s) 
 
Final Selected Model 2 Joinpoint(s) 
                75+ 
 
0 21 2 19 6.5E-04 -10.1 
 
#1 
 
0 3* 6 13 4500 0.000 
  
1 21 4 17 2.5E-04 -10.8 
 
#2 1 3* 4 13 4500 0.008 
  
2 21 6 15 1.9E-05 -10.7 
 
#3 2 3* 2 13 4500 0.013 
  
3 21 8 13 1.2E-05 -10.9 
        
 
Final Selected Model 2 Joinpoint(s)   
 
Final Selected Model 2 Joinpoint(s)   
                BIC: Bayesian Information Criterion df:degrees of freedom JP: joinpoints n: number of observations  P: number of parametersΣ SE: sum of squared errors  
 N, df: numerator degrees of freedom D,df:Denominator degrees of freedom * hypothesis accepted ** p : p value with multiple comparisons adjustment (Bonferroni) 
1
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A2. The Polish IMPACT Model: Methods and data sources 
 
IMPACT is a deterministic, cell-based policy model. It uses epidemiological information to estimate 
the contributions of population-level risk factor changes (impacting mainly on incidence) and changes in 
the uptake of evidence-based treatments (impacting mainly on case fatality) between two points in time 
(the start-year and the end-year).  The primary outcome measure of the model is the deaths prevented 
or postponed (DPPs).  
The starting point for the model is to calculate the ‘target’ number of deaths the model needs to 
explain. This target number is obtained by using death counts recorded in the official registration system 
to calculate the difference between the actual observed Coronary Heart Disease (CHD) deaths recorded 
in the end-year from expected deaths, i.e. the number that would have occurred in the end-year had the 
CHD mortality rates remained the same as in the start-year.   
The calculation of the modelled estimate of DPPs rests on utilising two well-studied relationships: 
firstly, that between risk factor change and the relative reduction in CHD mortality; secondly, that 
between treatment uptake and reductions in case-fatality in patients with a specific form of CHD.  
The model applies the relative risk reduction quantified in previous randomised controlled trials 
and meta-analyses to estimate the mortality reduction attributable to: a) temporal change in risk factor 
prevalence (in those without diagnosed CHD) to calculate the DPPs ‘explained’ by specific risk factor 
trends; b) net change over the period in the uptake of specific treatments in patients with each specific 
form of CHD to estimate DPPs ‘explained’ owing to improved 1-year case fatality rates. Great care is 
taken to avoid double counting the same individuals. 
The mortality benefits from risk factor changes in the population, and treatment benefits in 
patient groups are then summed. This sum represents the DPPs ‘explained’ by the model. 
At the end of the modelling process, the total DPPs ‘explained’ by the model is then compared 
with the observed fall in deaths (the ‘target’ to be explained).  Model fit is therefore calculated as the 
difference between the observed deaths and model DPPs, and expressed as the percentage explained. 
This measures the extent to which the model was successful in explaining the observed change in the 
CHD mortality in the population.  
A policy model like IMPACT stands in contrast to a typical multivariate regression model because it 
seeks to synthesise best estimates from a variety of sources to reliably estimate the extent to which a 
range of factors, acting in combination, explain or predict an outcome.  We did not obtain the parameters 
for this model by running regressions. Rather, the model incorporates the best coefficients from the 
largest meta-analysis or randomised controlled trials of the reduction in case fatality attributed to 
treatment or the independent effect sizes of a unit change in each risk factor on CHD mortality.   
 The tables included in this appendix document provide details about the methods that were 
used in creating the Polish IMPACT model.  This model examines the effects of changes in treatments and 
risk factors trends on changes in mortality from coronary heart disease (CHD) among Polish adults aged 
25-74 years.  Earlier versions of the IMPACT mortality model have been previously applied to data from 
Europe, USA, New Zealand and China.1-7  This cell-based mortality model, developed in Microsoft Excel, 
has been described in detail online and elsewhere3-4 
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A2-1 Expected and observed number of deaths from CHD 
 The data sources needed to estimate the expected and observed numbers of deaths from CHD 
for 2005 are shown in Table A2-2. The expected number of deaths from CHD in 2005 was calculated by 
multiplying the age-specific mortality rates from CHD in 1991 by the population counts for 2005 in that 
age-stratum. Summing over all age strata then yielded the expected numbers of deaths from CHD. The 
difference between the number of expected and observed number of deaths from CHD represents the 
mortality fall, the total number of deaths prevented or postponed (DPPs) from the combined changes in 
treatment patterns and risk factor prevalence.   
A2-2 Treatments in the Polish IMPACT Model. 
 The treatment arm of the Model includes the following populations of patients:  
 those hospitalized with an acute myocardial infarction (AMI),  
 patients admitted to the hospital with unstable angina,  
 community-dwelling patients who have survived an AMI, 
 patients who have undergone revascularization procedure (coronary artery bypass 
grafting (CABG), or a percutaneous coronary intervention (PCI), with or without 
stent. 
 community-dwelling patients with angina pectoris (no revascularization) 
 patients admitted to hospital with heart failure, 
 community-dwelling patients with heart failure (no hospital admission). 
 Hypertensive individuals eligible for hypotensive therapy 
 Hypercholesterolaemic subjects eligible for cholesterol lowering therapy  
 
The main data sources used to estimate the numbers of these groups are shown in Table A2-2.  For each 
of the groups, we estimated the number of DPPs that were attributable to various treatments.  A listing 
of the treatments that were considered in the model and the data sources used to estimate the 
percentages of patients receiving treatments are shown in Tables A2-3 and A2-4.  
 The general approach to calculating the number of DPPs from an intervention among a particular 
patient group was first to stratify by age and sex, then to multiply the estimated number of patients in 
the year 2005 by the proportion of these patients receiving a particular treatment, by the 1-year case-
fatality rate, and by the relative reduction in the case-fatality rate due to the administered treatment. 
Sources for estimates of efficacy (relative risk reductions) are shown in Table A2-3. Sources for treatment 
uptakes are shown in Table A2- 4.   
Age-specific case-fatality rates for each patient group are presented in Table A2-5. 
 We assumed that compliance (concordance), the proportion of treated patients actually taking 
therapeutically effective levels of medication, was 100% among hospital patients, 70% among 
symptomatic community patients, and 50% among asymptomatic community patients8-9 
All these assumptions were tested in subsequent sensitivity analyses. 
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 EXAMPLE 1: estimation of DPPs from a specific treatment 
 For example, in Poland, in 2005, approximately 12 230 men aged 55-64 were hospitalized with 
acute myocardial infarction (AMI).  The expected age-specific 1-year case-fatality rate without treatment 
for this group was approximately 5.4%.  From registry data10 96% of them were given aspirin or other 
antiplatelet drug, interventions with an expected mortality reduction of 15%.  the number of deaths 
prevented or postponed for at least a year by the use of aspirin among men aged 55 to 64 were then 
calculated as:  
 
[Eq1]  12 230 x 0.054 x 0.96 x 0.15 = 95 
 
This calculation was then repeated  
a) for men and women in each age group, and  
b) incorporating a Mant and Hicks adjustment for multiple medications  
c) using maximum and minimum values for each parameter in each group, to generate a 
sensitivity analysis (see below).   
 
A2-3 Risk factors in the Polish IMPACT model 
 The second part of the IMPACT model involves estimating the number of coronary heart disease 
DPPs related to changes in cardiovascular risk factor levels in the population.  The Polish IMPACT model 
includes smoking, total cholesterol, systolic blood pressure, body mass index, diabetes, and physical 
activity. Data sources used to calculate the trends in the prevalence (or mean values) of the specific risk 
factors are shown in Table A2-2.  
 Two approaches to calculating DPPs from changes in risk factors were used.  
In the Regression approach—used for systolic blood pressure, total cholesterol, and body mass index--
the number of deaths from CHD occurring in 1991 (the base year) were multiplied by the absolute change 
in risk factor prevalence, and by a regression coefficient quantifying the change in CHD mortality that 
would result from the change in risk factor level.  Natural logarithms were used, as is conventional, in 
order to best describe the log-linear relationship between changes in risk factor levels and mortality. 
In the Population attributable risk fraction approach, the reduction in deaths attributable to  change in a 
risk factor level is calculated based on the change in the attributable risk fraction for that risk factor 
between the initial and final year of the model.  
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EXAMPLE 2: estimation of DPPs from risk factor change using regression method: 
Mortality fall due to reduction in systolic blood pressure in women aged 55-64 
For example, in 1991, there were 2534 CHD deaths among women aged 55-64 years. Mean systolic blood 
pressure in this group decreased by 5.4 mmHg between 1991 and 2005. The meta-analysis reports an 
estimated age- and sex-specific reduction in mortality of 50 percent for every 20 mmHg reduction in 
systolic blood pressure, generating a logarithmic coefficient of –0.035. 11 The number of deaths 
prevented or postponed was then estimated as:  
 
[Eq2]  [deaths in 1991] * (1-EXP(coefficient*change) 
= 2534 (1-EXP(-0.035*5.4)) = 436 
This calculation was then repeated  
a) for men and women in each age group, and  
b) using maximum and minimum values in each group, to generate a sensitivity analysis. 
 Data sources for the number of CHD deaths are shown in Table A2-2, sources for the population 
means of risk factors are shown in Table A2-2, and sources for the coefficients used in these analyses are 
listed in Table A2-6.  
 
EXAMPLE 3: estimation of DPPs from risk factor change using PARF method 
 The population-attributable risk factor (PARF) approach was used for smoking, diabetes, and 
physical activity.  PARF was calculated conventionally as 
 (P x (RR-1)) / (1+P x (RR-1))  
where P - prevalence of the risk factor and RR - the relative risk for CHD mortality associated with that 
risk factor. To assess the decline in CHD mortality the number of coronary heart disease deaths in 1991 
(the base year) was multiplied by the difference between the population-attributable risk fraction in 1991 
and that in 2005. 
 For example, the prevalence of diabetes among women aged 65-74 years was 8.7% in 1991 and 
12.9% in 2005.  Assuming a Relative Risk of 2.5912, the PARF was ~0.1215 in 1991 and ~0.1702 in 2005. 
Assuming the number of CHD deaths in 1991  = 7,180, The number of deaths attributable to the increase 
in diabetes prevalence from 1991 to 2005 was therefore  
 (7 180) * ( 0.170 - 0.122 ) = ~350 DPPs 
 
This calculation was then repeated  
a) for men and women in each age group,b) for physical inactivity and smoking  
204 
 
c) using maximum and minimum values in each group, to generate a sensitivity analysis 
 Data sources for the prevalence of risk factors and for the number of CHD deaths are shown in 
Table 2.  Sources for the relative risks used in these PARF analyses are listed in Table 7. All come from the 
InterHeart study12, the largest international study to provide independent RR values, adjusted for other 
major risk factors. 
The rationale for choosing the regression or PARF approaches for specific risk factors in the Polish 
IMPACT Model is detailed in Table A2-8. 
 
A2-4 Other Methodological Considerations 
 Several methodological issues will be discussed below.  These include adjusting the relative 
reduction in case-fatality rate for patients receiving multiple treatments, establishing rules for avoiding 
double-counting individual patients who may fall into more than a single disease category (patient 
group), treatment overlaps, and sensitivity analyses. 
 
Polypharmacy Issues 
 Individual CHD patients may take a number of different medications.  However, data from 
randomized clinical trials on efficacy of treatment combinations are sparse.  Mant and Hicks suggested a 
method to estimate case-fatality reduction by polypharmacy13.  This approach was subsequently 
endorsed by Yusuf14 and Law and Wald15.  
EXAMPLE 4: estimation of reduced benefit if patient taking multiple medications (Mant and Hicks 
approach) 
 If we take the example of secondary prevention following acute myocardial infarction, good 
evidence (Table A2-3) suggests that, for each intervention, the relative reduction in case fatality is 
approximately: aspirin 15%, beta-blockers 23%, ACE inhibitors 20%, statins 22% and rehabilitation 26%.  
The Mant and Hicks approach suggests that in individual patients receiving all these interventions, case-
fatality reduction is very unlikely to be simply additive, i.e. not 106% (15% + 23%+ 20% + 22% + 26%).  
Instead, having considered the 15% case fatality reduction achieved by aspirin, the next medication, in 
this case a beta-blocker, can only reduce the residual case fatality (1-15%). Likewise, the subsequent 
addition of an ACE inhibitor can then only decrease the remaining case fatality, which will be 1 - [(1- 0.15) 
X (1-0.23)]. 
 The Mant and Hicks approach therefore suggests that a cumulative relative benefit can be 
estimated as follows:  
Relative Benefit = 1 - [(1-relative reduction in case-fatality rate for treatment A) X (1- relative reduction in 
case-fatality rate for treatment B) X ...X (1- relative reduction in case-fatality rate for treatment N).  
In considering appropriate treatments for AMI survivors, applying relative risk reductions (RRR) for 
aspirin, beta-blockers ACE inhibitors statins and rehabilitation then gives: 
Relative Benefit = 1 - [(1 –aspirin RRR) X (1 - beta-blockers RRR) X (1 - ACE inhibitors RRR) X (1- statins 
RRR) X (1- rehabilitation RRR)]  
= 1 - [(1- 0.15) X (1-0.23) X (1-0.20) X (1- 0.22) X (1- 0.26)] 
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= 1 - [(0.85) X (0.77) X (0.80) X (0.78) X (0.74)] 
= 0.70 i.e. a 70% lower case fatality 
This represents a 34% relative reduction (0.70/1.06) on the simple additive value of 106%. 
Potential overlaps between patient groups: avoiding double counting 
 There are potential overlaps between CHD patient groups (Table A2-9).  
For example, approximately half the patients having CABG surgery have a previous AMI16, approximately 
25% of AMI survivors develop heart failure within 12 months17, and over 50% of CHD patients have a 
history of hypertension18.  All these assumptions were tested in subsequent sensitivity analyses.  
 
Sensitivity Analyses 
 Because of uncertainties surrounding many of the values, a multi-way sensitivity analysis was 
performed using the analysis of extremes method19.  For each model parameter, a lower and upper value 
was assigned using either 95% confidence intervals where available (for instance therapeutic 
effectiveness quantified as a relative risk reduction in the relevant meta-analyses), or otherwise plus or 
minus 20%.  
An analysis of extremes was therefore performed whereby the maximum and minimum feasible values 
were fed in to the model.  By multiplying through, the resulting product then generated maximum and 
minimum estimates for deaths prevented or postponed (Table A2-1).   
EXAMPLE: sensitivity analysis for AMI patients given aspirin 
 An example of calculating lower and upper-bound estimates for DPPs for treatment with aspirin 
among men aged 55-64 years who were hospitalized with an AMI is presented here. 95% confidence 
intervals from the meta-analysis were used for relative mortality reduction; lower and upper bound 
estimates for the other parameters were calculated as minus or plus 20% [except for treatment uptake 
that was capped at 99%]. Multiplying all the lower-bound estimates yielded the minimum [lower bound] 
estimate and multiplying the upper-bound estimates yielded the maximum [upper bound] estimate.   
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Table A2-1 Example of sensitivity analysis 
 
 
Patient 
numbers 
Treatment 
Uptake 
Relative 
mortality 
reduction* 
One 
year 
case 
fatality 
Deaths 
prevented or 
postponed 
 
A B C D (A x B x C x D) 
Best 
Estimate 
12 226 0.96 0.15 0.054 95 
Minimum 
estimate 
9 781 0.77 11%* 0.043 36 
Maximum 
estimate 
14671 0.99 19%* 0.065 179 
* 95% CI from the Antithrombotic Trialists’ Collaboration meta-analysis20, see Table A2-3. 
 
A2-5 Sources of data used in Polish IMPACT Model 
 
Table A2-2. Main Data Sources for the Parameters Used in the Polish IMPACT Model  
Item 1991 2005 
Population statistics (number) Central Statistical Office Central Statistical Office 
Deaths by age and sex (number) NIPH NIPH 
 (ICD-9 codes 410-414)* (ICD-10 codes I20-25) 
   
Number of patients admitted yearly  
Myocardial infarction: ICD9: 
410 
ICD 10: I21 
 
NIPH NIPH 
   
Angina pectoris: ICD9: 413 
ICD10: I20 
NIPH NIPH 
Heart failure: ICD10: I50 NIPH NIPH 
   Number of patients treated 
with 
  
CABG KROK KROK 
PCI Assume zero PL-ACS 
Cardiopulmonary resuscitation in the community  
Numbers & Uptake   
Uptake Assume 1% of admitted AMI 
patients 
Rudner et al
21
 
Acute myocardial infarction   
Hospital Resuscitation Assume 2% of admitted AMI  PL-ACS, NIPH 
 Thrombolysis MONICA PL-ACS, NIPH 
Primary angioplasty Assume zero PL-ACS, NIPH 
Aspirin MONICA PL-ACS, NIPH 
207 
 
  
Table A2-2 (Continued)   
Item     1991        2005 
Beta blockers MONICA PL-ACS, NIPH 
ACE inhibitors MONICA PL-ACS, NIPH 
Primary CABG surgery Assume zero PL-ACS, NIPH 
Primary PCI (angioplasty) Assume zero PL-ACS, NIPH 
Angina pectoris: unstable   
Prevalence Extrapolated NIPH 
Platelet IIB/IIIA Inhibitors Assume zero PL-ACS 
Aspirin alone Expert opinion PL-ACS 
Aspirin & Heparin Expert opinion PL-ACS 
Primary CABG surgery Assume zero PL-ACS, KROK 
Primary PCI (angioplasty) Assume zero PL-ACS 
Aspirin Pol-MONICA WOBASZ, SPOK 
Beta blockers Pol-MONICA WOBASZ, SPOK 
ACE inhibitors Assume zero WOBASZ, SPOK 
Statins Assume zero WOBASZ, SPOK 
Warfarin Assume zero WOBASZ 
Secondary prevention following CABG or PCI  
Aspirin Assume zero WOBASZ 
Beta blockers Assume zero WOBASZ 
ACE inhibitors Assume zero WOBASZ 
Statins Assume zero WOBASZ 
Warfarin Assume zero WOBASZ 
Rehabilitation Assume zero EUROASPIRE 
Congestive Heart Failure   
ACE inhibitors Assume zero HF2005 
Beta blockers Assume zero HF2005 
Spironolactone Assume zero HF2005 
Aspirin Assume zero HF2005 
Statins Assume zero HF2005 
Treatment for chronic angina   
CABG surgery KROK NHDS 
PCI (angioplasty) Assume zero NHDS 
Community angina pectoris: total   
Prevalence  WOBASZ 
Aspirin Assume zero WOBASZ 
Statins Assume zero WOBASZ 
Community Chronic heart failure   
Prevalence  Expert opinion, Spanish data 
ACE inhibitors Assume zero HF2005 
Beta blockers Assume zero HF2005 
Spironolactone Assume zero HF2005 
Aspirin Assume zero HF2005 
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Table A2-2 (Continued)   
Item     1991        2005 
Statins Assume zero HF2005 
Hypertension   
Prevalence NATPOL II (1996) WOBASZ 
Treated (%) NATPOL II (1996) WOBASZ 
Statins etc for primary prevention   
Hypercholesterolemia (%) not needed WOBASZ 
Treated (%) Assume zero WOBASZ 
Population RISK FACTOR prevalence  
Current smoking Central Statistical Office Central Statistical Office 
Systolic blood pressure NATPOL 1997 (extrapolated 
to 1991) 
WOBASZ 
Cholesterol MONICA MONICA 
Physical activity NATPOL 1997 (extrapolated 
to 1991) 
WOBASZ 
Obesity (BMI) NATPOL 1997 (extrapolated 
to 1991) 
WOBASZ 
Diabetes NATPOL 1997 (extrapolated 
to 1991) 
WOBASZ 
*corrected for change in death registry system
22
 
 
 
 
 
 
 
Key: 
ACE denotes angiotensin-converting enzyme, AMI acute myocardial infarction, CABG coronary artery 
bypass graft surgery, GUS – Central Statistical Office,  HF2005 – Multicenter Study of Heart Failure 
Treatment in Poland (2005),  ICD International Classification of Diseases, KROK – Cardiosurgery 
Registry, NATPOL – set of country representative cardiovascular risk factors surveys, NIPH – National 
Institute of Public Health,  PL-ACS Polish Acute Coronary Syndromes Registry, PCI percutaneous 
coronary intervention, WOBASZ – Multicenter Study on Health of Polish Citizens. 
 
  
Table A2-2. Clinical efficacy of interventions:  relative risk reductions obtained from meta-analyses, and randomised controlled trials* 
Treatments Relative risk reduction
† 
Comments Source paper: First author (year), 
notes 
ST elevation myocardial infarction (STEMI) 
 Thrombolysis 31% (95% CI: 14,45) <55 years: Odds Ratio (OR)=0.692; Relative Risk Reduction 
(RRR)=30.8% (95% CI: 14,45) 
55-64 years: OR=0.736; RRR=26.4% (95% CI: 17,40) 
65-74 years: OR=0.752; RRR=24.8% (95% CI: 15,37) 
> 75 years: OR=0.844; RRR=15.6% (95% CI: 4,30) 
 
Estess (2002)
23
 
Aspirin 23% (95% CI: 15,30) 
 
RRR=23% (95% CI: 15,30): outcome is vascular deaths 
 
ISIS-2 (1988)
24
 
Primary CABG surgery 39% (95% CI: 23,52) OR=0.61 (95% CI: 0.48,0.77); RRR=39% (95% CI: 23,52) on 
page 565, 0-5 year mortality 
 
Yusuf (1994)
25
 
Primary PCI 30% (95% CI: 15,42) OR=0.70 (95% CI: 0.58,0.85); RRR=30% (95% CI: 15,42) 
outcome compares primary angioplasty to thrombolytics. 
Keeley (2003)
26 
Beta blockers 4% (95% CI: -8,15) OR=0.96 (95% CI: 0.85,1.08); RRR=4% (95% CI: -8,15) on 
page 1732 
 
Freemantle (1999)
27
 
ACE inhibitors 7% (95% CI: 2,11) OR=0.93 (95% CI: 0.89,0.98); RRR=7% (95% CI: 2,11) for 30 
day mortality in myocardial infarction 
ACE Inhibitor Myocardial Infarction 
Collaborative Group (1998)
28
 
 
Clopidogrel 3% (95% CI: 1,6)  RRR=3% (95% CI: 1,6) for 30 day mortality in myocardial 
infarction 
 
Chen (2005) 
29 
Sabatine (2005)
30
 
Hospital CPR 
 
33% (95% CI: 10,36) Survival at 24 hours estimated to be 32%, discharge to 
home at 21%, and 1 year survival to be 15% overall. 
 
Tunstall-Pedoe (1992)
31
 
Nadkarni 
32 
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Table A2-2(continued)    
Treatments Relative risk reduction
† 
Comments Source paper: First author (year), 
notes 
Non-ST-segment elevation acute coronary syndrome (NSTEACS): 
Aspirin alone 15% (95% CI: 11,19) OR=0.85 (95% CI: 0.49,0.95); RRR=15% (95% CI: 11,19). 
Outcome is vascular and nonvascular deaths on page 75. 
Assume appropriate for patients with NSTE-ACS. 
 
Antithrombotic Trialists’ Collaboration 
(2002)
33
 
 
Aspirin & heparin 33% (95% CI: -2,56) OR=0.67 (95% CI: 0.48,1.02); RRR=33% (95% CI: -2,56%) in 
Table 2. The study outcome is composite MI death and non-
fatal MI; compares those on aspirin & heparin to aspirin 
only. 
 
Oler (1996)
34
 
Platelet glycoprotein 
IIB/IIIA inhibitors 
9% (95% CI: 2,16) OR=0.91 (95% CI: 0.84,0.98); RRR=9% (95% CI: 2,16). Study 
looked at acute coronary syndrome without persistent ST 
elevation. 
 
Boersma (2002)
35
 
Early PCI 
 
32% (95% CI: 5,51) OR=0.68 (95% CI: 0.49,0.95); RRR=32% (95% CI: 5,51) 
 
RITA 3 (Fox 2005)
36
 
Primary CABG surgery 39% (95% CI: 23,52) OR=0.61 (95% CI: 0.48,0.77); RRR=39% (95% CI: 23,52) on 
page 565, 0-5 year mortality 
 
Yusuf (1994)
25
 
Assumed similar as STEMI. 
 Clopidogrel 
 
7% (95% CI: 2,11)  RRR=7% (95% CI: 2,11) Yusuf (2001)
37
 
Beta blockers 4% (95% CI: -8,15) OR=0.96 (95% CI: 0.85,1.08); RRR=4% (95% CI: -8,15) on 
page 1732 
Freemantle (1999)
27
 
Assumed similar as STEMI. 
 
ACE inhibitors 7% (95% CI: 2,11) OR=0.93 (95% CI: 0.89,0.98); RRR=7% (95% CI: 2,11) for 30 
day mortality in myocardial infarction 
ACE Inhibitor Myocardial Infarction 
Collaborative Group (1998)
28
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Table A2-2(continued)    
Treatments Relative risk reduction
† 
Comments Source paper: First author (year), 
notes 
Secondary prevention post myocardial infarction/revascularisation: 
 Aspirin 15% (95% CI: 11,19) OR=0.85 (95% CI: 0.49,0.95); RRR=15% (95% CI: 11,19). 
Outcome is vascular and nonvascular deaths on page 75. 
This data seems to be appropriate to this outcome in CHD 
patients. 
 
Antithrombotic Trialists’ Collaboration 
(2002)
33
 
 
Beta blockers 23% (95% CI: 15,31) OR=0.77 (95% CI: 0.69,0.85); RRR=23% (95% CI: 15,31) on 
page 1734. Odds of death in long term trials. 
Freemantle (1999)
27
 
ACE inhibitors or 
Angiotensin-II receptor 
antagonists 
20% (95% CI: 13,26) OR=0.80 (95% CI: 0.74,0.87); RRR=20% (95% CI: 13,26 on 
page 1577, death up to four years [endpoint of study 
looking at those with heart failure or LV dysfunction]. 
Flather (2000) 
38
 
Statins 24% (95% CI: 10,26) RRR=24% (95% CI: 10,26) 
Intensive statin therapy in acute coronary syndromes. 
 
Hulten (2006)
39 
Baigent(2004)
40 
Warfarin 22% (95% CI: 13,31) OR=0.78 (95% CI: 0.67,0.90); RRR=22% (95% CI: 10,33) Anand and Yusuf (1999)
41
 
Rehabilitation 26% (95% CI: 10,39) OR=0.74 (95% CI: 0.61,0.90); RRR=26% (95% CI: 10,39) in 
Figure 1, page 685 Taylor reference 
Taylor (2004)
42
 
Chronic stable coronary artery disease: 
CABG surgery years 0-5 
 
39% (95% CI:23,52) OR = 0.61 (95% CI: 0.48-0.77), RRR 39% (95% CI: 23,52) on 
page 565, 5 year mortality 
 
Yusuf (1994)
25
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Table A2-2(continued)    
Treatments Relative risk reduction
† 
Comments Source paper: First author (year), 
notes 
CABG surgery years 6-10 
 
32% (95% CI: 2,30) OR = 0.83 (95% CI: 0.70-0.98), RRR 17% (95% CI: 2,30) on 
page 565, 10 year mortality. 
OR = 0.68 (95% CI: 0.56-0.83), RRR 32% (95% CI: 17,44) on 
page 565, 7 year mortality 
CABG compared to medical treatment 
Yusuf (1994)
25
 
Angioplasty  No effect  Boden (2007)
43 
Aspirin 15% (95% CI: 11,19) OR=0.85 (95% CI: 0.49-0.95); RRR=15% (95% CI: 11,19). 
Outcome is vascular and nonvascular deaths on page 75. 
Antithrombotic Trialists’ Collaboration 
(2002)
33
 
Statins 23% (95% CI: 10,26) RRR=23% (95% CI 10,26) 
Standard dose statin therapy in coronary artery disease 
Wilt (2004)
44 
ACE inhibitors/ARB 
 
17% (95% CI: 6,28) RRR=17% (95% CI 6,28) Al-Mallah (2006)
45
 
Heart failure in patients requiring hospitalisation or in the community: 
ACE inhibitors 20% (95% CI: 13,26) OR=0.80 (95% CI: 0.74,0.87); RRR=20% (95% CI: 13,26) on 
page 1577 [death up to four years was study endpoint for 
those with heart failure or LV dysfunction] 
Flather (2000)
38
 
Beta blockers 35% (95% CI: 26,43) OR=0.65 (95% CI: 0.57,0.74); RRR=35% (95% CI: 26,43): all 
cause mortality 
Shibata (2001)
46
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Table A2-2(continued)    
Treatments Relative risk reduction
† 
Comments Source paper: First author (year), 
notes 
Spironolactone 30% (95% CI: 18,41) 
 
31% (95% CI: 18,42) 
OR=0.70 (95% CI: 0.59,0.82); RRR=30% (95% CI: 18,41) in 
those that had at least one cardiac related hospitalisation.  
OR=0.69 (95% CI: 0.58,0.82); RRR=31% (95% CI: 18,42) in 
entire study population consisting of those with community 
heart failure, page 711. 
 Pitt (1999)
47
 
Aspirin 15% (95% CI: 11,19) OR=0.85 (95% CI: 0.49,0.95); RRR=15% (95% CI: 11,19). 
Outcome is vascular and nonvascular deaths on page 75. 
Antithrombotic Trialists’ Collaboration 
(2002)
33
  
Statins No effect  Kjekshus (2007)
48
 
Tavazzi (2008)
49 
Primary prevention therapies: 
 Treatments for high 
blood pressure 
13% (95% CI: 6,19) OR=0.87 (95% CI: 0.81,0.94); RRR=13% (95% CI: 6,19) in 
those with high blood pressure without disease at entry. 
[RRR=29% (95% CI: 17,37) those with average blood 
pressure and CHD, treated with ACE inhibitors] 
 
Law (2003)
50
 
Statins 35% (95% CI: 11,52) OR=0.65 (95% CI: 0.48,0.89); RRR=35% (95% CI: 11,52) for 
CHD mortality (only trials using statins), Figure 3 on page 4 
Pignone (2000)
51
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Table A2-3. Data sources for treatment uptake levels in Poland 2005: Medical and surgical 
treatments included in the model 
 
Treatments 
Treatment Uptake in 
2005; data for 1991 in 
parentheses 
Source (year) 
Acute myocardial infarction 
Thrombolysis 4,3% (10%) 
National Registry of Acute Coronary Syndromes 
(2005) 
Pol-MONICA (1991) 
Antiplatelet 81% (65%) 
Primary angioplasty 39% (0%) 
Primary CABG 1% (0%) 
Beta blockers 64% (38%) 
ACE inhibitors 62%(13%) 
Cardio-pulmonary resuscitation 
In the Community 16% Rudner  (2004)21 
In Hospital 2%* Bunch (2003)52 
 Secondary Prevention (POST-AMI) 
Aspirin 56% (55%) WOBASZ (2003-2005) Pol-MONICA (1991) 
Beta blockers 48% (30%) WOBASZ (2003-2005) 
Pol-MONICA (1991) ACE inhibitors 49%  (0%) WOBASZ (2003-2005) 
Statins 35% (0%) WOBASZ (2003-2005) 
Warfarin 3% (0%) WOBASZ (2003-2005) 
Secondary Prevention (POST-REvascularisation) 
Aspirin 84% (0%) WOBASZ (2003-2005) 
Beta blockers 67% (0%) WOBASZ (2003-2005) 
ACE inhibitors 65% (0%) WOBASZ (2003-2005) 
Statins 66% (0%) WOBASZ (2003-2005) 
Warfarin 7% (0%) WOBASZ (2003-2005) 
Chronic Angina 
CABG surgery 11% (0%) National Registry of Cardiosurgery (2005) 
Aspirin in community 43% (?%) WOBASZ  (2003-2005) 
Statins in community 21% (0%) WOBASZ  (2003-2005) 
Unstable Angina 
Aspirin & Heparin 58% (10%) PL-ACS (2005) 
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Table A2-3 (continued)   
Treatments 
Treatment Uptake in 
2005; data for 1991 in 
parentheses 
Source (year) 
Aspirin alone 26% (30%) PL-ACS (2005) 
Platelet glycoprotein IIB/IIIA 
inhibitors 
1% (0%) PL-ACS (2005) 
CABG surgery for UA 1% (0%) PL-ACS (2005) 
Angioplasty for UA 14% (0%) PL-ACS (2005) 
Heart Failure including a hospital admission 
ACE inhibitors 86% (0%) 
HF2005 
 
Beta blockers 61% (0%) 
Spironolactone 64% (0%) 
Aspirin 65% (0%) 
Statins 41% (0%) 
Heart Failure in the community 
ACE inhibitors 49% (0%) 
HF2005 
Beta blockers 46% (0%) 
Spironolactone 27% (0%) 
Aspirin 37% (0%) 
Statins 31% (0%) 
Hypertension treatments 45% (32%) WOBASZ  (2003-2005) 
NATPOL (1991)** Hyperlipidaemia - 1’ prevention  
Statins 11% (0%) WOBASZ  (2003-2005) 
# Uptake percentages as reported in source papers. Values may differ from those in Table 1 of the thesis, which report weighted 
averages for ALL age groups 25-84 years included in the Model. 
* Assume approximately 2% of AMI admissions have primary ventricular fibrillation (Olmsted county)
51 
 
** Extrapolated from 1997-2002 data. 
 
 
  
Table A2-4. Age-specific case fatality rates for each patient group 
GROUP AMI Post AMI Unstable CABG Angioplasty 
        
Heart 
 Failure Hypertension Hypercholesteraemia 
   
Angina surgery 
 
Hospital Community 
  
Interval 30 day 
One 
year* One year* 
One 
year* One year* One year One year One year One year 
Mean 0.084 0.051 0.069 0.02 0.016 0.246 0.081 0.01 0.006 
MEN 
         25-34 0.011 0.008 0.016 0.003 0.003 0.034 0.011 0 0 
35-44 0.012 0.009 0.024 0.005 0.005 0.068 0.022 0.001 0.001 
45-54 0.023 0.017 0.034 0.007 0.007 0.096 0.032 0.002 0.002 
55-64 0.054 0.034 0.056 0.012 0.012 0.14 0.045 0.006 0.006 
65-74 0.101 0.073 0.07 0.023 0.025 0.283 0.093 0.014 0.014 
75-84 0.164 0.122 0.091 0.042 0.042 0.337 0.111 0.035 0.035 
85+ 0.279 0.189 0.118 0.075 0.074 0.418 0.138 0.094 0.094 
          WOMEN 
         25-34 0.011 0.004 0.016 0.003 0.003 0.034 0.011 0 0 
35-44 0.013 0.006 0.024 0.005 0.005 0.068 0.022 0.001 0.001 
45-54 0.026 0.01 0.034 0.007 0.007 0.096 0.032 0.001 0.001 
55-64 0.061 0.019 0.056 0.012 0.012 0.14 0.045 0.002 0.002 
65-74 0.114 0.084 0.07 0.023 0.027 0.222 0.081 0.007 0.007 
75-84 0.167 0.116 0.091 0.042 0.039 0.289 0.094 0.021 0.021 
85+ 0.267 0.177 0.118 0.075 0.061 0.368 0.121 0.079 0.079 
          
Source 
USA 
Medicare    
 USA 
Medicare 
Van 
Domberg53  
 USA 
Medicare   
 USA 
Medicare 
 USA 
Medicare 
 USA 
Medicare 
  NHANES  &  Vital Statistics 
2
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Table A2-5.  Beta coefficients for major risk factors 
Estimated β coefficients from multiple regression analyses for the relationship between absolute changes 
in population mean risk factors and percentage changes in coronary heart disease mortality for men and 
women, stratified by age. Data sources, values and comments. 
Table A2-5-1 Systolic blood pressure 
Systolic blood pressure Age group (years) 
 25-44 45-54 55-64 65-74 75+ 
      
Men (hazard ratio per 20 
mmHg) 
 
0.49 0.49 0.52 0.58 0.65 
Men (log hazard ratio per 
1 mmHg) 
-0.036 -0.035 -0.032 -0.027 -0.021 
      
Minimum -0.029 -0.028 -0.026 -0.022 -0.017 
Maximum -0.043 -0.042 -0.039 -0.032 -0.025 
      
Women (hazard ratio per 
20 mmHg) 
 
0.40 0.40 0.49 0.52 0.59 
Women (log hazard ratio 
per 1 mmHg) 
 
-0.046 -0.046 -0.035 -0.032 -0.026 
Minimum -0.037 -0.037 -0.028 -0.026 -0.021 
Maximum -0.055 -0.055 -0.042 -0.039 -0.031 
Source: Prospective studies collaborative meta-analysis, Lancet 200211 
Units: Percentage change in CHD mortality per 20 mmHg change in systolic blood pressure 
Strengths: Large dataset, includes US data, adjusted for regression dilution bias, consistent 
with randomised controlled trials, results stratified by age and sex, with 95% 
confidence intervals 
Limitations: Some publication bias still possible 
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Table A2-5-2  Cholesterol 
Cholesterol Age groups (years) 
 25-44 45-54 55-64 65-74 75-84 85+ 
Mortality reduction per 1 mmol/l 
Men 0.55 0.53 0.36 0.21 0.21 0.21 
Women 0.57 0.52 0.35 0.23 0.23 0.23 
Log coefficient 
Men -0.799 -0.755 -0.446 -0.236 -0.117 -0.083 
Minimum -0.639 -0.604 -0.357 -0.189 -0.093 -0.067 
Maximum -0.958 -0.906 -0.536 -0.283 -0.140 -0.100 
       
Women -0.844 -0.734 -0.431 -0.261 -0.174 -0.051 
Minimum -0.675 -0.587 -0.345 -0.209 -0.139 -0.041 
Maximum -1.013 -0.881 -0.517 -0.314 -0.209 -0.062 
Source: Prospective studies collaborative meta-analysis, Lancet 200754 
Units: Percentage change in CHD mortality per 1 mmol/l change in total cholesterol 
Strengths: Includes US data, adjusted for regression dilution bias, includes randomised 
controlled trials, RCT values consistent with observational data, results stratified 
by age and sex, with 95% confidence intervals 
Limitations: Some publication bias still possible 
 
 
 
Table A2-5-3 Body mass index 
Body Mass Index (BMI) Age groups (years) 
 <44 45-59 60-69 70-79 80+ 
James et.al (2004):      
Hazard ratio 0.89 0.91 0.95 0.96 0.97 
Risk reduction† per 1 kg/m2 0.11 0.09 0.05 0.04 0.03 
Age gradient (45-59 as reference) 1.22 1.00 0.56 0.44 0.33 
Bogers (2006):  
Relative risks, CHD deaths per 5 
BMI units (kg/m2) 
  
1.16 
   
Relative risks per 1 kg/m2 
applying age gradients from 
James et.al  
1.04 1.03 1.02 1.01 1.01 
Log coefficients 0.0363 0.0297 0.0165 0.0132 0.0099 
Minimum 0.0255 0.0209 0.0116 0.0093 0.0070 
Maximum 0.0466 0.0381 0.0212 0.0169 0.0127 
Source: Bogers et al (2006)55, James et al (2004)56 
Units: Percentage change in CHD mortality per 1 kg/m2 change in BMI 
Strengths: Large number of studies included. Adjusted for blood pressure, total 
cholesterol, and physical activity. 95% confidence intervals included. 
Limitations: Observational data; age gradient applied from James study 
 
 
  
Table A2-6. Relative Risks for CHD used in the IMPACTSEC model for Smoking, Diabetes and Physical Inactivity  (Best, Minimum and Maximum Estimates 
from the InterHeart Study12) 
 Both sexes Men Women 
Lifestyle factors: Young Old ≤ 55 years > 55 years ≤ 65 years > 65 years 
       
       
Smoking 3.33 (2.86-3.87) 2.44 (2.10-2.84) 3.33 (2.80-3.95) 2.52 (2.15-2.96) 4.49 (3.11-6.47) 2.14 (1.35-3.39) 
       
Exercise 0.95 (0.79-1.14) 0.79 (0.66-0.94) 1.02 (0.83-1.25)† 0.79 (0.66-0.96) 0.74 (0.49-1.10) 0.75 (0.46-1.22) 
Alcohol 1.00 (0.85-1.17) 0.85 (0.73-1.00) 1.03 (0.87-1.23) 0.86 (0.73-1.01) 0.74 (0.41-1.31) 0.83 (0.49-1.42) 
Hypertension 2.24 (1.93-2.60) 1.72 (1.52-1.95) 1.99 (1.66-2.39) 1.72 (1.49-1.98) 2.94 (2.25-3.85) 1.82 (1.39-2.38) 
       
Diabetes 2.96 (2.40-3.64) 2.05 (1.71-2.45) 2.66 (2.04-3.46) 1.93 (1.58-2.37) 3.53 (2.49-5.01) 2.59 (1.78-3.78) 
Abdominal obesity 1.79 (1.52-2.09) 1.50 (1.29-1.74) 1.83 (1.52-2.20) 1.54 (1.30-1.83) 1.58 (1.14-2.20) 1.22 (0.88-1.70) 
Psychosocial 2.87 (2.19-3.77) 2.43 (1.86-3.18) 2.62 (1.91-3.60) 2.45 (1.82-3.29) 3.92 (2.26-6.79) 2.31 (1.22-4.39) 
High ApoB/ApoA1 ratio 
 
4.35 (3.49-5.42) 2.50 (2.05-3.05) 4.16 (3.19-5.42) 2.51 (2.00-3.15) 4.83 (3.19-7.32) 2.48 (1.60-3.83) 
Smoking, adverse lipid profile, hypertension, and diabetes had a greater relative effect on risk of acute myocardial infarction in younger than older individuals. †The 
InterHeart study quoted a value of only 1.02 for exercise in men aged ≤ 55 years. This was clearly an outlier. We have therefore assumed a value of 0.77 in line with men and 
women in the other age groups, and consistent with most other studies. 
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Table A2.7 Main assumptions and overlap adjustments used in the Polish IMPACT Model 
Treatment category Assumptions and Overlap Adjustments Justification 
   
Post-AMI patients Assume 25% already counted as HF patients  Unal (2004)4 
 Therefore assume residual case fatality halved, 
having      transferred these HF patients to the HF 
group 
Unal (2004) 4 
Post-CABG patients Assume 2/3 had MI, already counted as Post AMI Unal (2004) 4 
Post-PCI survivors Assume 50% had prior AMI, already counted as 
Post AMI 
Unal (2004) 4 
 Assume 25% also had CABG, thus already counted 
as Post CABG 
NHDS 
 Assume 25% had prior PCI, i.e. repeats, already 
counted 
NHDS 
   
Chronic angina treatment: 
PCI patients progressing to 
CABG surgery 
Assume that 20% of PCI go to CABG  NHDS 
   
   
Angina in the community Start with the total patient numbers with angina in 
the community, based on NHANES prevalence 
Then deduct patients counted elsewhere: 
-Patients already treated for unstable 
angina in hospital, 
-50% of those receiving CABG for angina 
-50% of those receiving secondary 
prevention post AMI/post CABG/Post Angioplasty, 
Capewell (2000) 
3 
   
Heart failure in the 
community 
Based on NHANES prevalence 
-Assume 50% of heart failure is due to CHD  
-Deduct patients treated for severe heart 
failure in the hospital (already counted) 
NHANES 1999-
2000  
   
221 
 
Table A2-7 (continued)   
Treatment category Assumptions and Overlap Adjustments Justification 
   
Hypertension treatment: 
overlaps with other CHD 
patient groups 
Total hypertensive patient numbers in community 
calculated, then deduct:  
-50% of post AMI patients 
-50% of community angina patients  
-50% of community heart failure 
patients  
NHANES 1999-
2000 
Fall in population blood 
pressure 
Estimate the number of DPPs by hypertension 
treatment  
-Then subtract this from the total 
DPPs attributed to the secular fall in 
population BP 
Capewell 
(1999)57 
 
 
AMI : acute myocardial infarction, CABG: coronary artery bypass graft surgery, CHD:coronary heart 
disease, DPPs:deaths prevented or postponed, HF: heart failure, NHDS: US National Hospital 
Discharge Survey; NHANES: National Health and Nutrition Examination Survey, and PCI: 
percutaneous coronary intervention. 
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A3. Age standardized CHD mortality rates by age, gender and Index of Multiple 
Deprivation, England 1982-2006 
 
Table A3-1 Age standardized CHD mortality rates by age, gender and Index of Multiple Deprivation, 
England 1982-2006 
  Year   
Least 
deprived 
(Q1) Q2 Q3 Q4 
Most 
deprived 
(Q5) 
Englan
d 
Absolute 
gap (Q5-
Q1) 
Rate Ratio 
(Q5/Q1) 
95% CI for 
rate ratio 
Men 1982 
 
577.8 645.8 702.5 778.3 878.3 719.5 300.5 1.52 
(1.50 - 
1.54) 
  1983 
 
568.0 639.9 697.0 773.0 878.7 713.8 310.7 1.55 
(1.53 - 
1.57) 
  1984 
 
562.6 639.5 699.2 778.3 886.2 715.2 323.6 1.58 
(1.56 - 
1.60) 
  1985 
 
552.0 627.4 686.6 768.7 880.8 704.6 328.8 1.60 
(1.58 - 
1.62) 
  1986 
 
537.2 611.6 669.7 750.5 867.4 688.1 330.2 1.61 
(1.59 - 
1.64) 
  1987 
 
518.3 586.4 639.8 718.0 839.3 660.4 321.0 1.62 
(1.60 - 
1.64) 
  1988 
 
494.2 563.6 620.7 690.2 815.9 636.2 321.7 1.65 
(1.63 - 
1.67) 
  1989 
 
476.0 546.3 596.6 667.6 795.5 615.1 319.5 1.67 
(1.65 - 
1.69) 
  1990 
 
462.5 533.2 586.7 654.9 777.0 601.0 314.5 1.68 
(1.66 - 
1.70) 
  1991 
 
453.3 519.9 568.3 641.9 759.7 586.1 306.4 1.68 
(1.65 - 
1.70) 
  1992 
 
448.8 510.0 560.0 631.7 746.9 576.3 298.1 1.66 
(1.64 - 
1.69) 
  1993 
 
435.4 487.7 533.8 603.7 720.6 552.5 285.3 1.66 
(1.63 - 
1.68) 
  1994 
 
419.9 468.9 513.6 583.8 693.6 531.8 273.7 1.65 
(1.63 - 
1.68) 
  1995 
 
398.1 444.0 488.8 555.9 658.8 504.6 260.7 1.65 
(1.63 - 
1.68) 
  1996 
 
376.7 424.0 468.2 534.5 635.5 482.8 258.8 1.69 
(1.66 - 
1.71) 
  1997 
 
356.7 405.2 447.7 508.1 612.0 460.5 255.4 1.72 
(1.69 - 
1.74) 
  1998 
 
336.6 380.9 424.4 482.8 586.1 436.3 249.6 1.74 
(1.72 - 
1.77) 
  1999 
 
318.9 361.6 403.6 461.0 557.8 414.5 238.9 1.75 
(1.72 - 
1.78) 
  2000 
 
299.4 340.5 382.8 441.0 531.3 392.6 231.8 1.77 
(1.75 - 
1.80) 
  2001 
 
281.6 324.8 361.9 424.7 509.6 373.6 228.0 1.81 
(1.78 - 
1.84) 
  2002 
 
266.1 311.1 343.6 404.4 493.5 356.4 227.4 1.85 
(1.82 - 
1.88) 
  2003 
 
251.6 293.3 324.0 381.4 469.0 336.3 217.4 1.86 
(1.83 - 
1.89) 
  2004 
 
234.7 274.1 305.1 355.0 442.1 314.7 207.4 1.88 
(1.85 - 
1.92) 
  2005 
 
217.5 250.0 284.4 331.2 412.6 291.5 195.1 1.90 
(1.86 - 
1.93) 
  2006 
 
202.1 232.1 263.6 310.8 391.7 272.2 189.5 1.94 
(1.90 - 
1.97) 
  Overall % fall -65.0 -64.1 -62.5 -60.1 -55.4 -62.2 -36.9 
  
  
Average annual % 
change (AAPC)* -4.3 -4.2 -4.0 -3.7 -3.3 -4.0 
   
  
95% CI for AAPC (-4.1 to -
4.5) 
(-4.0 
to -
4.4) 
(-3.7 
to -
4.2) 
(-3.5 
to -
4.0) 
(-3.2 to -
3.5) 
(-3.8 to 
-4.1) 
   Notes:  Rates are three year moving averages, central year reported. AAPC: average annual percent 
change. Rates adjusted to European standard population. 
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Table A3-1 (continued) 
  Year   
Least 
deprived 
(Q1) 
Q2 Q3 Q4 
Most 
deprived 
(Q5) 
Englan
d 
Absolute 
gap (Q5-
Q1) 
Rate Ratio 
(Q5/Q1) 
95% CI for 
rate ratio 
Women 1982   250.2 284.1 303.8 340.4 410.9 320.7 160.7 1.64 
(1.62 - 
1.67) 
  1983 
 
247.0 282.9 304.8 342.9 414.6 321.3 167.6 1.68 
(1.65 - 
1.70) 
  1984 
 
249.1 286.0 309.2 350.1 419.7 325.5 170.6 1.68 
(1.66 - 
1.71) 
  1985 
 
247.3 283.8 306.8 349.5 417.9 323.3 170.6 1.69 
(1.67 - 
1.72) 
  1986 
 
242.0 276.3 301.5 342.5 411.9 316.7 170.0 1.70 
(1.68 - 
1.73) 
  1987 
 
233.5 266.5 291.5 330.5 402.8 306.4 169.3 1.73 
(1.70 - 
1.75) 
  1988 
 
226.4 258.1 283.7 322.2 397.1 298.6 170.7 1.75 
(1.73 - 
1.78) 
  1989 
 
221.8 252.8 275.8 315.5 389.2 291.7 167.4 1.75 
(1.73 - 
1.78) 
  1990 
 
218.2 249.8 272.3 313.0 383.7 287.8 165.5 1.76 
(1.73 - 
1.79) 
  1991 
 
214.6 247.1 268.3 307.2 376.7 282.9 162.1 1.76 
(1.73 - 
1.78) 
  1992 
 
212.5 244.8 265.3 306.1 370.4 279.7 157.9 1.74 
(1.72 - 
1.77) 
  1993 
 
206.3 234.6 254.6 294.0 354.6 268.3 148.2 1.72 
(1.69 - 
1.74) 
  1994 
 
198.1 224.6 244.3 283.4 338.3 257.0 140.3 1.71 
(1.68 - 
1.73) 
  1995 
 
187.0 212.7 232.6 267.9 321.2 243.3 134.3 1.72 
(1.69 - 
1.75) 
  1996 
 
178.1 202.2 222.8 256.3 308.2 232.3 130.1 1.73 
(1.70 - 
1.76) 
  1997 
 
169.2 192.8 214.5 247.2 296.0 222.5 126.8 1.75 
(1.72 - 
1.78) 
  1998 
 
159.2 181.1 203.5 234.7 282.8 210.6 123.6 1.78 
(1.75 - 
1.81) 
  1999 
 
149.2 170.7 192.6 222.5 267.5 198.7 118.2 1.79 
(1.76 - 
1.82) 
  2000 
 
141.2 159.1 181.6 208.6 254.1 186.9 112.9 1.80 
(1.77 - 
1.83) 
  2001 
 
135.0 151.6 171.3 199.7 243.6 177.9 108.6 1.80 
(1.77 - 
1.84) 
  2002 
 
129.1 146.0 164.3 193.9 237.6 171.6 108.6 1.84 
(1.81 - 
1.87) 
  2003 
 
121.5 138.6 155.1 183.3 226.5 162.2 105.0 1.86 
(1.83 - 
1.90) 
  2004 
 
113.3 129.5 146.2 171.0 212.4 151.6 99.1 1.87 
(1.84 - 
1.91) 
  2005 
 
103.6 119.1 134.3 157.4 195.4 139.0 91.8 1.89 
(1.85 - 
1.92) 
  2006 
 
96.4 110.0 124.2 147.3 182.9 129.2 86.6 1.90 
(1.86 - 
1.94) 
  Overall % fall -61.5 -61.3 -59.1 -56.7 -55.5 -59.7 -46.1 
  
  
Average annual 
% change 
(AAPC)* 
-3.9 -3.9 -3.7 -3.4 -3.3 -3.7 
   
  
95% I for AAPC (-3.6 to -
4.2) 
(-3.5 
to -
4.2) 
(-3.3 
to -
4.0) 
(-3.1 
to -
3.8) 
(-3.2 to -
3.5) 
(-3.4 to 
-4.0) 
   Notes:  Rates are three year moving averages, central year reported. AAPC: average annual percent 
change. Rates adjusted to European standard population. 
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A4. The English IMPACTSEC Model: methods and data sources 
 
We have extended the IMPACT model to accommodate sub-national variation in CHD mortality 
trends by socioeconomic circumstances (IMPACTSEC model). We used the Index of Multiple Deprivation 
2007 (IMD) quintiles as a proxy indicator of socioeconomic circumstances. This model examines the 
effects of changes in treatment uptake and risk factor trends on changes in mortality from coronary heart 
disease (CHD) among adults in England aged 25 years and over, stratified into equal quintiles by 
population size. The tables included in this appendix provide details about the sources and methods that 
were used.  
Only those aspects of the IMPACT SEC model that differ from the IMPACT model described in 
chapter 6 and appendix A2 will be discussed here.  
Data sources used to estimate the observed and expected number of deaths from CHD for 2000 
and 2007 are shown in Table A4-1. The expected number of CHD deaths in 2007 was calculated by 
multiplying the age-sex-IMD quintile specific mortality rates from CHD in 2000 by the population counts 
for 2007 in that age-sex-IMD quintile stratum. Summing over all strata then yielded the expected number 
of deaths. The difference between the number of expected and observed deaths from CHD represented 
the mortality fall, or the DPPs in 2007 relative to 2000.  
Data sources for estimating eligible patients for treatments included in the model is available in 
Table A4-1, and their uptake levels in table A4-2. 
Sources of relative risk reductions for treatments and effects measures for risk factors are the 
same as the one used in the Polish IMPACT models (appendix A2) 
Data on risk factor sources and their levels is available in tables A4-3 and A4-4 
Details on model fit are available in table A4-5 
A4.1 IMPACT SEC specific issues 
Allocating areas to socioeconomic quintiles using the Index of Multiple Deprivation, 2007 
The Index of Multiple Deprivation (IMD) is a composite index of relative deprivation at small area 
level based on seven domains: income; employment; health deprivation and disability; education, skills 
and training; barriers to housing and services; crime and disorder; and living environment.1  The IMD 
2007 score of all small areas in England (average population 1,500) were ranked in ascending order and 
grouped into equal quintiles (about 6,500 areas in each), with quintile one (IMDQ1) including the most 
affluent and quintile five (IMDQ5) the most deprived areas. Based on their postcode of residence, 
patients treated in hospital (e.g. recorded in Hospital Episode Statistics) or in the community (e.g. in the 
General Practice Research Database) were matched via their area of residence to the corresponding 
deprivation quintile by the data providers to protect patient anonymity. Mortality counts were similarly 
aggregated into deprivation quintiles by the Office for National Statistics before being released to us for 
research purposes.  
As the IMD 2007 includes rates of premature total mortality in the health domain, its use to 
quantify health inequalities risks a tautology. However UK studies have shown that removing the health 
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domain had little effect on either the assignment of areas into their deprivation quintile or the 
relationship between area-based deprivation and health.2 
Conceptually, the IMD 2007 is a measure of deprivation, not a measure of affluence. Hence, areas 
with the lowest scores are not necessarily the most affluent; rather they have the lowest concentration 
of deprived people. In this paper for clarity and to easily distinguish between the extreme ends of the 
deprivation spectrum, we have used the term ‘most affluent’ and ‘most deprived’ rather than ‘least 
deprived’ and ‘most deprived’. 
Uncertainty analyses 
We implemented uncertainty analysis in Excel using Ersatz (version 1.0 available at 
http://www.epigear.com), an add-in that allows probabilistic bootstrapping in Excel. Ersatz allows 
repeated random draws from specified distributions for input variables and then calculates the 95% 
uncertainty intervals from the realised values of the output variable (deaths prevented or postponed). 
For the IMPACTSEC model, we calculated the uncertainty intervals based on 1000 draws. The parameter 
distributions used for the input variables are shown in Table A4-6. 
Estimating  DPPs attributed to treatments: Net effects and patient groups overlaps. 
“Net effects” 
As all treatments were in use in 2000, the net benefit of an intervention in 2007 was calculated 
by subtracting the expected number of deaths prevented if the uptake rates in 2000 remained constant 
from the estimated number of deaths prevented calculated using the 2007 uptake rates.  
Example 1: Net effects for treatments 
Calculating net effects for clopidogrel use in STEMI cases in men aged 75-84 in the most affluent quintile 
With an estimated total of 1,440 men aged 75-84 in the most affluent quintile (of whom 40% 
were assumed to be STEMI cases), 89% uptake, a relative risk reduction of 3%, a one-year case fatality 
rate of 34%, and 100% compliance, the total number of DPPs in 2007 was calculated as: 
Patient numbers × treatment uptake2007 × relative mortality reduction × one year case fatality 
= (1,440 × 40%) × 89% × 3% × 34% ≈ 5 DPPs 
Applying the uptake rate in 2000 (31%) gave a total of 2 DPPs: 
Patient numbers × treatment uptake2000 × relative mortality reduction × one year case fatality 
= (1440 × 40%) × 31% × 3% × 34% ≈ 2 DPPs 
The net DPPs were therefore: 
Net DPPs = DPPs using uptake2007 – DPPs using uptake2000  
= 5 –2 = 3 
‘Fixed gradients’ for measuring risk factor change between two time points for deprivation 
quintiles 
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The annual sample size of the Health Survey for England (HSfE), roughly 14,000 adults aged 16 
years and over, was not large enough to provide accurate/precise estimates of risk factor levels, and 
hence rates of change over time by age, sex, and deprivation quintiles (70 groups in total). We considered 
three options for estimating risk factor change as key inputs into the regression and PARF deaths 
prevented or postponed calculations: 
Option 1: using single-year estimates for the base and final year (2000 and 2007 respectively). 
Both surveys, however, were half the usual adult size due to boost samples for population sub-groups. 
Option 2: using estimates based on three-year averages with pooled 1999-2001 survey data for the 
base year (2000) and 2005-7 for the final year (2006 as the mid-year). Estimates of risk factor change over 
2000-6 were scaled up by a factor of 8/7 (i.e. number of years between 2000 and 2007 divided by the 
observed number of years). 
Option 3: the ‘fixed gradient approach’ (discussed in detail below). 
 
The fixed gradient approach was based on the assumption that changes in pace and direction for 
each deprivation quintile were similar and therefore, most accurately measured by the overall national 
rates of change (across 14 age-sex groups). If this assumption holds, then relatively stable and plausible 
estimates for each quintile could be derived by scaling the national age-sex risk factor levels up or down 
using a fixed ratio/gradient.  
The fixed gradient was derived by pooling together survey data for all available years from 2000 to 
2007 to calculate risk factor estimates by age, sex, and deprivation fifths. Then the pooled national 
estimate for 14 age-by-sex groups was set notionally to one, and the corresponding estimates for each 
deprivation quintile re-indexed to be below or above one (i.e. expressing the ratio of the deprivation 
quintile to national estimate). These index rates for each of the 70 breaks were then applied to the single 
year national estimates to derive the corresponding 70 risk factor levels for that year. The fixed gradient 
was applied to both the start and end years of the model. An illustrative example, using the population-
attributable risk fraction (PARF), is set out below.   
EXAMPLE: Fixed gradient for change in smoking prevalence in men aged 45-54 
Step 1 
Using the pooled 2000-7 HSfE data the national estimate of current smoking was 25.7% for men 
aged 45-54. Estimates by deprivation quintile ranged from 14.0% for men in the most affluent quintile 
(IMDQ1) to 46.5% in the most deprived (IMDQ5). The best estimate, obtained from the InterHeart study, 
of the relative risk (RR) of smoking was 3.3.9 Using the smoking prevalence (P) and the RR (assumed the 
same across deprivation quintiles) we calculated the PARF for England as a whole and each deprivation 
quintile using the formula: 
PARF = [P × (RR - 1)]/[1 + P × (RR - 1)] 
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Applying step 1: Calculate the PARF gradient using 2000-7 pooled survey data 
Men 45-54 England 
2000-7 
IMDQ1 
2000-7 
IMDQ2 
2000-7 
IMDQ3 
2000-7 
IMDQ4 
2000-7 
IMDQ5 
2000-7 
Proportion smokers (P) 0.2569 0.1398 0.1949 0.2668 0.2882 0.4652 
RR 3.3 3.3 3.3 3.3 3.3 3.3 
PARF 0.3744 0.2457 0.3123 0.3834 0.4017 0.5201 
Gradient in PARF 1 0.656 0.834 1.024 1.073 1.389 
 The PARF calculated using pooled data at the national level was then set notionally to one, and 
the corresponding values for each deprivation quintile re-indexed to be below or above one. For 
example, the pooled gradient in the PARF for men aged 45-54 in Q1 was estimated to be 0.2457/0.3744 = 
0.656.  
Step 2 
Using the HSfE data for the start and final year of the model we then derived the national PARF 
for 14 age-by-sex groups. The national PARF for men aged 45-54 based on prevalence (P) of 28.3% and RR 
of 3.3 in 2000 was 0.3976; a prevalence of 25.1% in 2007 gave a PARF of 0.3688.  
 
Applying step 2: Calculate the national PARF in base and final year 
Men 45-54 England 
2000 
England 
2007 
Proportion smokers (P) 0.2832 0.2508 
RR 3.3 3.3 
PARF 0.3976 0.3688 
 
Step 3 
The fixed gradient (Step 1) was then applied to the national PARF (Step 2) to produce estimates 
of the PARF for each deprivation quintile, separately for the base and final years of the model. For 
example, for men aged 45-54 in Q1 the 2000 estimate of the PARF was equal to 0.3976 (national PARF) 
multiplied by the gradient (0.656), to give an estimate of 0.2608. The 2007 estimate was equal to 0.3688 
(national PARF) multiplied by the fixed gradient (0.656), to give an estimate of 0.2420.  
Applying step 3: Estimate the PARF by deprivation quintiles for single years 2000 and 2007 using fixed 
gradient 
Men 45-54 England 
2000-7 
IMDQ1 
2000-7 
IMDQ2 
2000-7 
IMDQ3 
2000-7 
IMDQ4 
2000-7 
IMDQ5 
2000-7 
PARF 2000 0.3976 0.2608 0.3316 0.4071 0.4265 0.5523 
PARF 2007 0.3688 0.2420 0.3076 0.3376 0.3957 0.5124 
 
Step 4: Calculating the DPPs 
The formula for calculating DPPs using the change in PARF approach was as follows: 
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Adjusted CHD deaths in 2000  × difference between the PARF in 2000 and 2007 
Adjusted CHD deaths in 2000  × (PARF2000 – PARF2007)  
Applying step 4: Estimate the DPPs due to change in PARF between 2000 and 2007 
Men 45-54 England 
2000-7 
IMDQ1 
2000-7 
IMDQ2 
2000-7 
IMDQ3 
2000-7 
IMDQ4 
2000-7 
IMDQ5 
2000-7 
CHD mortality rate (2000)† 0.9131 0.5434 0.6644 0.8177 1.1173 1.6448 
Population (2007) 3284291 736444 700676 660481 611424 575266 
Adjusted deaths (2007) 3035 400 466 540 683 946 
PARF 2000 0.3976 0.2608 0.3316 0.4071 0.4265 0.5523 
PARF 2007 0.3688 0.2420 0.3076 0.3776 0.3957 0.5124 
DPPs in 2007 93  8 11 16 21 38 
† Rate per 1000 
‡ The total DPPs for England was based on the sum of the DPPs across the deprivation quintiles. 
 
We tested all three options and selected Option 3 (‘fixed gradient’ approach). This method had 
the advantage of reducing the number of data breaks to a maximum of 14 (age by sex) for any single HSfE 
year and instead of discarding the survey information in the intermediate years, used the whole data 
series to improve and stabilise the 70 estimates. The disadvantage was that the assumption of a fixed 
gradient for each age-by-sex group remaining constant over time may not hold (e.g. the difference in risk 
factor level between a deprivation quintile and the national rate may be considerably larger in 2000 than 
in 2007).   
Patient overlaps: 
To avoid double counting of patients treated for two or more conditions within the year (e.g. 
heart failure develops within 1 year after myocardial infarction in approximately 30% of survivors) we 
quantified overlaps between different groups and made appropriate adjustments. Overlap adjustments 
were based on estimating the patient counts for each condition separately, and the counts of patients 
with two or more of the target conditions. The latter, or the probabilities of events intersecting, were 
then used to adjust single patient counts into unique non-overlapping counts by condition.  
We constructed nine non-overlapping patient groups.  Following the basic logic of the natural 
history of coronary disease, patients recorded as having two or more conditions were allocated to the 
condition that was further along the disease pathway. For instance, if an individual had both chronic 
angina and heart failure, they were allocated to heart failure. 
Therefore, to avoid double counting, potential overlaps between different groups of patients 
were identified and appropriate adjustments made by subtracting one group from another. For instance, 
we can subtract the number of severe heart failure patients treated in hospital from the total number of 
heart failure patients in the community (because community heart failure patients could be admitted to 
hospital on one or more occasions). Details of the overlap adjustments are available in Table A4-7 and 
figure A4-1. 
References for the English IMPACTSEC model appendix 
1. Noble M, mcLennan D, Wilkinson K et al. The English Indices of Deprivation 2007. 
Department for Communities and Local Government. 
2. Adams J, White M. Removing the health domain from the Index of Multiple Deprivation 
2004 - effect of measured inequalities in census measure of health. Journal of Public Health 
2006;28:379-83. 
3. Craig R, Mindell J. Health Survey for England 2006.  2008. London, United Kingdom, The 
Information Centre. 
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A4.2 Data Tables 
Table A4-1. Population and patient data sources used in the IMPACTSEC model 
Information Source 
Population data  
Population counts and CHD deaths 
stratified by age, sex, and Index of 
Multiple Deprivation quintiles 
 
Office for National Statistics (ONS):(2000: ICD9 410-414,429) 
(2007: ICD10 I20-I25) 
Number of patients admitted to hospital: 
Myocardial infarction (MI) Hospital Episode Statistics (HES). Emergency admissions with a 
primary diagnosis of MI (ICD10: I21). (www.hesonline.nhs.uk). 
The ratio of MI admissions to STEMI and nSTEMI cases taken as 
40/60.13Individual level data for 1998 to 2007 supplied by The 
NHS Information Centre (reference No ET2323).  
Angina pectoris HES. Emergency admissions with a primary diagnosis of angina 
pectoris (ICD10: I20).  
Heart failure  HES. Admissions with a primary diagnosis of heart failure 
(ICD10: I50).  
Number of patients undergoing revascularisation: 
CABG HES. OPCS Classification of Surgical Operations and Procedures 
– Fourth Revision (OPCS-4) K40-K46. 
PCI HES. OPCS Classification of Surgical Operations and Procedures 
– Fourth Revision (OPCS-4) OPCS K49, K50.1, K75.  
Patients in the community eligible for secondary prevention therapies: 
Post MI 
Angina without MI 
Heart failure  
General Practice Research Database (GPRD) 
(http://www.gprd.com/home/). 
Cardiac rehabilitation (CR) Number enrolled in CR programmes adapted from the National 
Audit of Cardiac Rehabilitation 
(http://www.cardiacrehabilitation.org.uk)14  
Patients eligible for primary prevention therapies: 
Lipid-lowering drugs Prevalence of never having had angina or heart attack and 
currently taking lipid lowering drugs prescribed by a doctor 
from the Health Survey for England (HSfE 1998, 2003, and 
2006) (http://www.ic.nhs.uk/statistics-and-data-
collections/health-and-lifestyles-related-surveys/health-
survey-for-england) 
Hypertension treatment Prevalence of never having had angina or heart attack and 
currently taking medication specifically prescribed to treat high 
blood pressure from the Health Survey for England (HSfE 1998, 
2003, and 2006)  
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Table A4-2. Data sources for treatment uptake levels for the Medical and surgical treatments 
included in the model 
Information Source 
Medication use in hospital:  
(ST-segment elevation myocardial 
infarction): 
Aspirin 
Beta Blockers 
ACE I or Angiotensin-II receptor 
antagonists (ARB) 
Thrombolysis 
Clopidogrel 
 
Myocardial Ischaemia National Audit Project (MINAP) 
2003to2007. (http://www.rcplondon.ac.uk/clinical-
standards/organisation/partnership/Pages/MINAP-.aspx). 
STEMI cases defined by the final diagnosis field (includes those 
with threatened infarction). 
Non-ST-segment elevation acute coronary 
syndrome (NSTEACS): 
Aspirin without heparin 
Aspirin & heparin 
Platelet glycoprotein IIB/IIIA 
inhibitors 
 
 
Beta Blockers 
ACE I/ARB 
Clopidogrel 
MINAP 2003 to 2007. nSTEMI cases defined by the final 
diagnosis field. 
Heart failure due to CHD: 
Aspirin† 
Beta blockers†† 
ACE I/ARB†† 
Spironolactone†† 
† Assumed equal to post MI rates in the community obtained 
using the General Practice Research Database (GPRD) 
(http://www.gprd.com/home/) †† NHS Heart Failure Survey 
2005.15 Start year values for beta-blockers, ACE I/ARB and 
spironolactone assumed to be to 10% lower than 2005 values.  
In-hospital cardio-pulmonary resuscitation 
(CPR)  
 
MINAP 2003 to 2007. 
 CPR in the community  Net benefits assumed to be zero. 
Cardiac rehabilitation for MI and 
revascularisation survivors 
Number enrolled in CR programmes adapted from the 
National Audit of Cardiac Rehabilitation 
(http://www.cardiacrehabilitation.org.uk)14  
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Table A4-2(Continued)  
Information Source 
Medication use in the community: 
Post MI and revascularisation survivors, 
chronic stable coronary artery disease 
(CAD), heart failure  
Aspirin 
Beta blockers 
ACE I/ARB 
Statins  
Warfarin 
Spironolactone 
General Practice Research Database (GPRD) 
(http://www.gprd.com/home/). 
Primary prevention therapies:  
Lipid-lowering drugs  Prevalence of never having had angina or heart attack and 
currently taking lipid lowering drugs prescribed by a doctor 
from the Health Survey for England (HSfE 1998, 2003, and 
2006). 
 Anti-hypertensive medication  
 
Prevalence of never having had angina or heart attack and 
currently taking medication specifically prescribed to treat 
high blood pressure from the Health Survey for England (HSfE 
1998, 2003, and 2006). 
 
 
Table A4-3  Risk factors – variable definitions and source 
The Health Survey for England (HSfE), an annual nationwide household survey of the English 
population, has been described in detail elsewhere.3 Briefly, members of a stratified random sample 
(drawn from the Postcode Address File) that is socio-demographically representative of the English 
population were invited to participate. The annual household response rate was 75% in 2000, falling 
steadily to 66% in 2007. Data were collected at two visits: an interviewer’s visit, during which a 
questionnaire was administered, followed by a visit from a trained nurse for all those interviewed who 
agreed. The nurse visit, which did not take place in 2004 among the general population sample, includes 
measurements and collection of blood, as well as additional questioning including use of prescribed 
medication (1998, 2003, and 2006). The magnitude of risk factor change from 2000 to 2007 used for the 
calculation of DPPs (see Examples 2 and 3) was estimated using a ‘fixed gradient’ approach across 
deprivation quintiles to maximise precision. For details on this approach see above. Risk factor levels in 
2000 and 2007 by deprivation quintiles and sex are shown in Table A4-5. 
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Table A4-3  Risk factors – variable definitions and source (continued) 
Risk factor HSfE survey year Description 
Current cigarette smoking 2000-7 Self-reported status 
SBP (mmHg) All years between 2000-7 
except 2004 
Calculated as the mean of the 2nd and 
3rd readings for those who had not 
eaten, consumed alcohol or smoked in 
the 30 minutes prior to measurement 
Body Mass Index 2000-7 Weight (kg) divided by height squared 
(m2) for all respondents with valid 
height and weight measurements. 
Those reporting taking blood pressure 
lowering drugs were included 
Total cholesterol (mmol/l) 1998,2003,2006 Those reporting taking lipid lowering 
drugs were included 
Diabetes 1998,2003,2006 Those reporting diabetes that was 
doctor-diagnosed, excluding women 
who had only had diabetes during 
pregnancy 
Physical activity 1998,2003,2006 High levels defined as spending 30 
minutes or more of moderate or 
vigorous activity on at least five days 
per week. Occupational activity was 
excluded. 
Fruit and vegetable consumption 
 
2001-7 
 
Measured in portions per day 
  
 
Table A4-4. Risk factor levels in 2000 and 2007 by sex and deprivation quintiles 
 England IMDQ1 IMDQ2 IMDQ3 IMDQ4 IMDQ5 
 2000 2007 2000 2007 2000 2007 2000 2007 2000 2007 2000 2007 
Smoking prevalence (%)             
Male 27.2 23.6 19.2 16.6 22.7 19.6 26.7 23.0 31.0 26.9 36.0 31.2 
Female 23.4 19.9 17.2 14.7 20.0 17.0 22.9 19.5 26.2 22.2 29.9 25.2 
Diabetes prevalence (%)             
Male 3.7 6.5 3.3 5.7 3.5 6.1 3.7 6.5 3.6 6.1 4.5 8.1 
Female 2.9 4.8 2.5 4.1 2.3 3.6 2.6 4.2 3.0 5.2 4.0 6.8 
Physical inactivity (%)             
Male 80.9 74.0 81.3 74.5 79.6 72.9 80.4 73.6 80.5 73.6 82.7 75.5 
Female 82.4 78.1 82.3 78.0 82.5 78.3 81.6 77.4 81.9 77.7 83.9 79.5 
Systolic blood pressure, mmHg            
Male 133.1 130.6 133.1 130.5 133.4 130.8 133.3 130.7 133.0 130.6 133.0 130.6 
Female 131.0 125.6 130.7 125.3 131.6 126.6 131.2 125.7 131.1 125.6 130.6 125.1 
Cholesterol, mmol/L             
Male 5.6 5.4 5.6 5.4 5.6 5.5 5.6 5.4 5.5 5.4 5.5 5.4 
Female 5.7 5.5 5.7 5.6 5.8 5.6 5.7 5.5 5.6 5.4 5.6 5.5 
Body mass index, kg/m2
 
            
Male 27.3 27.7 27.2 27.6 27.4 27.8 27.4 27.7 27.5 27.8 27.1 27.4 
Female 26.9 27.2 26.3 26.5 26.7 26.9 27.0 27.2 27.2 27.5 27.6 27.9 
Fruit and vegetable consumption, portions per day           
Male 3.4 3.7 3.7 4.1 3.6 4.0 3.4 3.8 3.2 3.5 2.8 3.2 
Female 3.6 4.0 4.0 4.4 3.8 4.3 3.6 4.0 3.4 3.8 3.0 3.3 
2
36 
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Tables  A4-5. Model fit by age, sex and deprivation quintiles 
 England IMDQ1 IMDQ2 IMDQ3 IMDQ4 IMDQ5 
Male 71% 67% 68% 69% 74% 79% 
Female 114% 101% 108% 112% 121% 134% 
       Male 25-34 225% 17% 45% 43% 63% 233% 
Male 35-44 77% 32% 47% 189% 301% 71% 
Male 45-54 34% 36% 36% 33% 33% 35% 
Male 55-64 69% 60% 66% 63% 67% 85% 
Male 65-74 66% 63% 64% 65% 68% 70% 
Male 75-84 75% 70% 75% 69% 80% 82% 
Male 85+ 84% 77% 70% 88% 91% 105% 
       
Female 25-34 146% 85% 35% 281% 108% 104% 
Female 35-44 86% 68% 58% 34% 58% 84% 
Female 45-54 72% 128% 113% 63% 59% 68% 
Female 55-64 60% 54% 57% 80% 63% 52% 
Female 65-74 104% 97% 95% 92% 105% 130% 
Female 75-84 108% 91% 111% 106% 112% 125% 
Female 85+ 141% 118% 118% 139% 164% 212% 
       
Total 89% 81% 85% 87% 94% 102% 
% Model fit = ABSOLUTE (1- ((total DPPs – model DPPs)/total DPPs)) × 100 
 
Table A4-6. Uncertainty analysis: parameter distributions use in the probabilistic sensitivity analysis 
Parameter Distribution 
Population and deaths 
counts Poisson 
  Risk Factors 
Prevalence beta 
Continuous Normal 
Relative Risk Erzats RR 
function Beta coefficients Normal 
  Treatments 
Eligible patients Poisson 
Uptake beta 
Relative Risk Reduction Erzats RR 
function Case fatality rate beta 
238 
 
Table  A4-7: Main assumptions and overlap adjustments used in the IMPACTSEC model 
Treatment category Assumptions and overlap adjustments Justification 
Post-AMI  Assume 30% already counted in the heart failure in 
community group. 
 
 Weir (2006)50  
Post-CABG  Assume two-thirds had AMI, already counted as post 
AMI 
 
Unal (2004)1  
Post-angioplasty  Assume 50% had prior AMI, already counted as post 
AMI  
Assume 25% also had CABG, thus already counted as 
post CABG 
Assume 25% had prior PCI, i.e. repeat procedures, 
already counted 
 
Unal (2004)1  
 
 
 
 
Angina in the 
community 
Start with the total numbers with angina in the 
community (without MI) based on GPRD prevalence. 
Then deduct persons counted elsewhere: 
 
Persons already treated for unstable angina in 
hospital 
50% of those in the heart failure in the community 
group 
2/3 of those receiving secondary prevention post 
CABG/post PCI 
 
Capewell (2000)3  
Heart failure in the 
community 
Based on GPRD prevalence.  
Assume 50% of heart failure is due to CHD 
Deduct persons treated for severe heart failure in the 
hospital (already counted) 
 
NHANES 1999-2000  
Fall in population 
blood pressure 
Estimate the number of DPPs by hypertension 
treatment 
Then subtract this from the total DPPs attributed to 
the secular fall in population blood pressure 
 
Capewell (1999)4  
Capewell (2000)4  
Fall in population 
total cholesterol 
Estimate the number of DPPs by cholesterol lowering 
medication 
Then subtract this from the total DPPs attributed to 
the secular fall in population cholesterol 
 
AMI denotes acute myocardial infarction, CABG coronary artery bypass graft surgery, CHD coronary heart disease, 
DPPs deaths prevented or postponed, GPRD General Practice Research Database 
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Figure A4-1: Patient overlaps for IMPACTSEC (2007)  
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STEMI (20,702)
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(excluded) (24,624)
Primary 
prevention
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35.2 million)
Statins for hypercholesterolemia (3,159,505)
Anti-hypertensive medication (4,754,711)
MI denotes myocardial infarction; STEMI ST-segment elevation; NSTE-ACS non-ST segment 
elevation; CHD Coronary heart disease; CABG Coronary artery bpass grafting; PTCA Percutaneous 
transluminal coronary angioplasty. Figures in bold represent patient numbers used in IMPACTSEC
model (i.e. minus relevant overlaps).
Heart failure due to CHD (24,624)
Secondary 
prevention
Post MI 
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year period 
(71,027)
Overlap with Post MI (252,540  
0.5)
Overlap with 
CABG 
(252,540  
0.5  0.75)
Repeat PTCA 
procedures 
(252,540  
0.5  0.75  
0.75)
AMI denotes acute myocardial infarction; CHD Coronary heart disease; HF heart failure; CABG Coronary artery bpass grafting; PTCA Percutaneous 
transluminal coronary angioplasty. † MI & unstable angina admissions having PTCA/CABG in 2007 subtracted from revascularisation counts. Figures in bold 
represent patient numbers used in IMPACTSEC model (i.e. minus relevant overlaps).
